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Summary 
Pentameric ligand gated ion channels (pLGICs) have an essential role in mammals, insects and some 
prokaryotes. These membrane receptors convert chemical signals of neurotransmitters into electrical 
signals of an ion flow, mainly at synapses. Due to this function, the channels are involved in a breadth of 
biological systems including metabolism, sensory processing and cognition. All the members of the 
family share a similar structure. A receptor is made up of five subunits. Each subunit has three domains, 
the extracellular (ECD), transmembrane (TMD) and intracellular (ICD). Neurotransmitters bind in the 
orthosteric pocket formed at the interface of two ECDs. Ligand binding induces conformational 
changes that allow ions to flow through a pore generated by the TMD. The ICD is the site of cell- 
receptor communication. 
This work focuses on the glycine receptor (GlyR), which has a role, among others, in chronic pain and 
whose malfunction leads to diseases such as epilepsy and hyperekplexia. In adults, the primary 
functional oligomer is a heteromeric arrangement of α1β, with other subtypes dispersed throughout the 
central nervous system (CNS). Current research has produced models of homomeric receptors, 
however, no structural data are available for the physiologically relevant heteromeric form. 
An objective of this work was to characterise a new model for the ECD of the heteromeric GlyR, called 
glycine binding protein (GBP). GBP is based on Aplysia californica acetylcholine binding protein 
(AcAChBP), a surrogate for the nicotinic acetylcholine receptor (nAChR). Other objectives were the 
production of another surrogate of a GlyR heteromer utilising models of the homomeric form. Also, the 
homologous histamine receptor (HisR) from Apis mellifera was investigated to understand how 
histamine binds and relate this binding to potentially mislabelled receptors in mammals. More detailed 
descriptions and experimental sections can be found in Chapter 1 and 2. 
In Chapter 3, the biophysical techniques surface plasmon resonance (SPR), isothermal titration 
calorimetry (ITC) and tryptophan fluorescence (WF) were assessed utilising AcAChBP and three of its 
ligands. Comparison of computational docking and thermodynamic parameters led to insights into 
ligand binding in AcAChBP. Data showed good corroboration between the techniques and highlighted 
some limitations when considering small molecule interactions. 
The archetypal ligands strychnine of GlyR and N-methylbicuculline of the GABAA receptor (GABAAR) were 
utilised to investigate binding in GBP. Structural, computational and biophysical data were used for 
comparisons. Chapter 4 also presents a structure of the GBP:N-methylbicuculline complex at 2.4 Å and 
a preliminary model of the AcAChBP:N-methylbicuculline complex at 2.9 Å. These structures emphasise  
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the promiscuous binding properties of N-methylbicuculline and give the first insight into its interaction 
with GlyR and nAChR. Data from the study of N-methylbicuculline suggest that it is promiscuous due to 
the flexibility of the orthosteric binding site of pLGIC members as well as the number of interactions 
the ligand can form, therefore a favourable orientation can always be adopted. Comparisons of 
structural sequence and binding data for both ligands suggested that GBP may be a good surrogate of 
the GlyR heteromer. 
Utilising GBP and AcAChBP as targets, two ligand screens were carried out; an NMR screen of 435 
fluorinated compounds and a computational docking screen of 2,000 small molecules from Maybridge. 
The screens were conducted to discover new ligands of the proteins. Investigation of these ligands 
could further understanding of protein-ligand interactions with GBP and AcAChBP, as well as the 
physiological receptors GlyR and nAChR. Similarities in chemical structure and binding poses of 
compounds that were shown to bind the target proteins were investigated. Validation of binding for 
selected small molecules was attempted. Two compounds were successfully validated by WF with KD 
values of 237-393 µM. Exploiting published structures, the possibility to extend the small molecule 
scaffolds into empty pockets of the two proteins was examined. Extensions of three compounds were 
carried out suggesting potential group additions that may improve binding interactions. 
Prior to the initiation of this study, the crystal structures of homomeric GlyR α1 and α3 were reported. It 
was then considered possible to engineer the sequence to present a heteromeric binding site using a 
homomeric assembly. Utilising the homomeric channels, more sequence and structural conservation to 
the GlyR heteromer could be achieved. Therefore, a new surrogate was designed by substituting five 
residues of loop C of GlyR α3. Loop C acts as a flexible loop that closes upon ligand binding leading to 
conformational changes, therefore is an important feature for the binding mechanism. Comparison of 
sequence and structural models of potential HisR constructs was also conducted, which led to the 
identification of AmHisR. Attempts were made to produce the proteins, however, problems were 
encountered. Chapter 6 details the approaches attempted to solubilise these membrane proteins. 
Due to there being no structural studies of HisR, binding models were constructed, and key residues 
were highlighted. Potentially, the same approach as for GBP could be employed using these models to 
produce an AcAChBP-based surrogate for HisR. 
Chapter 1 






1.1 Pentameric ligand gated ion channels 
1.1.1 pLGICs role in synaptic transmission 
Pentameric ligand gated ion channels (pLGICs) are a large family of receptors located at neuronal 
synapses in vertebrates, invertebrates and are also present in a few prokaryotes. At synaptic junctions, 
they function as an intermediate translator between chemical and electrical signals for the 
continuation or inhibition of action potentials. There are two classes of pLGICs, dependent on ion 
selectivity, excitatory including nicotinic acetylcholine receptors (nAChR) and serotonin receptors (5- 
HT3R) as well as inhibitory, which comprises GABAA receptors (GABAAR) and glycine receptors (GlyR) 
(1). 
Due to their location at the synapse, they are implicated in a breadth of human biological processes 
including motor control, sensory processing, sleep and pain (2). Owing to this involvement in key 
biological processes, when these receptors malfunction this leads to a variety of diseases (3). 
Malfunctions in nAChR and GABAAR are linked with Alzheimer’s (4,5), Parkinson’s (6,7) and epilepsy 
(8,9), whereas defective GlyR function is linked with hyperekplexia (10) and chronic pain (11). These 
receptors are subject to the influence of some widely known compounds with examples including 
propofol and nicotine. The anaesthetic propofol acts as an allosteric modulator of both excitatory and 
inhibitory channels (12). Whereas nicotine is the cause of smoking addiction but is now also used to 
aid smoking cessation and targets nAChR (13). Therefore, a detailed understanding of pLGIC function 
and of how chemicals can modulate these receptors could inform early-stage drug discovery. 
 
1.1.2 Structural insights of pLGICs 
 
1.1.2.1 General architecture 
Important insights into pLGIC structural configuration came from cryo-EM models of the nAChR from 
Torpedo marmorata. Unwin et al. served to define the overall architecture of pLGICs. Each subunit 
consists of three domains, the extracellular (ECD), transmembrane (TMD) and intracellular (ICD), 
arranged in a pseudo-pentameric motif of five subunits (14-16). Since then the amino acid sequences 
and the structures of many different members of the family have been elucidated (Table 1.1) and have 
been found to share similarities (17). The discovery of the prokaryote homologues, Erwinia 
chrysanthemi ligand gated ion channel (ELIC) (18) and Gloeobacter violaceus ligand gated ion channel 
(GLIC) (19), gave further structural insights and highlighted the importance of this family across 
organisms (20). Depending on receptor subtype, several different combinations can assemble as a 
pentamer. For example, GABAAR has 19 genes linked to different subunit types (21). Both homomeric 
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and heteromeric receptors can be formed, as is the case in GlyR (one homomeric and four 
heteromeric (22)). These subtypes can function differently and are separated spatially and/or 
temporally (1). Structures of homomeric receptors were reported for the glutamate receptor (GluCl) 
(23), GABAAR β3 (21), GlyR α3 (24) and α1 (25). The first heteromeric receptor of nAChR α4β2 was 
published in 2016 (26) and is present in two stoichiometric forms (3α:2β or 2α:3β) (1). Further to 
this, structures of GABAAR heteromers were reported between 2017 and 2020 (27-33). Some of these 
models are important as they provide the first examples of tri-heteromeric receptors. 
Organism Protein Technique Resolution (Å) Year (ref) 
Lymnaea stagnalis AChBP X-ray 2.7 2001 (34) 
Aplysia californica AChBP X-ray 2.2 2004 (35) 
Torpedo marmorata nAChR αβγδ Cryo-EM 4.0 2005 (16) 
Erwinia chrysanthemi ELIC X-ray 3.3 2008 (18) 
Gloeobacter violaceus GLIC X-ray 3.1 2009 (19) 
Caenorhabditis elegans GluCl X-ray 3.3 2011 (23) 
Homo sapiens GABAAR β3 X-ray 3.0 2014 (21) 
Mus musculus 5-HT3R X-ray 3.5 2014 (36) 
Homo sapiens GlyR α3 X-ray 3.0 2015 (24) 
Danio rerio GlyR α1 Cryo-EM 3.8 2015 (25) 
Homo sapiens nAChR α4β2 X-ray 3.9 2016 (26) 
Rattus norvegicus GABAAR α1β1γ2S Cryo-EM 3.8 2018 (31) 
Table 1.1 Published structures of members of the pLGIC family. Structures are ordered by date. X-ray: 
X-ray crystallography and Cryo-EM: cryogenic electron microscopy. 
1.1.2.2 Extracellular Domain 
The ECD contains the orthosteric binding site at the interface between two subunits, where 
neurotransmitters interact with the receptor. The domain is generated by ten β-strands (β1-10) which 
generates a β-sandwich core (37). The study of acetylcholine binding protein (AChBP), a homologue 
of the ECD of pLGICs, has contributed to the understanding of the structure and function of this 
domain. AChBP is a small, soluble and highly stable protein found in molluscs, where it has a 
modulatory role in synaptic transmission. The structure of Lymnaea stagnalis (Ls) AChBP was first 
determined in 2001 (34) and later the orthologue from Aplysia californica (AcAChBP) was reported 
(35). This protein, AcAChBP, is used in this work. The two subunits involved in ligand binding are 
assigned as (+)-principal and (-)-complementary. The principal subunit donates three loops (A, B and 
C), then the complementary subunit donates four loops (D, E, F and G, Figure 1.1) to generate the 
orthosteric site (38). 
Heteromeric channels offer distinctive binding sites within the pentamer. Due to the stoichiometry 
and arrangement of subunits a range of interfaces can be observed, generated by different binding 
site residues. For example, GlyR can be made up of α and β subunits, however, glycine preferentially 
Chapter 1 
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Figure 1.1 Binding loops of the orthosteric site of GBP. A) View of the binding site showing, loop A 
(red), loop B (orange), loop C (yellow) from the principal-(+) subunit and loop D (blue), loop E (green), 
loop F (purple), loop G (cyan) of the complementary-(-) subunit. Four residues of the aromatic cage 
are shown as sticks, defining the edges of the binding site. B) Schematic representation of the 
binding site, starred residues are responsible for the aromatic cage, shown in sticks. 
binds at the β+α- site (39). Some key similarities occur in the orthosteric binding pockets of the pLGIC 
family. There is a motif of four conserved aromatic amino acids, which form interactions with the 
ligand. In AcAChBP, these are Y72, W164, Y205 and Y212 (37). Another conserved feature is loop C, a 
flexible region able to adjust position during ligand binding (25). The closure of loop C is linked with 
global conformational changes of the ECD that may promote the binding of ligands in other pockets 
as well as transferring the signal to the TMD (29). When strychnine, an antagonist of GlyR, binds to 
the ECD, it blocks the closing of loop C and thus prevents any conformational changes from occurring 
(Figure 1.2) (25). 
1.1.2.3 Transmembrane Domain 
The TMD consists of four membrane-spanning α-helices (M1-4). The inner helix (M2) lines the 
vestibule which is punctuated by charged residues that are utilised for ion selection (40). The M1/M3 
helices provide a barrier between M2 and the lipid environment. Helix M4 is the main site of 
interaction with the lipid bilayer (41). 
The channels cycle through three states: resting, open and desensitised (Figure 1.3B). The resting 
state is present before ligand binding to the ECD. The ion pore is constricted and contains a 
conserved hydrophobic patch, which generates an energetic barrier preventing solvated ions from 
passing through the pore (42). Upon ligand binding, conformational changes of the ECD are 
communicated to the TMD via a covalent bond between β10 and M1, as well as non-covalent 
interactions between the β1-2 and β6-7 (Cys) loops with M2 and M3 (21,41). This leads to a twist and 
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Figure 1.2 Key orthosteric binding loops of GlyR structures superimposed. Complexes with glycine 
(magenta, PDB code: 5VDH) and strychnine (cyan, PDB code: 5CFB) are compared. Strychnine and 
glycine are shown as sticks. 
tilt of the pore-lining helix M2, opening the gating region and allowing solvated ion flow along the 
electrochemical gradient. This conformational change is a transition from the closed to open state. 
Ion selection is determined by the residues lining the pore. In nAChR, the residues of the channel are 
negatively charged, therefore select for cations whereas in inhibitory receptors, the residues are 
positively charged and select for Cl-. The desensitisation state is finally adopted (41). This results in 
constriction of the pore towards the ICD preventing ion flow due to rearrangement of the TMD 
helices (17). This state also has an increased affinity for ligands (41). It is proposed that the receptor 
returns to a resting state by an untwisting of the ECD in an apo configuration (17). 
Modification of lipid composition can reduce the agonist response or lead to slower desensitisation 
states (41,43,44). Several sites have been identified where lipids bind at the protein-lipid interface 
(annular) and between helices of the TMD (non-annular) (45). Structural evidence from nAChR models 
implies that specific lipids e.g. cholesterol do interact with these sites (46,47) and may affect the 
kinetics of transition state switching. However, more research is required before firm conclusions can 
be made about the role lipids have on pLGIC function (41). 
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Figure 1.3 Subunit organisation and receptor function. A) The organisation of domains in an individual 
subunit. The β-strands (blue) that make up the ECD are labelled as are the helices (red) that form the 
TMD. The ICD was removed from the protein to aid crystallization (24). B) Schematic of the resting, 
open and desensitised states that a pLGIC proceeds through. The ECD and TMD are shown for each 
step. Ligands (blue sphere) and ions (red sphere) are also shown. 
1.1.2.4 Intracellular domain 
The ICD consists of a mostly disordered loop between the M3-M4 helices. The disordered regions have 
roles in membrane localisation and modulation (48). However, the initial and final sections of the loop 
are structured into helices which are involved in ion conductance (36). 
As well as providing receptor-specific functions, the ICD provides a binding site for many proteins to 
interact with the channel, in order to modulate its function and downstream effectors. One example 
of an interacting protein is collybistin, which binds a proline-rich motif of the ICD and is a GTP/GDP 
exchange factor linked to the binding of gephyrin (49). Like collybistin, gephyrin is another ICD binder 
that leads to the anchoring and clustering of GlyRs, and some GABAARs at the membrane (50). 
1.1.3 Nicotinic acetylcholine receptors 
There are two types of nAChRs, muscle and neuronal. The muscle nAChRs are located at the 
neuromuscular junction and can be made of five subunits in a stoichiometry of 2α, 1β, 1γ, 1δ or 1ε, 
similar to the electric organ in T. marmorata. The other nAChR subunits (α2-7, 9, 10 and β2-4) were first 
identified from neuronal tissues, however, are located throughout the nervous and other systems 
(51). These receptors are implicated in a host of biological systems including learning and metabolism 
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(52). They are formed from α subunit homomers or α and β heteromers with stoichiometry affecting 
ligand binding, receptor function and downstream applications (53). For example, the α5 subunit has 
no role in ligand binding (51,54), however, when partnered with the α4β2 receptor, the predominant 
oligomer of the central nervous system (CNS) (55), the α5 subunit affects receptor assembly and 
ligand-mediated upregulation (54,56). Also, the α7 receptor, the other main oligomer of neuronal 
nAChRs, is primarily a homomer that is more permeable to Ca2+ ions than other nAChRs (57). This 
may seem trivial until one considers that a Ca2+ influx is linked to many secondary signalling cascades 
(58). Even though nAChRs are diverse, only a few structures have been published. This includes the 
first heteromeric structure of a mammalian pLGIC, α4β2, which provides insights into how 
heteromeric and homomeric receptors differ (26). 
Due to the experimental challenges of producing full length pLGICs, AChBP has been utilised as a 
surrogate. AChBP, as previously mentioned (Chapter 1.1.2.2), shares homology with the ECD of 
pLGICs. It shares most sequence homology with the α subunits of nAChR (27% α4 and α7), therefore 
has been utilised in the investigation of ligand interactions with these receptors (59) and for early-
stage drug discovery (60). Amino acid substitutions have been made to AChBP to generate better 
surrogates of nAChR oligomers (61-64) as well as to study 5-HT3R (23% sequence identity) (65). During 
these investigations, many techniques using AChBP as a surrogate have been validated including 
tryptophan fluorescence (66), isothermal titration calorimetry (35), X-ray crystallography (34), 
surface plasmon resonance (67) and computational docking (68), providing a basis for future work 
utilising similar surrogate proteins. 
1.1.4 Glycine receptors 
GlyR has been linked to different biological processes including motor control and sensory signalling, 
therefore is important for the functioning of the human body (69). GlyR can be constructed from five 
different subunits α1-4 and β. As there are fewer subunits compared to nAChR, there are fewer possible 
oligomers of the receptor. In adults, the main form is an α1β heteromer with either a 2:3 or 3:2 
stoichiometry (39). Experiments utilising antibodies and atomic force microscopy suggest a 2α:3β ratio 
(70). The α1β heteromer is therefore essential for the majority of GlyR function in the body and loss 
of either gene has been linked to impairment of reflex circuits resulting in hyperekplexia (22). In 
embryos, the main oligomer is a homomer of α2 (71). It has been shown in some areas of the brain 
that, upon the switch from α2 to α1β, α2 is still maintained in combination with β (72). α3 also forms 
heteromers with β and has been confirmed to localise in the retina and the dorsal horn of the spinal 
cord (22). Experiments on the later localisation have linked the α3β receptor with chronic 
inflammatory pain and highlighted it as a potential therapeutic target (11). The final α subunit, α4, is 
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a pseudogene with a stop codon before the fourth transmembrane helix (73). The receptor co-
localises with β at various locations including the spinal cord and retina but its role is unknown 
(22,74). Structures of GlyR homomers have been reported (24,25,42), which give some insight into 
how GlyR functions. However, even though the heteromeric forms of GlyR are predominant and are 
essential, no structural data are available. 
Dawson et al. reported a heteromeric GlyR surrogate, termed glycine binding protein (GBP), which 
utilises the similarity between AcAChBP and the pLGIC family. The heteromeric β+α- interface is the 
site at which glycine binds (39), therefore it is of interest for drug discovery. To generate GBP nine 
substitutions of important binding residues in the orthosteric pocket were conducted and the 
interactions it makes with ligands were investigated. These residues were chosen based on sequence 
and structural alignments. The impact of the substitutions on protein stability was assessed by 
differential scanning fluorimetry. This was followed up by determining the structure and KD of 
important ligands, such as strychnine, by X-ray crystallography and biophysical techniques (75), 
some of which are included in this thesis. GBP could also provide an option for the utilisation of 
different high throughput screening platforms to discover new ligands of the GlyR heteromer. 
1.1.5 Histamine receptors 
Histamine receptors in mammals were considered to be G-protein coupled receptors (GPCR) (76). 
However, evidence from rat showed fast inhibitory post synaptic potentials, which were blocked by 
the channel blocker picrotoxin (77). This was taken to infer the presence of an unknown histamine 
receptor or binding site. Data demonstrating that histamine binds and generates a current in GABAAR 
(78) were further confirmed when a structure of the molecule bound at a β+β- homomeric interface
of the human GABAAR was reported (21). Therefore, it may be possible that subunits of GABAAR may 
have been misassigned or have dual functionality. Insects possess histamine receptors (HisRs) which 
are members of the pLGIC family, these channels are important for sensory signalling (79). It appears 
that most insects studied possess two subtypes of the receptor, but it is still to be established if these  
form predominantly homomeric or heteromeric channels (80-82). These receptors are inhibitory and 
share sequence identity to the insect GABAAR (19%) (83). 
1.2 Biophysical techniques for ligand screening 
Nuclear magnetic resonance (NMR), surface plasmon resonance (SPR) and X-ray crystallography are 
commonly used to identify and characterise protein-ligand interactions. These biophysical techniques 
are also frequently used for screening compound libraries against protein targets (84-86). 
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1.2.1 NMR 
This technique relies on the magnetic properties of certain isotopes (87), most commonly: 1H, 13C, 15N 
and 19F. These isotopes have a nuclei spin of ½, therefore can exist in one of two orientations (88). 
When an external magnetic field is applied to these nuclei, they align in one of two orientations, 
which have different energies. Slightly more nuclei will adopt the lower energy level, however, it is 
possible to excite these nuclei and shift them to the higher energy level. The oscillation between the 
two orientations occurs at a characteristic frequency that is equal to the difference between energy 
levels. When the number of nuclei in the higher energy level equals that of the lower level, no more 
excitation can occur, and the system becomes saturated. Higher energy nuclei can lose energy 
through T1 (longitudinal) and T2 (transverse) relaxation returning to the lower energy level. Detection 
of the energy difference between states leads to the determination of resonance frequency and 
identification of nucleus type (89). Measurement of individual nuclei oscillations are summed and 
recorded as a free induction decay (FID), which is Fourier transformed into the standard NMR 
spectrum. Three observable parameters are commonly reported from this spectrum, chemical shift, 
intensity/area under the curve and linewidth at half of the peak maximum, which identify the 
environment nuclei occupy, the population in that environment and the dynamic properties in 
solution, respectively. Differences in the local chemical environment lead to shielding or deshielding 
of nuclei by electrons of other atoms, which affects resonance frequency and signal location or 
chemical shift. Comparison of spectra, for example, with and without ligand present should lead to 
differences being observed for these three parameters, deducing if and potentially where a molecule 
binds (88).  
NMR can be utilised in ligand screening via two approaches, protein- or ligand-observed (84). Both 
techniques require one component to be isotope labelled. For protein-observed NMR, the whole 
protein can be labelled during recombinant production by utilising 13C and 15N sources in the medium. 
Alternatively, site-specific labelling can be carried out (90). Once labelled, spectra with and without 
ligand are recorded. A change in one of the three observable measurements could indicate if binding 
occurs and in some cases the location (91). However, due to the labelling process, the amount of 
protein required and extensive optimisations, ligand-observed NMR is more commonly used for initial 
screening (92). 
Two common approaches for ligand-observed NMR are saturation transfer difference and water 
ligand observed via gradient spectroscopy (waterLOGSY). In general, there should be a fast exchange 
of compounds between the free and bound states, and affinity is limited to 0.1-1000 µM (92). These 
two techniques require either the protein or solvent to be saturated by irradiation at a specific radio 
frequency, which is transferred to the compounds (93,94). Differences between initial and binding  
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spectra lead to the detection of changes in one of the three observable measurements. 19F NMR 
further simplifies ligand-observed NMR, as fluorine atoms are not present in proteins, therefore 
can be utilized as a label (95). When a 19F labelled ligand binds to a protein it adopts the slow tumble 
of the macromolecule resulting in fast relaxation and broad signals (larger linewidth). In comparison, 
unbound ligands tumble fast leading to slow relaxation and sharp peaks (smaller linewidth). 
Broadening of the peak (increase in linewidth) leads to the detection of binding (96). As well as 
linewidth, the chemical shift could change upon binding, but this is dependent on the location of the 
19F atom/s with respect to the protein (92). In this study, 19F NMR was used to identify potential 
ligands for the proteins of interest. 
 
1.2.2 X-ray crystallography 
To investigate ligand binding, two approaches are generally used to form crystals for X-ray 
crystallography, co-crystallisation and ligand soaking (97). Co-crystallisation is when the ligand and 
protein are mixed in solution and most often incubated for a period of time before crystallisation trials 
are set up. Crystal soaking relies on the production of crystals of the protein. The protein crystals are 
soaked in a high concentration ligand solution (protein:ligand, 1:>2), depending on solubility, to 
saturate the binding sites (98). The ligand in the solution will diffuse through the pores and channels 
in the protein crystal and results in protein-ligand complexes. In some cases, high concentrations of 
compounds can be used, providing the potential to detect binding of weaker ligands that other 
methods may miss (84). Crystal formation is based on the theory of thermodynamic equilibrium. Due 
to vapour diffusion in the cell, which contains a reservoir and the protein-ligand drop, water 
transfers from the drop to the reservoir. This process supersaturates the protein within the drop, 
which is thermodynamically unstable. Protein molecules organise into a lattice and produce a crystal, 
which increases stability (99). 
 
The scattering of X-rays by electrons in an ordered crystal gives rise to a structure-specific diffraction 
pattern. This diffraction pattern consists of discrete scattered X-ray beams, called reflections, which 
can be observed when Braggs law is obeyed. The scattering angles (the positions on the detector) and 
associated intensities of reflections are determined by the symmetry and three-dimensional electronic 
structure of the crystal. It is possible to calculate the distribution of electron density in the crystal with 
knowledge of the mathematical relationship between the diffraction pattern and the electronic 
structure. Interpretation of the electron density, in terms of atomic structure, then allows for a 
molecular model to be constructed (100,101). After data processing and refinement, protein-ligand 
interactions can be inferred. Conversely, X-ray crystallography does not give any information about 
affinity and therefore needs to be paired with other techniques (84).  
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1.2.3 Surface plasmon resonance (SPR) 
SPR utilises p-polarised light, which is refracted by a glass prism directing the light on to the sensor 
chip. The electrons on the gold surface of the chip interact with the photons of light, generating 
surface plasmons. Generation of plasmons is dependent on absorption energy and results in a 
decrease of light intensity being reflected from the surface, at a specific (SPR) angle. Gold is generally 
used to coat the sensor surface as it produces an SPR signal and it is non-reactive to solutions used 
for the technique. Ligand binding to the protein on the biolayer causes a change in mass and the 
refractive index that leads to a change in SPR angle, which is detected. Changes in SPR angle are 
proportional to mass changes (102,103). Proteins can be immobilised on the surface by several affinity 
tag capture systems (104,105) and/or chemical processes (106) to prevent drift. Drift is caused by 
the protein detaching from the biolayer during experiments (107). 
 
SPR is a high-throughput, sensitive technique that can be utilised to detect ligand binding, calculate 
KD and measure binding kinetics during screening (84). Kinetic measurements of small molecules may 
require optimisation, however, KD can still be calculated from the steady-state equilibrium (108). Due 
to its high-throughput properties, experiments can be optimised quickly, identifying problems such as 
off-target effects (102).  
 
1.3 Complementary biophysical methods for the characterisation of protein-ligand interactions 
After ligand screening, other biophysical techniques can be utilised to confirm binding and to gather 
additional data to improve the understanding of the binding interaction. These data can then be used 
to develop better compounds against the target. 
 
1.3.1 Biolayer interferometry (BLI) 
BLI is an optical technique similar to SPR, but it takes advantage of changes in the wavelength of the 
interference patterns rather than a change in the angle of reflection. White light is reflected from two 
layers, the reference and the sample layers. The sample or biolayer is the location at which protein is 
immobilised and where ligands can bind. A binding event causes a change in the density of this layer, 
which alters the optical properties leading to a wavelength change (109). The change in wavelength is 
directly proportional to the thickness of the biolayer (110). Changes are monitored continuously 
allowing kinetics to be investigated, as well as the affinity constant (111). 
 
1.3.2 Tryptophan fluorescence quenching (WF) 
The technique monitors the fluorescence of the aromatic amino acid tryptophan, which is sensitive to 
the environment it is present in. The other aromatic residues phenylalanine and tyrosine are less 
sensitive to the surrounding environment. In these residues (tryptophan>tyrosine, Figure 1.4), 
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excitation of electrons at 280 nm transitions them from a low to a high energy level, which is less 
stable. Energy absorbed by tyrosine is generally either quenched by its interactions with other 
residues or can be transferred to neighbouring tryptophans. Excitation is followed by a relaxation 
(high to low), which emits energy as fluorescence in a certain range (300-400 nm) (112-114). The 
introduction of a ligand changes the electronic environment of the protein leading to the formation 
of different interactions that affect the energy transfer and, generally, a quenching effect of the 
fluorescence is observed (115). As more ligands interact with more binding sites a larger quenching 
effect is observed until saturation occurs. Utilising changes in fluorescence, the affinity of a 
compound for a protein can be determined. 
 
 
Figure 1.4 Absorption and emission spectra of aromatic amino acids. Example absorption (dashed line) 
and emission (solid line) spectra for tryptophan (blue), tyrosine (red) and phenylalanine (purple) 
residues when excited at 280 nm with white light. 
 
1.3.3 Nano differential scanning fluorimetry (nanoDSF)/Differential scanning fluorimetry (DSF) 
The intrinsic fluorescence of a protein can be monitored whilst increasing temperature to elucidate 
the stability of the sample. The fluorescence of the protein is monitored at two wavelengths, 330 and 
350 nm corresponding to emission maxima for tyrosine and tryptophan residues (116). As in 
tryptophan fluorescence, as the electronic environment of these residues changes due to protein 
unfolding, so does the fluorescence (114). The ratio of the wavelengths is recorded over temperature 
and from this data the stability of the protein can be inferred. The presence of a ligand can alter the 
stability of a protein and can be quantified by the change in melting temperature. DSF works 
similarly except a dye is used to monitor unfolding. As a protein unfolds the hydrophobic core is 
revealed, therefore more dye binds to the protein. Water quenches the fluorescence of the dye, 
therefore binding of hydrophobic regions excludes water and increases fluorescence. Upon addition 
of ligands, the protein stability will be affected and the magnitude can be reported (117). 
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1.3.4 Isothermal titration calorimetry (ITC) 
ITC measures the change in heat energy, either exothermic or endothermic, within a closed system. 
Two cells are present in the calorimeter, one is a reference and the other is a sample cell, both are 
maintained at a constant temperature. Upon ligand binding to the protein in the sample cell, it forms 
different interactions. Generating these interactions can lead to energy being released or taken up, 
which can lead to a temperature change of the cell. The instrument records the power, proportional 
to the energy, required to maintain the sample cell at the same temperature as the reference 
(118,119). If ligand binding is exothermic then the temperature in the sample cell increases. The supply 
of power decreases until the temperature of the sample and reference cells are equal. The trace of 
power usage gives rise to a negative peak. In the case of an endothermic process, a positive peak is 
noted since power increases to heat the sample cell to compensate for the drop in temperature. As 
binding sites become saturated the number of binding events and therefore energy change decreases, 
leading to smaller peaks. The peak areas represent a change in energy and the total change in enthalpy 
can be calculated as explained in Chapter 2.4.3 and the binding curve constructed. From the binding 
curve, five parameters can be determined, KD, stoichiometry (N), change in Gibbs free energy, change 
in enthalpy and change in entropy (120). These parameters give additional information about the 
binding event and can be used to inform and improve compound development (121). 
 
1.4 DMSO, a good solvent or a complicating factor? 
DMSO is a highly effective solvent for organic molecules, therefore is widely used in ligand screening 
and characterisation. However, its use can lead to complications. Some compounds stored in DMSO 
have been shown to precipitate, aggregate or degrade (122-124), which generates false results when 
utilising such solutions in screens. The solvent can also act as a chaotropic agent and affect proteins 
by destabilising the structure, even at low concentrations (125,126). Disruption of protein structure 
may affect the interactions a ligand makes, therefore leading to false results in screening and 
inaccurate thermodynamic and kinetic parameters when characterising the binding interactions. To 
overcome issues with DMSO different approaches have been suggested, for example, designing more 
soluble compounds or utilising other solvents (126,127). 
 
 
1.5 Computational ligand screening 
Computational modelling can complement experimental techniques and be used to investigate a wide 
array of biological processes. For drug discovery, there are an array of computational methods that 
can be utilised to discover new ligands of target proteins (128), some of which are discussed below. 
 
Molecular docking uses macromolecular structures as templates to dock compounds into and scores 
the binding based on the interactions they make. By varying the flexibility and restraints of the protein 
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and/or ligand in the docking programme different protein and ligand conformations can be accounted 
for (129). Flexible methods are the most computationally expensive, as all aspects of the protein and 
ligand are allowed to move. Semi-flexible docking allows for the ligand to move within the binding 
site, which can lead to optimisation of interactions. Sometimes, key amino acids are also allowed to 
be flexible to further improve binding orientations. Rigid docking prevents any protein or ligand 
movement (128,130). 
 
Assessment of chemical properties of known ligands can be used to inform computational ligand 
screening. For these methods, the known ligands are assessed, and attempts made to identify key 
features, such as the number of hydrogen bonding groups (131,132). Pharmacophores can then be 
used to screen compound databases to identify common chemical groups and conformations (133). 
Quantitative structure-activity relationships (QSAR), calculate properties of a ligand that are linked to 
biological activity (128) and can also be used to search for common compounds in a database (134). 
 
‘Fragment-based’ and de novo drug design have established a new paradigm in drug discovery (128). 
Small molecules are screened against targets, upon confirmation of binding these compounds are 
used as scaffolds to develop selective ligands with improved properties (135). Computational 
modelling allows for the investigation of libraries of different chemical groups and linkers, which may 
allow for the improvement of the identified scaffolds (136). These analyses can then be used to direct 
synthetic chemical modifications to be tested experimentally. 
 
1.6 Aims 
This research aims to advance our understanding of how selected members of the pLGIC family 
interact with and are modulated by ligands. In addition, this work aims to develop reagents and 
protocols that will support further research seeking new chemical modulators of pLGIC members in 
early-stage drug discovery. 
 
Assessment of GBP as an appropriate model and surrogate of heteromeric GlyR ligand binding will be 
conducted. New models will also be generated, which may give insights into the ligand binding of 
other pLGICs. Appropriate methods for the characterisation of protein and ligands need to be 
identified and robust protocols developed. To address these aims the following objectives have been 
set: 
 
- Assess the use of the biophysical techniques, WF, ITC and SPR for studying protein-ligand 
interactions with the surrogate proteins AcAChBP and GBP 
- Characterise GBP binding to strychnine in order to establish if this is an appropriate surrogate 
of GlyR 
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- Demonstrate the use of GBP in experimental and computational ligand screening to 
develop an understanding of key protein-ligand interactions and to discover new chemical 
matter 
- Generate an improved heteromeric GlyR surrogate utilising the GlyR α3 homomer that could 
further aid early-stage drug discovery 
- Characterise interactions of N-methylbicuculline with AcAChBP and GBP to investigate how 
this important compound may interact with selected members of the pLGIC family 
- Attempt production of HisR to identify residues involved in histamine binding 
 
Completion of these objectives should provide new models of ligand binding for various pLGICs and 
ligands, which will develop the understanding of ligand binding in the pLGIC family. Since the start of 
the project the field has advanced, for example, the publication of the first heteromeric GABAAR 
structure (Table 1.1). These developments were considered as the project progressed. 
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2. Materials & methods 
 
2.1 Construct design 
Vectors for the recombinant production of AcAChBP and GBP were already available having been 
constructed by Dr. Alice Dawson (75). The sequence for AcAChBP was taken from Uniprot (137) 
(Q8WSF8) but modified with two conservative substitutions: A60V and A135V, as previously reported 
(66). The GBP sequence is the same as for AcAChBP with the following substitutions: T53F, Q74R, Y110A, 
I135S, G162E, S206CCP_KGTG. These substitutions provide a surrogate of the physiologically relevant 
β+α- orthosteric binding site of GlyR (75). These vectors, based on the pFastBac1 system (Invitrogen), 
encoded a product with a C-terminal tobacco etch virus (TEV) protease cleavage site followed by a His6 
tag. The His tag allows for purification by immobilised metal affinity chromatography (IMAC), after 
which the His tag can be removed by use of TEV protease (138). 
To aid the design of other constructs, various sequence and structural alignments were made. The 
following sequences were extracted from the Uniprot database: AcAChBP (Q8WSF8), Homo sapiens (Hs) 
GlyR α1 (P23415), HsGlyR α2 (P23416), HsGlyR α3 (O75311), HsGlyR β (P48167), HsGABAAR β1 (P18505), 
Apis mellifera (Am) HisR1 (Q0GQR2), AmHisR2 (A0A1B1QGD8), Drosophila melanogaster (Dm) HisR1 
(Q9VGI0), DmHisR2 (Q9VDU9), Nasonia vitripennis (Nv) HisR1 (D3UAF0), NvHisR2 (D3UAF1), Tribolium 
castaneum (Tc) HisR1 (A8DMU7) and TcHisR2 (A8DMU8). Sequence alignments were constructed in 
Jalview (139) using the Clustal Omega or Tcoffee algorithms. These alignments were used to investigate 
conservation between related sequences, particularly concentrating on the orthosteric binding site. 
Experimentally determined structures of relevant proteins were used for comparison. These structures 
were retrieved from the Protein Data Bank (PDB) (140): GlyR α1 (PDB code: 3JAF), GlyR α3 (PDB code: 
5TIN and 5CFB) and GABAAR β3 (PDB code: 4COF). Structures were not available for HisR, therefore a 
homology model was built using the Phyre2 platform (141) and SymmDock (142). Structures were 
superimposed by the secondary structure method (SSM) in Coot (143), which aligns the Cα backbone 
atoms in multiple iterations. Calculations of root-mean-square deviation (RMSD) of Cα backbone 
alignments between subunits was carried out by the PDBeFold web server (143). In PyMol (The PyMol 
Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC), structures were aligned over multiple 
cycles. Important residues identified in the sequence alignments were examined further in the 
superimposed structures. 
Protein sequences were also inputted into XtalPred web server (144) to investigate the properties of the 
proteins further. The server gives information about signal sequences, secondary structure, 
transmembrane and disordered domains as well as a propensity for crystallisation prediction. All these 
parameters are important considerations when designing constructs. 
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2.2.1 General cloning methods 
2.2.1.1 Transformation of vectors 
Transformations of plasmids with competent cells were performed. Plasmid (1 µL, 10 ng) was added to 
a cell suspension (15-50 µL, depending on competency) and gently mixed. The cells were then incubated 
on ice for 30 m, next they were heat shocked at 42 °C for 45 s, followed by a further 5 m incubation on 
ice. SOC (Super Optimal broth with Catabolite repression) medium (150 µL) was added and the culture 
was incubated at 37 °C for 1 h. The cell suspension (150 µL) was gently mixed then plated out onto the 
relevant plate type. Plates were incubated for 24 h at 37 °C, unless otherwise stated, to allow for 
sufficient colony growth. All media and plates used in this study were sourced from the Media Kitchen, 
School of Life Sciences, University of Dundee. 
 
2.2.1.2 PCR 
PCR was used for the amplification of DNA and to introduce modifications. A solution of DNA, buffer, 
dNTPs, MgSO4, DMSO, forward and reverse primers, water and polymerase was prepared (Table 2.1). 
The PCR was run in duplicate. A negative control without the addition of polymerase was also run. All 
PCR reactions (Table 2.2) were conducted on a Perkin Elmer GeneAmp PCR system 2400. 
Primers contained overhangs, terminal residues that were not encoded in the original DNA sequence. 
Overhangs are necessary to allow the restriction digest enzymes to be able to bind the DNA and to cleave 
at the correct site (New England Biolabs [NEB], Cleavage Close to the End of DNA Fragments). DMSO is 
added to reactions to prevent DNA secondary structure formation, therefore improving yields (145). 
Touchdown PCR (146) was sometimes employed for the construction and amplification of modified 
constructs. The reaction mix is the same for a basic PCR, however, the protocol is different (Table 2.2). 
Colony PCR is an analytical approach that can be used to detect if colonies contain the plasmid/gene of 
interest, before sequencing (147). A different solution is prepared of DNA extract, GoTaq Green Master 
Mix, forward and reverse primers and water (Table 2.1). As this is a preliminary analysis only one reaction 
per colony was conducted and no controls were included. The method for a basic PCR reaction was run 
(Table 2.2). Analysis of the DNA gel led to the identification of colonies with the plasmid/gene of interest 
for use to miniprep (Qiagen kit), and to acquire enough sample for sequencing. All sequencing was 
carried out by the DNA Sequencing and Services facility, School of Life Sciences, University of Dundee. 
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DNA (10 ng) 1 1 1 
Hot Start Buffer (10x) 5 5 - 
dNTPs (10 mM each) 5 5 - 
MgSO4 (25 mM) 2.5 2.5 - 
DMSO (100%) 2.5 2.5 - 
Forward primer (10 
µM) 
3 3 3 
Reverse primer (10 
µM) 
3 3 3 
KOD Hot Start 
polymerase (1 U µL-1) 
1 1 - 
GoTaq green master 
mix (2x) 
- - 25 
Water 27 27 18 
Total 50 50 50 
Table 2.1 PCR solution set up. 
PCR Touchdown PCR Colony PCR 
Initialise 94 °C for 5 m 94 °C for 3 m 94 °C for 5 m 
Denature 94 °C for 30 s 94 °C for 30 s 94 °C for 30 s 
Anneal 65 °C for 30 s 68-50 °C for 30 s 65 °C for 30 s 
Extension 72 °C for 1 m kbp-1 72 °C for 1 m kbp-1 72 °C for 1 m kbp-1 
Final 72 °C for 10 m 72 °C for 5 m 72 °C for 10 m 
Cycles 35 5 each for 68, 60, 55 °C 
15 for 50 °C 
35 
Table 2.2 Methods for running a PCR. 
2.2.1.3 TOPO cloning 
TOPO blunt end ligation does not require digestion of the PCR products and can be ligated into a TOPO 
vector. This vector can then be sequenced using the M13 primers. The Zero Blunt TOPO PCR Cloning kit 
(Invitrogen, ThermoFisher) was utilised for this process. 
2.2.1.4 Restriction digests 
Restriction digestion uses enzymes that recognise certain DNA sequences and cleave at a specific site 
(148). The cleavage leaves an overhanging, single-stranded piece of DNA known as a ‘sticky end’. DNA 
(1 µL, 1 µg) was mixed with FastDigest Green Buffer (ThermoFisher) and two of the relevant FastDigest 
restriction enzymes (1 µL each, ThermoFisher). The solution was mixed and left at room temperature 
(RT) for 15-30 m. Controls were also set up with one enzyme and no enzymes. After the digestion, the 
solutions were heated at 80 °C for 5 m to denature the enzymes and stop the digestion. Samples were 
then analysed/purified by DNA gel electrophoresis. 
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Ligations take advantage of the complementary ‘sticky ends’ resulting from restriction digestion. A 
higher ratio of insert to vector is used to improve the ligation of the two, instead of just religating the 
vector closed. In a typical reaction, the vector (0.5 µL, 0.025 pmol) and insert (2 µL, 0.1 pmol) are mixed 
with the Clonables Ligation Premix (2.5 µL, 2x, Novagen, Merck). This is then left for 5 m at RT, after 
which it is transformed into NovaBlue cells (Novagen, Merck) and plated on lysogeny broth (LB) agar 
ampicillin plates. 
 
2.2.1.6 DNA gel electrophoresis 
Gel electrophoresis was used to analyse and purify DNA products, using a 1% (w/v) agarose gel with 
ethidium bromide (1 µL, 10 mg mL-1, Sigma). Samples (40 µL) mixed with loading dye (6 µL, 0.25% [w/v] 
bromophenol blue, 0.25% [w/v] xylene cyanol FF, 30% [v/v] glycerol) were loaded into one of the eight 
wells of the gel and compared to a DNA ladder (Hyperladder 1 kb, Bioline). Colony PCR and digested 
samples already contained dye, therefore this addition was not required. The gel was then run for 45 m 
at 100 V, or until the dye front reached the end of the gel. Ethidium bromide can intercalate into the 
DNA and fluoresces under UV light (149), therefore the DNA bands can be observed using a UV 
illuminator (BDH) or a BioRad GelDoc EZ system. Bands representing the desired products were excised 
from the gel and the DNA purified using an extraction kit (Qiagen). 
 
2.2.1.7 DNA concentration determination 
DNA concentration determination was conducted on all final constructs, using a DeNovix 
spectrophotometer (A280, Cambridge Bioscience) and was measured in µg µL-1. The constructs were 
labelled, frozen and stored at -20 °C. 
 
2.2.2 Preparation of baculovirus for expression in insect cells 
A crystal structure of the human GlyR α3 homomer was published (24). The gene encoding for the subunit 
was modified with the removal of the M3-M4 loop and replaced with an AGT tripeptide linker (23,24). 
The gene for this construct was ordered. The gene for the GlyR β+α- surrogate was identical to the 
previous construct except for five substitutions (H234Y, N236KG, K239Y, F240Y), designed to make a 
surrogate heteromeric β+α- orthosteric binding pocket. The gene for the full length AmHisR1 was 
ordered with a C-terminal TEV cleavage site and His6 tag. All three genes, codon optimised for 
baculovirus expression, were ordered from GenScript in pFastBac1 vectors. 
To generate the GFP-encoding constructs, different cloning strategies (Figure 2.1) were adopted utilising 
touchdown PCR (146). The GlyR β+α- surrogate and HisR plasmids were used as templates to design the 
new constructs. The final PCR products were ligated back into the pFastBac1 vector. 
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Figure 2.1 Cloning strategy for the construction of GFP-tagged HisR. Touchdown PCR was utilised. Three 
vectors were used (HisR, GlyRGFP and GlyR) to derive the relevant parts of the new vector. HisR signal is 
the signal sequence of the histamine receptor to target the receptor to the membrane and also 
contains the sequence for the BamHI restriction site. GFP is the green fluorescent protein for imaging. 
PP is the precision protease cleavage site to remove the GFP tag. HisR is the histamine receptor protein. 
TEV is the tobacco etch virus protease cleavage site to remove the StrepII tag. Underlined segments are 
overhangs and are used to stitch the gene fragments together in order 1-5. The 10xT are thymine 
overhangs at the N- and C-terminus to allow for restriction digest. The new construct was then digested 
using BamHI and EcoRI then inserted into a pFastBac1 vector. 
Baculovirus production utilised the Bac-to-Bac system (Invitrogen). DH10Bac cells (Invitrogen) were 
transformed with the pFastBac1 vector containing the gene of interest. The culture was plated out onto 
insect cell plates (50 µg mL-1 kanamycin, 10 µg mL-1 tetracycline, 7 µg mL-1 gentamycin, 100 µg mL-1 X-gal 
and 40 µg mL-1 IPTG) and incubated for 3 d at 37 °C. Antibiotic selection is important, limiting growth to 
only a specific bacterium that contains both the viral DNA and the transformed pFastBac vector. 
Afterwards, a plate was checked for both blue and white colonies. X-gal can be cleaved by β- 
galactosidase (β-gal) into a molecule that forms an insoluble blue pigment (5,5'-dibromo-4,4'-dichloro- 
indigo). An inactive form of the enzyme (β-gal) is present in the host Escherichia coli. The bacmid (viral 
DNA) contains an α-peptide sequence, which when produced can generate an active form. If the 
gene of interest is transferred from the vector to the bacmid, this disrupts the α-peptide. The result is 
that white colonies are observed if the β-galactosidase remains inactive since no pigment is produced. 
This should signal that the gene of interest has been inserted. 
A single white colony was spread onto a new insect cell plate and left for a further 3 d. The plate was 
checked again for blue and white colonies. A white colony streak was used to inoculate a culture of insect 
cell medium (500 mL). The culture was shaken at 200 rpm for 24 h at 37 °C, then centrifuged at 1,912 g 
for 15 m at 4 °C (Sigma 4K15 centrifuge, 11150 rotor). The resulting pellet was used to extract the bacmid 
(carried out by the DNA Sequencing and Services facility), which was stored at -20 °C until required. 
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2.2.3 Preparation of a lentivirus-based expression system for use in mammalian cells 
A published method was utilised (150). The main safety concern is the formation of a virus that can 
self-replicate, therefore steps to ensure this does not happen were taken. Three plasmids are required 
to generate the lentivirus particles: transfer (pTransfer), packaging (pPackaging) and envelope 
(pEnvelope). Among these three plasmids are the minimal required viral elements necessary for protein 
production. As the components are separated, a replication-competent virus should not be formed. 
However, in the small number of cases a self-replicating virus occurs, a deletion within pTransfer inhibits 
replication after one cycle (150). The pTransfer (pHR-CMV-TetO2_3C-mVenus-Twin-Strep) vector was 
ordered from Addgene. The pPackaging and pEnvelope plasmids were acquired from the laboratory of 
Dr. Ignacio Moraga (University of Dundee). PCR was used to change the restriction sites of the HisR and 
GlyR surrogate genes to match that of the pTransfer vector. The vector and inserts were digested, 
ligated and transformed, then plated onto LB-agar ampicillin plates. 
 
2.3 Recombinant protein production 
2.3.1 General methods for the analysis of protein production and purification samples 
2.3.1.1 SDS-PAGE 
Samples (10 µL) were mixed with urea (10 µL, 6 M) and Laemmli sample buffer (10 µL, 2x, BioRad and 
355 mM β-mercaptoethanol [BME]), before being heated at 70 °C (membrane proteins) or 100 °C 
(soluble proteins) for 4 m. Samples (13 µL) were loaded onto a polyacrylamide protein gel (Mini- 




Vector Restriction Sites Tags [(C) or (N) 
terminal] 
AcAChBP Baculovirus pFastBac1 - TEV-His6 (C) 
GBP Baculovirus pFastBac1 - TEV-His6 (C) 
GlyR α3 Baculovirus pFastBac1 BamHI/EcoRI StrepII (C) 
GlyR α3 surrogate Baculovirus pFastBac1 BamHI/EcoRI StrepII (C) 
GlyR α3 surrogate Baculovirus pFastBac1 BamHI/EcoRI StrepII-PP-GFP (C) 
GlyR α3 surrogate Baculovirus pFastBac1 BamHI/EcoRI GFP-PP (N) StrepII 
(C) 
GlyR α3 surrogate Lentivirus pTransfer EcoRI/XhoI PP-mVenus- 
StrepII-StrepII (C) 
HisR Baculovirus pFastBac1 BamHI/EcoRI TEV-His6 (C) 
HisR Baculovirus pFastBac1 BamHI/EcoRI GFP-PP (N) TEV- 
StrepII (C) 
HisR Lentivirus pTransfer EcoRI/XhoI PP-mVenus- 
StrepII-StrepII (C) 
Table 2.3 Protein production vectors. 
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Standards, BioRad), and run at 300 V for 17 m in TGS buffer (Table 2.4). If the gel was to be analysed by 
Western blotting a stained marker (8 µL, Prestained Protein Standards All Blue, Biorad) was also 
included. Gels were visualised with a BioRad GelDoc EZ system. 
 
2.3.1.2 Western blot analysis 
After visualisation, gels were transferred using the Trans-Blot Turbo Transfer System (BioRad) onto 0.2 
µm polyvinylidene difluoride (PVDF) membranes (BioRad). The top left corner of each membrane was 
cut to define the orientation. The membrane was agitated with milk powder (5% [w/v]) in phosphate-
buffered saline (PBS)-Tween (0.1% [v/v] Tween-20) for 1-24 h at 4 °C, to block non-specific binding 
sites. The primary antibody was added with further agitation for 1-24 h at 4 °C. The primary antibodies 
used were mouse anti-His (1:4,000, Abcam) and rabbit anti-Strep (1:10,000, Abcam). The membrane 
was then washed three times at RT with PBS-Tween. The secondary antibody was diluted in PBS-Tween 
and poured onto the membrane. Goat anti-mouse IgG (1:150,000, Abcam) and goat anti-rabbit IgG 
(1:50,000, Abcam) secondary antibodies were used. The membrane was agitated for 1 h at 4 °C. Again, 
the membrane was washed three times with PBS-Tween at RT. Enhanced chemiluminescence (ECL) 
Western blotting substrate (Pierce) was applied (2 mL blot-1) to the membrane for 5 m, after which the 
excess was removed. The membrane was enclosed in a plastic wallet inside a dark box (Kodak). In a 
dark room, the film (Lumi-film chemiluminescent detection film, Sigma) was exposed to the membrane 
(0.5-10 m) and developed (Protec ECOMAX X-Ray Film Processor). The film and blot were overlaid, and 
the stained ladder intervals were marked. 
 
2.3.1.3 Analytical gel filtration 
Analytical gel filtration (AGF) was used to investigate the size and quaternary state of proteins. A 
Superdex 200 10/300 GL (GE Healthcare) column was equilibrated overnight in buffer then a sample 
(600 µL, 1 mg mL-1) was loaded onto the column from a 0.5 mL loop. The sample was run for 1.5 
column volumes with buffer. Due to the matrix within the column, large proteins/complexes run 
through faster than small proteins, which interact with the pores (151). The retention time of each peak 
was noted, and the molecular weight (MW) was extracted from a previously determined calibration 
curve. For GBP and AcAChBP there are usually three peaks representing monomeric, pentameric and at 
least one other multimeric state (Figure 2.2). 
2.3.1.4 Native gel analysis 
Native-PAGE analysis was used to investigate the size of proteins in their native states (152). The native- 
PAGE gel was prepared as per the manufacturer’s instructions (Novex), then a sample of protein (0.5 mg 
mL-1) was loaded onto the gel with a marker (8 µL, NativeMark, Novex). The sample was run through the 
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gel for 90 m at 150 V. The gel was fixed (40% [v/v] methanol, 10% [v/v] acetic acid) and destained (8% 
[v/v] acetic acid), then visualised using a BioRad Gel Doc EZ Imager. 
Figure 2.2 Examples of data used to inform protein purification. (A) A native-PAGE gel of GBP showing 
the presence of monomeric, pentameric and a higher-order form, possibly two pentamers. (B) A size 
exclusion chromatography profile showing the separation of different GBP assemblies: a multimer in the 
void (peak A), pentameric (peak B) and monomeric (peak C) forms with the retention times (RT) and 
estimated molecular weights (MW) shown for each peak. (C) SDS-PAGE gel relating to samples taken 
from the column in (B), showing that peaks A, B and C contain GBP. Fractions comprising peak B were 
pooled and used for binding assays and the crystallographic studies. 
 
2.3.1.5 Protein concentration determination 
Absorbance measurements at 280 nm were measured on a DeNovix spectrometer (Cambridge 
Bioscience). Determination of protein concentration was carried out using the Beer-Lambert law and the 
predicted molar extinction coefficients (ProtParam, (153)). Concentrated protein samples were kept at 
4 °C if they were going to be used immediately. Samples were flash-frozen and stored long term at 
-80 °C. 
 
2.3.2 The use of baculovirus for protein production 
2.3.2.1 Virus production 
All cell work was conducted in a tissue culture laminar flow cabinet, to reduce the risk of contamination. 
Spodoptera frugiperda (Sf9, Protein Production Team, University of Dundee) cells were plated out into a 
six-well plate in 1 mL of medium (Sf900 III, Gibco) at a density of 8x105 cells mL-1 per well. A transfection mix 
consisting of 1 mL medium, 5 µL GeneJuice transfection reagent (Novagen) and 500 ng of the relevant 
bacmid, was pipetted dropwise into each well. Transfections were set up with the bacmid of interest, a 
positive control (dihydrofolate reductase bacmid) and negative control (no bacmid), each condition was 
carried out in duplicate. The plate was placed in a sealed container with a damp (sterile PBS, Gibco, 
Sigma) paper towel, to prevent wells from drying out. This container was then placed in a static 
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incubator at 27 °C. The following day, each well was topped up with dropwise addition of medium (1 mL), 
so as not to disturb the adherent cells. The samples were then left for 6 d at 27 °C. 
The supernatant from each well was collected, this contained the virus (P0). Cultures of Sf9 cells (50 mL) 
were set up at a density of 20x105 cells mL-1 in medium (supplemented with glutamine, penicillin and 
streptomycin), then the P0 virus (125 µL) was added from each of the three conditions (gene of interest, 
positive and negative controls), into separate flasks. This step was to amplify the virus. Cultures were 
left shaking at 135 rpm for 3-4 d at 26.5 °C. Three parameters were recorded from the cell counter 
(Cellometer Auto 1000, Nexcelom): cell density, diameter and viability. Sf9 cells double every 24 h 
depending on the medium, therefore a potent virus should limit their growth and reduce the cell density. 
Upon infection the cells swell as the virus replicates, therefore cell diameter should increase (usually 
from 15 to 18 µm). Viability is calculated from the ratio of live to dead cells, therefore as cells die due to 
the release of viral particles the viability should decrease. Typical parameters before harvesting the virus 
are cell density 30-40x105 cells mL-1, diameter 18 µm and viability <96%. As the virus replicates mutations 
can occur, therefore the virus was collected early (90-95% viability) to ensure high quality. Transfection 
success can be determined by the length of time taken until virus collection. Cultures were centrifuged 
at 1,000 g for 10 m at 4 °C (Beckman Allegra X-12R centrifuge with a SX4750 rotor). The supernatant was 
collected and stored at 4 °C, this contains the virus (P1). 
A final amplification step was conducted to maximise the number of high-quality virus particles present 
in the supernatant. Cultures of Sf9 cells (200 mL) were set up at a density of 20x105 cells mL-1, then the 
P1 virus (500 µL), containing the gene of interest, was added. Flasks were left at 26.5 °C for 3-4 d, shaking 
at 135 rpm. Cell density, diameter and viability were measured as previous. Cultures were centrifuged 
at 1,000 g for 10 m at 4 °C (Beckman Allegra X-12R centrifuge with a SX4750 rotor) then the supernatant 
was collected and stored at 4 °C. This supernatant contains the virus (P2). 
 
2.3.2.2 Soluble protein production 
For the production of both AcAChBP and GBP, cultures of 500 mL Trichoplusia ni (Hi5, a gift from Dr. 
Ignacio Moraga, University of Dundee) cells were set up at a density of 20x105 cells mL-1 in medium 
(Insect Xpress, Lonza, supplemented with glutamine, penicillin and streptomycin). Virus (5% [v/v], P2) 
was added to the flask and the culture was left shaking at 135 rpm at 26.5 °C for 2 d. 
 
2.3.2.3 Soluble protein purification 
Cultures were subjected to two centrifugation steps to remove whole cells and cell debris as AcAChBP 
and GBP are secreted into the medium. Firstly, at 1,140 g for 10 m at 4 °C, then secondly at 2,910 g for 
10 m at 4 °C (Beckman J6-MC centrifuge with a JS4.2 rotor). The supernatant was concentrated, and 
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buffer exchanged into buffer A1 (Table 2.4) with a Satorius Stedim Sartojet using a 10 kD membrane 
cassette (PESU). The solution was then passed through a 0.8/0.2 µm filter (Acrodisc, Pall), to remove 
contaminants. The filtered solution was then purified by IMAC (5 mL HisTrap Ni-NTA column, GE 
Healthcare) with an ӒKTA Purifier system (GE Healthcare) using Unicorn software. The column was 
washed with buffer A1 and then the non-specific binding proteins were eluted off the column with a 10- 
20% gradient of buffer B1 (Table 2.4, 50 and 100 mM imidazole). The protein eluted at 50% buffer B1 
(Table 2.4, 250 mM imidazole) and was fractionated. Samples of the fractions were analysed by SDS- 
PAGE. Appropriate fractions identified as containing the protein of interest were pooled and 
concentrated (Macrosep Advance device with 10 kD cutoff, Pall), then buffer exchanged into buffer A1 
(Table 2.4). Measurements of Ti were recorded for concentrated samples using a NanoTemper Tycho to 
check protein quality. This measurement can quantify batch-to-batch variation (see details in nanoDSF 
section later). 
 
2.3.2.4 Attempts to produce and purify membrane-integral proteins 
For the production of membrane proteins, cultures of Sf9 (50-500 mL) cells were set up at a density of 
20x105 cells mL-1 in medium (Sf900 III, Gibco, supplemented with glutamine, penicillin and streptomycin). 
Virus (1-5% [v/v], P2) was added to the flask and the culture was left shaking at 135 rpm at 26.5 °C for 1- 
3 d. 
Cells were pelleted at 2,554 g for 15 m at 4 °C (Beckman J6-MC centrifuge with a JS4.2 rotor). Pellets 
were kept on ice and then resuspended in buffer A2 (Table 2.4) with the addition of protease inhibitors 
(10 µL, 100x, Expedeon, Abcam) and DNase (100 µL, 10 mg mL-1 in 0.15 M NaCl, Sigma). Cells were either 
sonicated (10 s on, 10 s off for 10 cycles, Soniprep 150, MSE) on ice or broken open by the use of a chilled 
cell disruptor (30 kpsi, Constant Systems). Intact cells were removed by centrifugation at 10,000 g for 
15 m at 4 °C (Beckman Avanti J25 with a JA-25.50 rotor). The supernatant was centrifuged at 45,000 g 
for 1 h at 4 °C (Beckman Optima L-100K ultracentrifuge with a 70 Ti rotor) to pellet the membranes. 
The supernatant containing the soluble fraction was removed. Membrane pellets were kept on ice and 
resuspended in buffer A2 (Table 2.4) supplemented with detergent by manual homogenisation. A range 
of detergents were screened for each construct at or above their critical micelle content (1-6% [w/v]). 
The suspension was then agitated for 3-24 h at 4 °C. A final ultracentrifugation was conducted at 
45,000 g for 1 h at 4 °C (Beckman Optima L-100K ultracentrifuge with a 70 Ti rotor) and the 
supernatant was collected. Samples were taken at various stages and analysed by SDS-PAGE and 
Western blot. 
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2.3.3 Attempts to produce recombinant protein in mammalian cells 
2.3.3.1 HEK293T cell culture 
All lentiviral work was conducted in a category two laminar flow cabinet. A modified protocol (150) was 
used throughout the attempted protein production. HEK293T cells were grown in medium A (DMEM/F- 
12 nutrient mix [Gibco, ThermoFisher] supplemented with 10% fetal bovine serum [FBS, ThermoFisher]) 
at 37 °C with 5% CO2 for 3 d. Medium was then removed and the cells were washed with PBS (5 mL, 
ThermoFisher) followed by incubation with trypsin (1 mL, 1x, ThermoFisher) for 10 m. Cells were 
resuspended and then diluted with medium A (5 mL). Then the culture was split by the addition of 
medium A (5 mL) to cell suspension (1 mL). Cells were left to adhere and incubated at 37 °C with 5% CO2 
for 3 d. Cultures were split every 3 d. 
 
2.3.3.2 Lentivirus production 
A transfection mix was made up containing pTransfer (3.3 µg), pEnvelope (3.3 µg), pPackaging (3.3 µg) 
and medium B (100 µL DMEM/F-12 supplemented with 1% non-essential amino acids solution [Gibco, 
ThermoFisher]). A separate solution of polyethylenimine (PEI, 25 µL, 1 mg mL-1, Aldrich) in medium B 
(100 µL) was prepared and mixed. The PEI and transfection solutions were mixed and incubated at RT 
for 20 m. Medium A was removed from the cells and replaced with medium C (4 mL, DMEM/F-12 
supplemented with 2% FBS) then 0.2 mL of the DNA/PEI mixture was added dropwise. The culture was 
incubated at 37 °C with 5% CO2 for 3 d, after which the medium, containing the lentivirus, was collected. 
The virus was supplemented with fresh medium A (2 mL) and filtered (0.45 µm, Minisart, Satorius). 
Polybrene (6 µL, 10 mg mL-1, Merck) was added to increase transfection efficiency and the virus was 
frozen and stored at -20 °C. 
 
2.3.3.3 Membrane-integral protein production 
A new culture of HEK293T cells was grown to 90% confluency in medium A (6 mL). The medium was 
removed, and the cells were washed with PBS (5 mL) then this was replaced with medium containing the 
lentivirus (6 mL). The culture was incubated at 37 °C with 5% CO2 for 3 d, then the medium was removed 
and the cells were washed with PBS (5 mL, 3x). The cells were trypsinised (1 mL, 10 m) then medium A 
(5 mL) was added. The cells were expanded by the addition of cell suspension (2 mL) to medium A 
(10 mL) per flask. These transfected cultures should have formed stable cell lines, continually producing 
the protein of interest. Stable cell lines are produced when the gene of interest has been incorporated 
into the host cell genome. Cultures were centrifuged at 500 g for 10 m at RT (Beckman Allegra X-12R 
centrifuge with a SX4750 rotor). Pellets were incubated at RT with SDS (1% [w/v]) and samples were 
analysed by SDS-PAGE gel electrophoresis and Western blotting. 
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Buffer Contents 
A1 50 mM Tris-HCl pH 7.5, 250 mM NaCl 
A2 50 mM Tris-HCl pH 8, 150 mM NaCl 
B1 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 500 mM imidazole 
TGS 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS 
Table 2.4 Buffers. 
2.4 Biophysical techniques 
2.4.1 X-ray crystallography 
2.4.1.1 Crystal screening 
Commercial screens were used initially to find conditions that supported crystal growth. Various screens 
were used including JCSG+ (Molecular Dimensions), PEGS (Qiagen) and Morpheus (Molecular 
Dimensions and dispensed by MRC Reagents and Services, University of Dundee). JCSG+ and PEGS are 
examples of sparse matrix screens, which sample conditions used previously to crystallise proteins. 
These conditions have been followed up and verified (154). The Morpheus screen is based on commonly 
ordered ligands from structures deposited in the PDB, these are then used as additives (155). Fresh 
protein preparations of AcAChBP and GBP were concentrated immediately before use. To form co-
crystals, ligand (5-10 mM) was incubated with the protein (1-8 mg mL-1) for at least 30 m at 4 °C, before 
plate setup. N-methylbicuculline and small molecules identified from the NMR screen were utilised in 
these studies. MRC 1, 2 and 3 drop plates (Molecular Dimensions) were used for the screens. Reservoirs 
(50 µL) were either pipetted by hand or using a Matrix Hydra (Thermo Scientific) microdispenser. 
Protein (100 nL) and reservoir (100 nL) drops were pipetted by either a Phoenix DT (ARI) or Mosquito 
Xtal3 (TTP LabTech) crystallisation robots. Plates were sealed with clear adhesive covers (Molecular 
Dimensions) and stored at RT. Plates were checked every few days for crystal growth. 
2.4.1.2 Optimisation of conditions for crystal growth 
Screening identified conditions that supported crystal growth. Optimisation of these conditions by 
variation of different parameters including pH, temperature and composition of the drops led to the 
formation of better crystals. Reservoir solutions were made in-house and pipetted into plates (24-well, 
VDX with sealant, Hampton) by a Scorpion (ARI) robot. Drops were pipetted by hand, further varying the 
composition of the drops (protein:reservoir: 1:1, 2:1, 1:2). Again, plates were incubated at RT and 
checked regularly for crystal growth. In some cases, drops were seeded with crushed crystals. Seeding 
provides a nucleation site for crystal formation, which could initiate or speed up crystal growth (156). 
2.4.1.3 Data collection and processing 
Co-crystallisation proved most useful to generate samples of protein-ligand complexes for analyses, 
resulting in crystals that diffracted to a higher resolution, compared to soaking. In other cases, apo 
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protein crystals were grown and ligands were soaked in, to increase throughput. Trials of the most 
suitable ligand concentration were conducted. Crystals were taken out of drops using crystallisation 
loops, cryo-protected before being plunged into liquid nitrogen to freeze. Generally, cryo-protectants 
were utilised, these included paratone N and mother liquor with the addition of glycerol. Diffraction 
data were collected in-house on a rotating anode generator (Rigaku M007HF generator with Varimax 
Cu-VHF optics, Saturn 944HG+ CCD detector and AFC-11 4-axis partial χ goniometer), or from 
synchrotrons (Diamond Light Source, European Synchrotron Radiation Facility and Synchrotron Soleil). 
Data were indexed and integrated with Mosflm (157) or XDS (158), then merged and scaled with Aimless 
(159). Sometimes the data were automatically processed using the AutoPROC (160) or DIALS (161) 
pipelines. The Matthews coefficient to estimate solvent content and the potential number of subunits 
in the asymmetric unit was determined using RuppWeb (162,163). The structures were solved by 
molecular replacement with Phaser (164), exploiting previously determined structures. All the 
software, unless otherwise stated, is available from the CCP4 suite (165). 
 
2.4.1.4 Refinement 
Various structures have been refined and two of these are reported in this thesis, GBP:N-
methylbicuculline and AcAChBP:N-methylbicuculline. Structures were refined using Coot (166) and 
Refmac5 (167). Refmac uses prior chemical knowledge of bond lengths and angles, among other 
parameters to refine and restrain protein structures and B-factors. Various weighting schemes were 
utilised throughout the refinement. These schemes define how stringent the restraints are. In the 
graphic program Coot, the electron density (2FO-FC) and difference density (FO-FC) maps were visualised, 
where FO are the observed structure factors and FC are the calculated structure factors. The 2FO-FC map 
shows the electron density to which each residue of the protein should fit. The FO-FC map shows the 
difference density, which is a guide to where electrons (or atoms) should be added or removed. Due to 
the pentameric quaternary structure of AChBP, non-crystallographic symmetry (NCS) restraints were 
applied initially. Firstly, the backbone was investigated and any residues that did not fit into the density 
were deleted and where possible remodelled. Attempts to extend the model into unoccupied density 
were carried out, using knowledge of the protein and crystallisation conditions, for example, the 
presence of glycosylation, ligands and ions. Geometrical restraints for ligands were generated by the 
Grade server (grade.globalphasing.org). The dictionary and cif file generated were used to model ligands 
in Coot. Ions, glycosylation and ligands were modelled into density considering the surrounding chemical 
environment and restraints. Water molecules were introduced when only small features were left in the 
density, considering the peak height, shape and proximity to polar groups using hydrogen bonding 
distance criteria of 2.5-3.5 Å. When differences between the chains became apparent the NCS restraints 
were removed. Ramachandran outliers, indication that different rotamers might be present, density fit 
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and geometric analyses were used to inform decision making during the refinement process. B-factors 
are an indicator of the degree of flexibility and error of an atomic position in the model (168). Therefore, 
these were also monitored as a guide to infer if areas of the structures required attention. Each round 
of map and model inspection with Coot were followed by cycles of refinement with Refmac, with 
monitoring of the Rfactor and Rfree values. The refinement process was stopped when no further 
improvements to model geometry could be made, when the difference between the initial and modified 
Rfactor/Rfree values did not change significantly and when there were no significant features left in the 
difference density maps. All structural figures were prepared using PyMol and annotated in Microsoft 
PowerPoint. For the table of crystallographic statistics see Appendix A. 
 
2.4.2 Tryptophan fluorescence quenching assay 
Protein samples (10 µg mL-1, 2 mL) were prepared in buffer A1 (Table 2.4), along with stock solutions of 
the ligand to be tested. The ligand stocks were made at 2000x the final concentration so that 1 µL could 
be added to the protein solution and this would not cause drastic dilution effects. Experiments were 
run on an LS55 PerkinElmer spectrophotometer, using FL WinLab 4.00.03 software. The detector 
sensitivity was set to 750 V, exciting the sample at 280 nm and measuring emissions between 300-400 
nm with slit widths of 5 nm. Blanks of water and buffer were first run before every experiment to check 
background fluorescence. An initial check of intrinsic ligand fluorescence was also conducted at the 
highest ligand concentration. Protein samples were analysed to give a baseline fluorescence before 
additions of ligand were made. After each addition, the solution was mixed and reanalysed. 
Experiments were stopped when no change in absorbance was observed. The maximum absorbance 
for the initial protein was taken, then each titration point was measured at this wavelength (335-339 
nm). Control experiments (buffer with the same concentration of DMSO into protein) were deducted 
and the percentage change was calculated in Microsoft Excel. Percentage change measurements were 
input into GraphPad Prism 7, for plotting and calculation of KD using a non-linear regression model for 
ligand binding. 
 
Protein Ligand Stock concentrations 
(mM) 
Number of additions 
AcAChBP (-)-Nicotine 0.2, 1, 4 5, 3, 4 
AcAChBP (+/-)-Anatoxin 0.2, 1, 4 5, 3, 4 
AcAChBP (+/-)-Anatabine 4, 12 10, 10 
AcAChBP (-)-Hosieine 0.05, 0.2 8, 8 
AcAChBP Strychnine 0.2 18 
AcAChBP N-methylbicuculline 1, 2 10, 5 
AcAChBP 1d 50, 100 8, 6 
GBP Strychnine 20 20 
GBP N-methylbicuculline 4, 8 10, 5 
GBP 1d 50, 100 8, 6 
GBP 3b 200 10 
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Table 2.5 WF experimental conditions. Concentrations and additions of various ligands used in 
tryptophan fluorescence quenching assays and the relevant target protein. 
 
2.4.3 Isothermal titration calorimetry 
ITC was used to investigate AcAChBP and GBP interactions with selected ligands. Experiments were 
conducted on a Malvern MicroCal PEAQ-ITC instrument at 25 °C, using the manufacturer’s software. 
Buffer A1 was made fresh, filtered and degassed before making up stocks. Table 2.6 provides selected 
experimental conditions. Protein samples (350 µL) were made up in excess to allow for syringe error and 
to remove air in the chamber. Ligand stocks (500 µL) were made up in buffer A1, in excess to allow for 
pipetting error, and so that the same concentration of ligand was used in each follow up ITC experiment. 
Both protein and ligand samples were left at RT to equilibrate. The sample chamber and the syringe were 
washed with detergent and water, then the syringe was rinsed with methanol before each experiment. 
A protein sample (300 µL) was loaded into the cell, making sure to displace the air and not introduce 
bubbles, which can cause artefacts in the ITC traces. Ligand (100 µL) was pipetted into a micro-
eppendorf, then the instrument loaded this into the syringe, making sure to remove air bubbles. The 
reference was set to 10 µcal s-1, stir speed was set to 750 rpm, then the concentration of protein, 
concentration of ligand, number of injections, volume of each injection and spacing was set, depending 
on the experiment. Appropriate control experiments (buffer-buffer, buffer-protein and ligand-buffer) 
were carried out. The parameters KA, N and ΔH were measured, then the KD, change in Gibbs free 
energy (ΔG) and change in entropy (ΔS) were calculated. Mean data and standard errors are reported 
(n=3). 
The change in heat energy (ΔQ) is shown as the area above/below the peaks, in the raw titration 
isotherm. In the software this energy is adjusted for moles of injectant, giving a ΔH value, in kcal mol-1. 
The concentrations of ligand and protein per injection are also calculated, with knowledge of the exact 
cell volume and user set parameters. This considers dilution effects per injection. The molar ratio of 
ligand to protein is then calculated, per injection. The binding graph plots ΔH against the molar ratio, 
then the binding curve is modelled for the data, depending on the model selected (169). 
 








AcAChBP 25 (-)-Nicotine 250 18 2 180 
AcAChBP 25 (+/-)-Anatoxin 125 18 2 180 
AcAChBP 25 (+/-)-Anatabine 350 18 2 180 
AcAChBP 25 (-)-Hosieine 150 19 2 150 
AcAChBP 10 Strychnine 100 18 2 180 
AcAChBP 40 N-methylbicuculline 2000 13 3 180 
GBP 25 Strychnine 500 18 2 180 
GBP 40 N-methylbicuculline 2000 13 3 180 
Chapter 2 
30 | P a g e 
 
 
Table 2.6 ITC experimental conditions, ligand and protein concentrations used in experiments. 
 
2.4.4 Surface plasmon resonance 
SPR was used to investigate the association of AcAChBP with (-)-nicotine, (+/-)-anatoxin and (+/-)- 
anatabine. Experiments were conducted on a Biacore T100 with T200 sensitivity upgrade and analysis 
software (GE Healthcare). A sensor chip (Ni-NTA series S, GE Healthcare) was loaded into the instrument 
and equilibrated with water then buffer A1. The chip was prepared by washing it with EDTA, buffer A1, 
NiCl2 and buffer A1 again, then NHS (N-hydroxysuccinimide) and EDC (1-ethyl-3-(3- 
dimethylaminopropyl)carbodiimide hydrochloride) were mixed to prepare the sensor surface to further 
immobilise the protein and prevent drift during the experiment. NHS and EDC are used for the 
secondary coupling of protein to the sensor chip surface. AcAChBP was loaded onto channel two and 
GBP was loaded onto channel four reaching a response level of 3,500 RU. Starting stocks of ligands were 
prepared in a 96 well plate then a two- or three-fold serial dilution was applied to give eight 
concentrations. Buffer A1 was also pipetted into some wells for start-up blank controls. DMSO (50% 
[v/v]) was used to remove the chance of ligand transfer between concentrations. If a ligand is observed 
as transferring after washing in DMSO it is classified as ‘sticky’, therefore may affect the interpretation 
of the results. To remove the need for a solvent correction, buffer A1 was supplemented with DMSO to 
the same concentration as in the 96 well plate. Sensorgrams were produced showing the effect of each 
concentration on the response over time. The end of each trace was taken to be steady-state 
equilibrium and recorded. These measurements were then plotted on a graph of response versus 
concentration and a curve of best fit was modelled. The KD was read as half of the Rmax. Due to the 
speed of association and dissociation, the kinetics of each binding event could not be measured. 
Further optimisation was underway to resolve these parameters, but due to time constraints, this was 
not completed. 
Detection, in Biacore instruments, of ligand binding is via the SPR/resonance angle alteration. This 
change is converted into response units and is correlated with increasing ligand concentration. A raw 
sensorgram shows 1) the association curve, when molecules are binding to the protein continuously, 2) 
steady-state equilibrium when the association and dissociation rates are equal and 3) the dissociation 
curve, the removal of the ligand from the protein until the baseline is reached (170). For some 
molecules, the rate of association and dissociation are so fast that curves cannot be seen. In these 
instances, only steady-state equilibrium can be measured and the affinity calculated. The response at 
steady-state is measured and plotted against concentration, then a binding curve is modelled (171). 
The affinity is calculated for steady-state equilibrium, by the following equations. 
Eq. 2.1 Req = C Rmax/KD + C, when C = KD, Req = Rmax/2 
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Protein Ligand Stock [Ligand] 
(µM) 
Dilution factor Number of 
dilutions 
AcAChBP (-)-Nicotine 30 3 8 
AcAChBP (+/-)-Anatoxin 60 3 8 
AcAChBP (+/-)-Anatabine 100 3 8 
Table 2.7 SPR experimental conditions. Stock ligand concentrations and dilutions for experiments. 
 
2.4.5 Nano differential scanning fluorimetry 
For analysis of AcAChBP and GBP, solutions of protein (0.5 mg mL-1, 20 µL) were diluted in buffer A1 and 
loaded into capillaries. The capillaries were then placed on the sample tray of the NanoTemper Tycho 
NT.6. The instrument checked for the presence of capillaries, calculated initial ratios and ramped the 
machine to the starting temperature of 35 °C. The fluorescence was monitored as the temperature 
increases from 35-95 °C, at a ramp rate of 30 °C m-1. Upon protein unfolding, a sharp increase in 
fluorescence was observed, which eventually plateaus. The inflection temperature was measured at 50% 
of the fluorescence increase. For GBP, a Ti of ~89 °C should be reached. For AcAChBP, a Ti should not be 
measured as it is greater than 95 °C, above the detection threshold of the instrument. Predicted values 
have been determined by previous nanoDSF and DSF experiments. 
DMSO is used as a solvent for many of the ligands being studied. Since this molecule is known to 
complicate ligand binding studies, due to action as a chaotropic agent (172), the influence of DMSO on 
GBP stability was investigated. Various solutions (20 µL) of GBP (0.5 mg mL-1) and a range of DMSO 
concentrations (0-10%) were set up. Screening identified that a DMSO concentration above 3% had a 
negative impact on GBP stability. A time course of 0-45 m, using 2% DMSO saw no change in protein 
stability. Therefore, in subsequent experiments the conditions were controlled to remain within this 
limit. 
 
Figure 2.3 Effect of DMSO concentration (%) on GBP stability. Stability measured by a decreasing 
inflection temperature (Ti) by nanoDSF on a NanoTemper Tycho. The starting Ti for GBP is 89.1 °C and 
the low [DMSO] does not affect this dramatically. After 2% DMSO, the protein starts to destabilise, until 
10% where a change of 1.2 °C is observed. A change of 0.5 °C is considered significant for this technique 
(173). 
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2.4.6 Biolayer interferometry 
AcAChBP or GBP samples (0.5 mg mL-1, 300 µL) were set up in a 96 well plate with two wells of buffer 
(300 µL). The number of sensors used determines how many rows of protein and buffer are needed (an 
example is shown in Figure 2.4). Ligand stock solutions (400 µL) were made up and aliquoted into the 
end well of a fresh 96 well plate. A serial dilution series, over the previous five wells, was conducted. 
Each dilution was into buffer A1. The first six wells were filled with buffer A1 (300 µL), an example is 
shown in Figure 2.4. Biosensors (Ni-NTA, Fortebio) were incubated in buffer A1 for 10 m. 
Figure 2.4 Example setup for BLI. A) The setup of the reagent plate for protein loading. Protein (orange, 
0.5 mg mL-1, 300 µL) and buffer A (blue, 300 µL) is pipetted into each labelled well. B) The setup of the 
sample plate for ligand binding. Buffer A (blue, 200 µL) is pipetted into the appropriate wells. The highest 
concentration of ligand (green) is made and pipetted into the last well (300 µL). For a 1 in 3 dilution, 
buffer A (200 µL) is pipetted into the other ligand wells (green), then 100 µL is transferred from the 
highest concentration into the next well and mixed. This is continued for the remaining four wells. 
Repeats are conducted in the other rows, three per ligand. 
An Octet red (ForteBio) instrument was used. The sensors in buffer, the sample plate (ligands) and 
reagent plate (protein) were loaded and the temperature set to 25 °C. For protein loading, steps of 
baseline (60 s) in buffer, loading (600 s) in protein solutions and wash (600 s) in buffer were conducted. 
For the ligand binding assay, steps of baseline (60 s) in buffer, association (120 s) in ligand solution and 
dissociation (120 s) in buffer were included. The sensors started at the lowest ligand concentration and 
worked up to the highest concentration. The raw traces were analysed to remove artefacts before 
subtraction of control data. Controls were two-fold, baseline into buffer and non-specific binding to 
another protein (TEV protease), either both or the former controls were used. The data were then 
processed using a global fit method and 1:1 interaction modelling. 
 
2.4.7 Nuclear magnetic resonance 
For the NMR screen, GBP and AcAChBP (500 μL, 10 μM) in buffer A1 supplemented with D2O (10% [v/v]) 
for locking, were used. All NMR experiments were performed on a Bruker AVANCE III HD spectrometer 
operating at 500 MHz and fitted with a quadruple resonance cryo-inverse probe (QCIP). A predetermined 
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cocktail of 9-10 chemical species was added to the protein solutions; a total of 435 compounds. 19F 
spectra were acquired in attempts to detect ligand binding. Strychnine (0.5 mM) was added in DMSO to 
the protein solution to displace bound ligands. 19F spectra were reacquired. Spectra were analysed with 
TopSpin 4.0.1 (Bruker). Analysis of the two spectra led to the identification of potential ligands. 
 
2.4.8 Differential scanning fluorimetry 
Measurements on AcAChBP and GBP were conducted on a Stratagene MX3005P QPCR machine 
(Agilent). Master solutions of protein (10 µM), Sypro orange dye (1:1000) and the ligand (varying 
concentrations) were made up. Samples (40 µL) were run in triplicate, with negative (no protein) and 
positive (protein but no ligand) controls. Data were collected utilising a Sypro appropriate filter 
(excitation: 490 nm, emission: 610 nm). The data were then analysed with Stratagene software, 
Microsoft Excel and GraphPad Prism 7. 
 
2.5 Computational tools 
2.5.1 AreaImol 
The software is available through the CCP4 suite and was used for solvent accessible surface area (SASA) 
calculations. The structure files AcAChBP:(-)-nicotine (PDB code: 5O87), AcAChBP:(+)-anatoxin (PDB 
code: 6SH0), AcAChBP:(-)-hosieine (PDB code: 6SGV), AcAChBP:strychnine (PDB code: 5O8T), 
GBP:strychnine (PDB code: 5OBG), GBP:N-methybicuculline (PDB code: 5OBH) were downloaded from 
the PDB and inspected in Coot. AreaImol (174) was utilised to calculate the total SASA of the ligand in 
isolation and remaining SASA after binding. From this the percentage SASA lost upon binding was 
calculated. Due to the pentameric nature of the proteins, 5-10 copies of the ligand were utilised in 
calculations then the mean and standard error were reported. 
 
2.5.2 Molsoft ICM 
Molsoft ICM-Pro + VLS (v3.8-4a) (175,176) was used for docking simulations of various ligands. Structure 
files from the PDB were used and the core components of a single orthosteric binding pocket were 
isolated. PDB structural complexes used were: AcAChBP:(-)-nicotine (PDB code: 5O87), AcAChBP:(+)- 
anatoxin (PDB code: 6SH0), AcAChBP:strychnine (PDB code: 5O8T), AcAChBP:apo (PDB code: 2Y7Y), 
GBP:glycine (PDB code: 5OAN), GBP:strychnine (PDB code: 5OBG) and GBP:N-methylbicuculline (PDB 
code: 5OBH). In most cases, two interacting chains of the protein, the ligand and key water molecules 
were kept. The PDB file was converted into an ICM object. Ligands were moved out of the binding site 
so pockets could be identified using the 3D predict ICM Pocket Finder. The pockets identified were the 
orthosteric binding site defined by the aromatic cage. Using the protein object (with any key water 
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molecules present) and the previously identified pocket for the orthosteric binding site, receptor maps 
were generated. These are required for the docking of molecules to the binding site. Definition of key 
binding residues, the addition of hydrogen atoms, where possible, and calculation of charges were 
conducted. In the docking simulation, the receptor is treated as a rigid object, whereas the ligand is 
allowed to be flexible. The docking software screens all the potential conformations of a ligand and 
selects the most favourable, in terms of energy. These conformations are then docked to the pocket, 
ranked and the lowest energy conformation is reported. Ligands and libraries were screened against 
the pocket. For screening, the Maybridge “Ro3 fragment diversity set” of 2,000 compounds was 
downloaded (maybridge.com). The docking effort for single ligands and small sets (from NMR 
screening) was set to 10, however, this was decreased to 3 for docking of the Maybridge set. The 
thoroughness is the length of the simulation run and a setting of 1 is recommended for most scenarios 
(177). The use of a higher thoroughness means that the final docked conformation is more likely to be 
correct. Racemic sampling was conducted for compounds where appropriate. 
 
Parameter Description 
ICM score The ranking for a compound depending on how well it is predicted to bind; the lower 
the score the better 
VLS score Similar to the ICM score but accounts for the energy of ligand strain 
Hbond Predicted hydrogen bonding energy 
Hphob Predicted hydrophobic energy using the solvent accessible surface area 
VDW Predicted van der Waals energy, which considers interactions (including repulsion) 
of atoms over distance 
RotB Number of rotatable bonds 
Dsolv Predicted energy for the desolvation of hydrogen bond donors and acceptors 
Table 2.8 ICM parameters and descriptions. 
 
Important parameters reported from the docking simulation are shown in Table 2.8 with brief 
descriptions. The docking software reports hydrogen bond distances as the separation between the 
hydrogen and the acceptor group. The ICM (Internal Coordinate Modelling) score takes into account 
various weighted terms including, internal torsion, van der Waals, electrostatics, hydrogen bonding and 
hydrophobic interactions (178). 
The 4D docking protocol was utilised to inform a decision as to which protein structures should be used 
to dock ligands and small molecules. 4D docking is used when conformational differences occur between 
different structures, for example, the closing of loop C in AcAChBP. The 4D protocol makes a stack of 
different structures, with alterations in the binding site. The software then makes maps for each and 
trials docking of the ligands into each member of the stack. In the output, the identity of the structure 
that each ligand binds to is highlighted. In the case of the molecules tested this was the same for all of 
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them, therefore a basic docking simulation was conducted. For GBP, the complex with strychnine (PDB 
code: 5OBG) was used, whereas for AcAChBP both the apo (PDB code: 2Y7Y) and nicotine complex (PDB 
code: 5O87) structures were utilised. 
Images were generated using Molsoft ICM then exported and edited in Microsoft PowerPoint. One key 
point to note is how hydrogen bonds are represented in Molsoft figures. Hydrogen bonds are shown as 
coloured spheres, the colour indicates the length, long to short (red-blue) and the size indicates the 
strength, strong-weak (thick-thin). 
When making alterations to the bound small molecules, for example when extending a molecule or 
testing if a group was necessary for binding, a different docking simulation was run. For trialling and 
removal of different groups, the specific chemical entity was changed and fitted into the pocket. This led 
to a virtual ligand screening (VLS) score, which rated if the change either improved binding or not. This 
new score was used as it also considered the effect of the additions on ligand strain. After selection of 
the relevant groups (Figure 2.5) and addition to the scaffold, the small molecules were redocked to the 
binding site. Different conformations of the modified molecule were calculated then a subset was 
screened against the pocket. Redocking was repeated until the VLS score did not change and a similar 
orientation of the compound was adopted. After these parameters had been met, the VLS score was 
recorded and compared to the original molecule. 
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Figure 2.5 Chemical groups extensions screen. The selection of chemical groups was screened when 
extending small molecule hits in Chapter 5. 
 
2.5.3 Ligplot 
The software (179) was downloaded from EMBL-EBI (https://www.ebi.ac.uk/thornton- 
srv/software/LigPlus/) and was used to make simplified interaction diagrams of structures from the PDB. 
 
2.5.4 BioRender 




2.6 Confocal microscopy 
GFP constructs were prepared and produced in insect cells, as detailed previously. Test and control 
cultures were set up. Samples were taken from cultures at 24 h time points. The samples were 
centrifuged at 1,000 g for 10 m at 4 °C (Beckman Allegra X-12R centrifuge with a SX4750 rotor) and the 
supernatant was discarded. Pellets were kept at 4 °C until they were required. Samples were 
resuspended in PBS and then imaged on a Zeiss LSM880 confocal microscope using the x63 Pan 
Apochromat objective (NA 1.4) by Dr. Alan Prescott (Microscopy Unit, University of Dundee). Excitation 
was with a 488 laser and emission collected from 493-598 nm. 
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3. Assessment of three biophysical techniques used for screening 
potential ligands for pLGICs 
 
3.1 Introduction 
A ligand screening campaign can serve two purposes. Firstly, it may detect binders and rule out non- 
binders. Secondly, it can be utilised to estimate affinity, so that follow up compounds can be prioritised 
for further study. The affinity of a compound for a target can be defined by the dissociation equilibrium 
constant (KD). The constant represents the ratio between unbound and bound protein and ligand, when 
equilibrium is reached, in terms of concentration (180). Here, KD will be utilised to assess three 
biophysical techniques: WF, ITC and SPR. The viability of the techniques to screen and characterise ligand 
binding with the pLGIC surrogates, AcAChBP and GBP, will be evaluated to identify new chemical matter 
that can modulate these receptors. 
The above techniques employ the measurement of different physical properties to study and quantify 
ligand binding. Excited electrons returning to a low energy state can emit fluorescence and this can be 
pronounced for the aromatic acid tryptophan (112,113,181). In our target proteins, a key tryptophan in 
the binding site should directly interact with ligands, resulting in a change to the environment of the Trp 
electronic structure, which can change the fluorescence associated with an electronic transition. Tyr and 
Phe residues also make a small contribution to the overall fluorescence signal (182). The physical 
property measured is a change in fluorescence parameters upon ligand binding (112,113,181).  
In an ITC experiment two cells, one containing the sample and one a standard, are maintained at a 
constant temperature. The energy used to maintain the constant temperature is measured. When a 
ligand binds to a protein, in the sample cell, it generally results in either an exothermic or endothermic 
interaction and so causes a change in the temperature of the chamber. The change in power required to 
maintain a constant temperature in the cell is recorded. This change is proportional to the enthalpy 
change when the ligand binds to the protein. From this, the KD, as well as a full thermodynamic profile of 
binding can be determined (120,183,184).  
SPR measures the change in light wavelength or reflection angle, dependent on the instrument used. A 
change in either is caused by a physical property of the metal sensor surface, known as surface plasmon 
resonance. The outer electrons of the metal surface interact with the photons of light and are excited,  
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turning into surface plasmons. These electrons are sensitive to their environment, therefore a change in 
density on the chip surface can alter the local index of refraction, which changes the resonance 




3.2 Data from three biophysical assays 
Three compounds: (-)-nicotine, (+)-anatoxin and (-)-anatabine are ligands of the nAChR that elicit a 
physiological response. Nicotine is present in cigarettes and linked to addiction by the modulation of 
nAChR (186). The (-)-enantiomer is the predominant naturally occurring and active form. Anatabine is a 
minor alkaloid present in tobacco with the (-)-enantiomer being the prevalent form (187). Anatoxin is a 
potent neurotoxin, which is produced by algae, its alternative name is ‘rapid death factor’ (188). The 
AcAChBP surrogate provides a small, extremely stable platform to test the binding of some nicotinic 
receptor ligands (for more detail, see Chapter 1.1.3) (34). The stability of AcAChBP has been assessed 
previously using DSF and nanoDSF with a Tm/Ti >95 °C, above the threshold of the instruments used. The 
methods described above were used to investigate the binding of these three ligands to AcAChBP. 
The relevant enantiomer (-)-nicotine was used, however, the commercially available anatoxin and 
anatabine samples are mixtures. Docking simulations suggest that both enantiomers of nicotine should 
bind similarly (ICM scores -26.3 to -28.5), however, (-)-nicotine is produced in excess naturally (187). 
Various techniques are available for separation of mixtures, for instance, high-performance liquid 
chromatography (HPLC) (189). However, trying to separate the enantiomers requires extensive 
optimisation of chiral selectors, column type, temperature and solvent contents (190,191). The use of 
racemic mixtures can be a problem when deducing the affinity of a compound for a target. This is because 
both enantiomers have the opportunity to interact with the protein, therefore contributing to or 
interfering with the parameters deduced. The extent to which they would interfere is dependent on their 
concentration and relative affinities. 
A 50:50 mixture was present for (+/-)-anatoxin. Previous data suggest that the naturally occurring 
enantiomer, (+)-anatoxin is more active (Ki 0.09 µM with nAChR α7) than the (-)-enantiomer (Ki 21 µM 
with nAChR α7) (192,193). To investigate this further both enantiomers were docked to the AcAChBP:(+)- 
anatoxin structure (PDB code: 6SH0). Docking simulations showed both enantiomers occupy a similar 
position in the binding pocket (Figure 3.1). However, the secondary amine is positioned differently (2 Å 
difference between the nitrogen atoms). The two predicted parameters, hydrogen bonding (-3.6 to           
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-4.2 kcal mol-1) and hydrophobic interaction (-4.4 kcal mol-1) energies are similar between the two 
enantiomers. Nonetheless, due to the change in position of the amine group, the van der Waals energy 
for (+)-anatoxin (-24.9 kcal mol-1) is improved by 3.7 kcal mol-1 relative to (-)-anatoxin (-21.2 kcal mol-1). 
Similarly, there is also a difference with the ICM scores with (+)-anatoxin scoring better (-28.3) than (-)-
anatoxin (-24.6). A difference in energy and score may have occurred owing to the π-cation interaction 
that (+)-anatoxin makes with W164, which does not occur for (-)-anatoxin. Therefore, as noted in Table 
3.1 and Figure 3.2-3.4 legends, the concentration for one enantiomer was used in analyses for (+)-
anatoxin dependent experiments. 
We assume that the commercial (+/-)-anatabine is a 50:50 enantiomeric mixture. Both enantiomers have 
similar potency (EC50 values) with the nAChR α7 receptor, 50 µM for (+) and 70 µM for (-) (194). The 
separation of enantiomers was carried out by chiral-phase HPLC (194). Again, both enantiomers were 
docked to investigate if there were any differences in binding (Figure 3.1). These compounds were docked 
to the AcAChBP:nicotine structure (75) due to chemical similarities between the ligands. There is minimal 
variation between the ICM scores (-22.5 to -25.4) and the three theoretical interaction energies, hydrogen 
bonding (-3.1 to -4.0 kcal mol-1), hydrophobic (-4.6 kcal mol-1) and van der Waals (-22.1 to -22.6 kcal   
mol-1). The pyridine ring of (+)- and (-)-anatabine occupy identical positions forming a hydrogen bond 
with an important binding site water molecule that will be discussed later (Chapter 3.4.2). The 
secondary amine occupies a different position in the two forms, therefore the hydrogen atoms are also 
shifted (0.7 Å difference between the nitrogen atoms). Due to this difference, the (-)-enantiomer is 
predicted to make a main chain (MC) hydrogen bond with W164, which is not present for the (+)-
enantiomer. The (+)-enantiomer may form other weaker hydrogen bonds which could make up for 
this loss of interaction. For the purpose of this study it was considered that both enantiomers may 
interact with AcAChBP similarly, therefore a single concentration for both (+/-) was used in experiments. 
 
Table 3.1 Binding data for the interaction of AcAChBP with three ligands, (-)-nicotine, (+)-anatoxin and 
(+/-)-anatabine. Mean thermodynamic parameters are derived from ITC as well as dissociation constants: 
KD1 from ITC, KD2 determined from fluorescence measurements, KD3 from SPR. The standard error for each 
measurement is given (n=3). (+/-)-Anatoxin has a more active (+)-enantiomer determined from literature 
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data and comparison of the binding pose in docking simulations. Therefore, the concentration of the (+)- 
enantiomer was assumed at 50% of the mixture. (+/-)-Anatabine, is a mixture of two enantiomers with 
similar binding affinities, therefore the individual KD values cannot be determined. The KD values for this 





Figure 3.1 Models of both enantiomers of three ligands of interest bound to AcAChBP. Parts of the protein 
backbone are shown as ribbons (light grey), important residues as sticks (grey), water molecules as 
spheres (red) and ligands as thick sticks (silver). Different atoms are coloured: oxygen (red), nitrogen 
(blue), sulfur (yellow) and hydrogen (white). Hydrogen bonding is shown (spheres), the colour represents 
long to short bond lengths (red-blue) and the sphere size shows strong to weak bonds (thick-thin). 
Residues are labelled in black and hydrogen bonds are labelled with their respective colours. The structure 
of each ligand is shown next to each image. (A) (+/-)-Nicotine docked into 5O87, (B) (+/-)-anatoxin docked 
into 6SH0 and (C) (+/-)-anatabine docked into 5O87. 
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Figure 3.2 Ligand binding to AcAChBP monitored by WF. Example traces obtained from titrations, 
starting with no ligand (blue) to maximum ligand concentration (cyan) and a plot of the mean 
percentage change versus concentration is shown for (-)-nicotine (A, B), (+)-anatoxin (C, D), and (+/-)-
anatabine (E, F). Standard error bars are behind each data point (n=3). Due to the (+)-anatoxin 
enantiomer being more active, the experimental concentration used accounts for this. (+/-)-Anatabine is 
a mixture of two enantiomers with similar affinities. 
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Figure 3.3 ITC data for AcAChBP binding various ligands. Example isotherms and curves with the best fit 
are shown for (-)-nicotine (A, B), (+)-anatoxin (C, D) and (+/-)-anatabine (E, F), respectively. In the 
examples, a baseline deduction has been applied. All data have had the relevant controls (buffer-buffer, 
buffer-AcAChBP, ligand-buffer) also deducted. Due to the (+)-anatoxin enantiomer being more active, the 







Figure 3.4 SPR data for AcAChBP binding selected ligands. A sensorgram from an example titration and curve of best fit are shown for (-)-nicotine 
(A, B), (+)-anatoxin (C, D) and (+/-)-anatabine (E, F), respectively. The response value was taken at steady state, at the end of each trace for each 
concentration. The colour of each point relates to the sensorgram traces. The vertical black line indicates the point at which the KD is measured. 
Due to the (+)-anatoxin enantiomer being more active, the experimental concentration used accounts for this. (+/-)-Anatabine is a mixture of two 
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3.3 Comparison of ligand affinity measured by different techniques 
To investigate the ligand affinities of the three compounds selected as chemical probes, a WF assay 
was first utilised. A protocol for the assay had been established in the laboratory by Dr. Alice Dawson. 
The use of fluorescence measurements to monitor ligand binding takes advantage of a key residue 
(W164) in the binding site (for more detail, see Chapter 1.3.2 and 2.4.2). All compounds were initially 
tested for intrinsic fluorescence before a quenching assay was performed. (-)-Nicotine, an archetypal 
ligand of nAChRs, gave a KD value of 0.41 ± 0.01 µM with AcAChBP (Table 3.1). This value is consistent 
with others in the literature (KD 0.25 µM by WF and 0.05 µM by ITC, (35,66)). Differences between the 
literature and measured values could have occurred due to differences in experimental setup for 
example buffers or equipment used to measure the fluorescent signal. (+)-Anatoxin gave a comparable 
KD (0.20 ± 0.01 µM), reflecting its high affinity for the family of receptors (193). However, with less 
research conducted on this molecule, there are no literature values for comparison with AcAChBP. 
Nonetheless, there is a KD for the interaction with Torpedo nAChR of 0.1-0.2 µM measured by 
competitive inhibition assays, which is comparable (195). For (+/-)-anatabine, a lower affinity value was 
observed (8.5 ± 0.2 µM), again no literature KD values are available for direct comparison. Other 
literature parameters will be discussed later (Chapter 3.6). 
To elucidate the different KD values for enantiomers present in a mixture, which could have given a 
combined affinity in tryptophan fluorescence, ITC was conducted. Fokkens and Klebe demonstrated 
that determination of individual enantiomeric binding affinity by ITC was possible for mixtures before 
resolution (196). This technique has also been used to calculate the affinity of different enantiomeric 
mixtures of serine protease inhibitors. For some examples two binding events could be seen, however, 
in other cases, it was more ambiguous. Plots from this example show two distinct binding curves if a 
racemic mixture can be separated (196). An optimal curve for such a mixture is shown in Figure 3.5. 
Data from ITC experiments gave comparable results when compared to WF. For (-)-nicotine, ITC gave a 
KD value of 2.3 ± 0.2 µM, compared to 0.41 ± 0.01 µM measured using the fluorescence-based assay. 
Similarly, a comparable value was measured by ITC for (+/-)-anatabine (3.4 ± 0.5 µM) compared to 8.5 ± 
0.2 µM by the fluorescence assay. The KD values for (+)-anatoxin are more similar, 0.30 ± 0.03 µM and 0.20 
± 0.01 µM by ITC and the fluorescence-based assay, respectively. Representative ITC binding curves for 
the three compounds are shown in Figure 3.3. An optimal curve is sigmoidal, giving information about 
the starting, mid and end-point of the protein-ligand interaction. The most comparable KD values were 
measured for (+)-anatoxin, which has an optimal sigmoidal curve. Despite efforts to optimise ITC 
measurements of the other two ligands, an ideal sigmoidal curve could not be achieved which may 
contribute to variations between WF and ITC data, however, the data are of sufficient quality to draw 
conclusions. 
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Figure 3.5 Optimal ITC binding curve for an enantiomeric mixture. The curve is plotted on axes of change 
of enthalpy against molar ratio. Two sigmoidal curves (red) are shown, one for each enantiomer. From 
each curve the thermodynamic parameters can be derived: change in enthalpy (ΔH, black), stoichiometry 
(N, blue) and affinity (KD, purple). 
The c value is a common reporter to whether an ITC experiment is reliable and if KD can be measured. It 
represents the ratio between the concentration of the protein/titrand and either the association (KA) or 
dissociation (KD) constant, depending on which form of the equation is used (Eq. 3.1). KA is derived 
from the ITC curve and is the inverse of KD (197,198). 
Eq. 3.1 c = KA [Titrand] = [Titrand] / KD 
 
There are a variety of recommendations to what an ideal c value should be. It should be in the range of 
1-1000 (169), but better ITC experiments are between 1-500 (199), with an ideal value of greater than 
40 (200). The c value was used as an indicator to aid optimisation of ITC experiments with the three 
ligands and AcAChBP. The c values for (-)-nicotine, (+)-anatoxin and (+/-)-anatabine are 11, 83 and 7, 
respectively using a protein concentration of 25 µM. All three values are within the ideal range, however, 
sigmoidal curves are not obtained for two ligands. 
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Figure 3.6 The effect of c in an ITC experiment. c has an effect on the formation of the binding curve. 
The curves are plotted on axes for change in enthalpy (ΔH) against molar ratio. The curves show the 
effect of increasing c value from low (c = 0.5, red) to medium (c = 5, orange) to an ideal value (c = 50, 
green). The c value is the ratio between the concentration of the protein and the dissociation constant 
(c = [Protein]/KD). 
Differences can be observed in the molar ratio determined for the three experiments (Figure 3.3). (+)- 
Anatoxin and (-)-nicotine have molar ratios close to one, whereas (+/-)-anatabine has a value above two. 
The molar ratio is determined by the concentration of ligand to protein in the sample cell. Therefore, 
binding site saturation may affect the formation of sigmoidal curves. Either binding sites are not 
saturated or are saturated too early. However, during optimisation problems were encountered when 
altering concentrations leading to decreased signal intensities, therefore no further improvement could 
be gained. 
Despite testing a range of protein and ligand concentrations to investigate the binding of (+/-)-anatoxin 
and (+/-)-anatabine, elucidation of the effect of different enantiomers was not achieved. This supports 
previous observations stated above for the two compounds. The active enantiomer, (+)-anatoxin could 
lead to the binding curve and parameters observed from the (+/-)-anatoxin mixture. Due to the 
concentrations used, the binding of (-)-anatoxin may not be sufficient to record a heat change. A higher 
concentration may not lead to the elucidation of a (-)-anatoxin binding curve as all the binding sites 
would be filled by the more favourable (+)-enantiomer. For (+/-)-anatabine, only one binding curve was 
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recorded. This supports the idea that the two enantiomers are of similar affinity, therefore the KD value 
will be an average. The ITC instrument used may not be able to detect the small differences between 
them. 
SPR was employed as a third method. Due to the size of the compounds, the signal from binding was 
low. This coupled with the speed of association and dissociation meant that values for kon and koff could 
not be measured. This finding is consistent with using SPR and other small molecules (108). The 
dissociation constant (9.1 ± 1.3 µM) for (+/-)-anatabine is consistent with WF (8.5 ± 0.2 µM) and 
comparable to the ITC result (3.4 ± 0.5 µM). Consistency is also observed with WF and ITC for (+)-anatoxin 
SPR data (0.12 ± 0.02 µM). SPR results for (-)-nicotine (0.8 ± 0.1 µM) agree more closely with the KD value 
from WF (0.41 ± 0.01 µM) than ITC (2.3 ± 0.2 µM). This corroboration of binding data further supports 
the idea that errors may be present in the ITC KD values derived from non-optimal titration curves. 
In summary, the data demonstrate that comparable values for the three techniques WF, ITC and SPR can 
be achieved. However, incomplete sigmoidal curves in the ITC experiments may have contributed to 
small KD discrepancies between techniques. For small molecule screening, SPR is commonly used for hit 
identification due to its sensitivity and high throughput (84,201,202). Our data suggest that tryptophan 
fluorescence could offer an equally effective alternative for this purpose, depending on instrumentation 
for throughput and if the ligands are not fluorescent. ITC requires a longer timeframe to get similar 
results, due to the need for extensive optimisation. Also, ITC requires a large amount of material to run 
each experiment in comparison with the other two techniques. Due to these considerations, ITC is 
generally utilised in drug discovery after hit selection in order to improve their properties through the 
extra information that can be derived (121,203). 
 
3.4 Thermodynamic parameters utilised to understand binding 
A problem just discussed is incomplete ITC binding curves. The optimum curve is sigmoidal, from which 
the appropriate information can be derived. The value for KD can be calculated from the gradient at the 
inflection point of the curve. Stoichiometry (N) is taken at half of the maximal response and is related to 
the molar ratio between ligand and protein. Change in enthalpy (ΔH) is measured from the bottom to 
the top of the curve (204). From these values, the change in Gibbs free energy (ΔG) can be calculated 
(Eq. 3.2). 
Eq. 3.2 ΔG = -RT ln KD 
 
The calculated change in Gibbs free energy value, change in enthalpy and the constant temperature of 
the assay, can be used to calculate the change in entropy by rearranging an alternate form of the Gibbs 
equation (ΔG = ΔH – TΔS). Therefore, from a single curve five parameters can be extracted, which 
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provides details on the binding. Estimation of some measurements can occur for incomplete curves, 
however, these predicted values can still be used to provide details of the interactions. 
 
3.4.1 The stoichiometry of ligand binding to AcAChBP 
The N value relates to how many molecules of a ligand are interacting with a protein entity. The 
simplest model is a 1:1 interaction. In the case of AcAChBP there are five binding sites and if each site 
acts independently of the others, a 1:1 model will describe the ratio of ligand to a subunit. The ITC data 
indicated that N is 0.5 for (+)-anatoxin consistent with 2-3 sites being occupied. Both (-)-nicotine and (+/-
)-anatabine have a lower N of 0.4, which suggests that less than half of the binding sites are occupied. 
The crystal structures of the AcAChBP:nicotine (75) and the AcAChBP:(+)-anatoxin complexes (PDB 
code: 6SH0) have all the orthosteric binding sites occupied with a single ligand. This discrepancy 
between the AcAChBP:(-)-nicotine crystal structure and the ITC data may be due to the high 
concentrations of ligand present in the crystallisation conditions, about 40x that of the ITC experiments 
(75). Similar to the data presented, Celie et al. showed that an N of 3 (ligand/pentamer) could be 
achieved for LsAChBP:nicotine ITC data (35). If this is taken per subunit a value of 0.6 is attained, which 
is consistent with the value measured (0.4). The reason why this is the case is still uncertain. 
 
3.4.2 Reasons behind the differences in change of enthalpy for AcAChBP ligands 
Firstly, the difference in enthalpy changes due to binding for the three ligands to AcAChBP will be 
considered. The value for ΔH comes from the energy released or utilised upon binding and is directly 
linked to what interactions are formed and/or disrupted, as well as changes in solvation. Enthalpy 
encompasses a more descriptive measurement, the heat of formation (ΔHf), this describes the energy 
to form or break a bond. For a ligand binding to a protein, ΔHf would describe the formation or 
breaking of an interaction (205). The energy of covalent bond formation, such as C-H, can be 
calculated; this is usually tens to hundreds of kcal mol-1. However, for non-covalent bonds or 
interactions, as in a protein-ligand complex, much weaker energies are involved. For an electrostatic 
interaction, the energy can be calculated by Coulomb’s law (Eq. 3.3). 
Eq. 3.3 E = k (q1 q2) / Dr 
 
For two equally but oppositely charged ions, electrostatic energies can range from 0-50 kcal mol-1, 
depending on the distance. Hydrogen bonding is a specific type of electrostatic interaction. Primarily, 
energies range from 1 to 3 kcal mol-1, dependent on distance. Van der Waals forces are caused by the 
movement of electrons in atoms generating dipoles, time-limited charges. Energies for this type of 
interaction are low (0.5-1 kcal mol-1), which range over their effective distance of 3-8 Å (206). 
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The binding of all three ligands to AcAChBP is an exothermic association. The largest ΔH value is observed 
for the interaction of AcAChBP and (-)-nicotine (-17.8 ± 0.9 kcal mol-1). A least-squares superposition of 
AcAChBP complexes with (-)-nicotine and (+)-anatoxin show they are similar. The key residues of the 
binding site occupy similar positions in both structures, as do the two chemical entities. Both compounds 
make π-cation interactions with W164. Due to the pKa values, 7.9 and 9.4 for nicotine and anatoxin 
respectively, a MC hydrogen bond is formed with W164 as well. A hydrogen bond is also between the N 
of the pyridine ring with a key, well-ordered water molecule. In both structures, these water molecules 
have low B-factors of 23-24 Å2. An ordered water molecule is consistently positioned here in AChBP 
complexes to donate a hydrogen bond to the ligand most notably in the LsAChBP:nicotine structure (35). 
In the AcAChBP complexes, the residues Y72, Y110, V125, M133, I135, W164, V165, Y205, C207, C208 
and Y212 make van der Waals interactions with the ligand, contributing to binding (Figure 3.1). The only 
notable difference between the (-)-nicotine and (+)-anatoxin complexes lies with the key water-
mediated hydrogen bond, previously mentioned. In the nicotine structure, this interaction links into a 
water-mediated hydrogen bond network through the protein, which will be highly stabilising, whereas 
the anatoxin structure lacks this hydrogen-bonding network throughout the protein. This may simply be 
due to the reduced resolution of the latter structure. (-)-Nicotine and (+)-anatoxin were docked into the 
binding sites of AcAChBP from the respective complexes (Figure 3.1) and a variety of binding interactions 
were predicted. Upon comparison, both compounds have similar hydrogen bonding and hydrophobic 
energies, however, the values for (-)-nicotine are better than for (+)-anatoxin. (+)-Anatoxin has a better 
predicted van der Waals interaction energy (-24.9 kcal mol-1) than (-)-nicotine (-23.5 kcal mol-1), 
however, this does not explain the difference in enthalpy change. The desolvation energy predicted 
details the energy required to remove waters upon binding of the molecule. For (-)-nicotine the value of 
5.6 kcal mol-1 is lower than that for (+)-anatoxin, 7.8 kcal mol-1, which suggests that nicotine can be more 
readily desolvated and may require less energy to bind. 
In the absence of an AcAChBP:anatabine structure, the (-)-ligand was docked into the binding pocket of 
the (-)-nicotine complex (Figure 3.1). The modelled protein-ligand interactions are similar and ICM 
scores of all three ligands are comparable with values between -29 to -25 (ranked (-)-nicotine, (+)- 
anatoxin and (-)-anatabine, respectively). However, the estimated van der Waals interaction energy     
(-22.6 kcal mol-1) is lower than for (-)-nicotine and (+)-anatoxin by 0.9 kcal mol-1 and 2.3 kcal mol-1, 
respectively. Also, the desolvation energy (7.3 kcal mol-1) is similar to (+)-anatoxin (7.8 kcal mol-1). These 
two factors may be contributing to differences in enthalpy change upon binding. 
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Table 3.2 Calculated parameters for computational docking of three AcAChBP ligands. The ligands (-)- 
nicotine and (-)-anatabine were docked into the AcAChBP:(-)-nicotine structure (PDB code: 5O87), 
whereas (+)-anatoxin was docked into the AcAChBP:(+)-anatoxin structure (PDB code: 6SH0). The ICM 
score indicates binding strength and the interaction energies for hydrogen bonding (Hbond), 
hydrophobic (Hphob), van der Waals (VDW) and desolvation (Dsolv) were predicted. 
The SASA of (-)-nicotine, and (+)-anatoxin in bound and unbound states were calculated to investigate 
any correlation with binding properties. As no crystal structure for anatabine is available the 
calculation could not be performed. (-)-Nicotine and (+)-anatoxin have unbound SASAs of 333 Å2 and 
321 Å2, respectively. There is already a difference in available surface to make contacts with the 
protein. This difference in surface area, 12 Å2, relates to a potential hydrophobic free energy of 0.3 kcal 
mol-1 (207). Upon binding of (-)-nicotine to AcAChBP there is a 59% (±0.2% SE) loss of SASA, compared 
to 56% (±0.2% SE) loss for (+)-anatoxin. If the solvent cannot access the surface of the ligand, this 
means that it is most likely buried in the protein and making contacts, therefore these data infer that 
nicotine has a greater area in contact with the protein. This indicates why the change in enthalpies may 
be different between the ligands. However, a 3% difference could also be caused by other factors 
including variation between binding pockets and ligand conformation/placement in the 
crystallographic structures. 
 
3.4.3 Entropy changes upon ligand interactions with AcAChBP 
Entropy is the measure of disorder in a system. In the context of macromolecular structures and 
interactions, this involves contributions from displacing water molecules, conformational changes, 
increased or reduced flexibility of ligands or protein residues. A positive value means that disorder is 
increased and this is more favourable as it leads to a spontaneous interaction (205,208). Table 3.1 shows 
the interaction between AcAChBP:(+/-)-anatabine has a negative entropy change value, in comparison 
to AcAChBP:(+)-anatoxin and AcAChBP:(-)-nicotine, which have a positive value. However, this value      
(-TΔS) is not the true entropy change (ΔS). The ΔS contributions of the compounds above are -0.03 ± 
0.003, -0.01 ± 0.001 and 0.01 ± 0.002 kcal mol-1 K-1, respectively for (-)-nicotine, (+)-anatoxin and (+/-)-
anatabine. (+/-)-Anatabine has a favourable binding entropy change, nonetheless, all of these values 
are small in comparison to enthalpy changes, and therefore have minimal effect on binding. 
Consequently, it can be concluded that the binding of these ligands appears to be enthalpy driven. 
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3.5 Widening the scope to other ligands of AcAChBP 
With robust assays in place, there was an opportunity to investigate other compounds that are potential 
ligands and to identify similarities or differences. Three further compounds were selected for study. 
Hosiene A, derived from the roots of Ormosia hosiei, is a highly potent agonist of nAChRs (209,210). As 
such this small molecule should also interact with AcAChBP. The two other compounds were strychnine, 
the archetypal ligand of GlyR, and N-methylbicuculline, an exemplary ligand of the GABAAR (Chapter 4). 
A new component was also brought forward for the study, the protein termed GBP, which is an 
engineered version of AcAChBP designed to mimic aspects of a heteromeric GlyR (Chapter 1.1.4). 
There is good agreement between the KD values for (-)-hosieine, strychnine and N-methylbicuculline 
(Table 3.3) for the techniques and proteins tested. The only outlier is N-methylbicuculline with GBP, 
however, the difference between WF and ITC may be due to a secondary non-specific interaction of N- 
methylbicuculline to the protein (N 2.3 sites). All three of these compounds also have a MW greater than 
300 Da, which is different from the small molecules previously discussed (Chapter 3.2) and may explain 
discrepancies when measuring binding and calculating affinity. 
 
Table 3.3 Binding data for the interaction of (-)-hosieine, strychnine and N-methylbicuculline. Mean 
thermodynamic parameters are given from ITC, as well as affinity values: KD1 from ITC and KD2 from the 
fluorescence-based assay. The parameters are for the interaction between AcAChBP or GBP and the 
ligands. The standard error for each measurement is given (n=3). The raw traces and graphs can be 
seen in Chapter 4 for strychnine and N-methylbicuculline and in Figure 3.7 for (-)-hosieine. 
 
One explanation to why these three compounds have a good agreement between ITC and WF data is 
that they are bigger (MW 230-367 Da) so may make more interactions (Figure 3.7), compared to (-)- 
nicotine and (+)-anatoxin. The structures for AcAChBP:(-)-hosieine (PDB code: 6SGV), 
AcAChBP:strychnine, GBP:strychnine (75) and GBP:N-methylbicuculline (211) complexes were available 
from the PDB. The percentage of SASA lost for each ligand was calculated using these structures. 
Comparing the starting SASA of (-)-hosieine (404 ± 0.3 Å2 [n=10]), strychnine (451 ± 0.4 Å2 for AcAChBP 
[n=5] and 451 ± 0.5 Å2 for GBP [n=4]) and N-methylbicuculline (527 ± 4.5 Å2 [n=5]) it can be observed 
that these compounds are larger than (-)-nicotine (333 Å2) and (+)-anatoxin (321 Å2). However, due to 
the difference in size, flexibility and binding pose of these compounds, there is a higher chance for their 
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Figure 3.7 (-)-Hosieine binding to AcAChBP data monitored by ITC (A, B) and WF (C, D). Graphs and traces 
are the same as those in Figure 3.2 and 3.4. Monitoring fluorescence both at constant and different 
wavelengths gave comparable KD values for WF. 
surface to not be in contact with the protein. This translates into lower values of percentage SASA lost 
upon binding (36-48%), in comparison with (-)-nicotine and (+)-anatoxin (56-59%). When accounting for 
the size of each compound and the SASA lost upon binding, all the compounds have a similar total 
contact area. Even though the total surface contact is similar for all the compounds, the number and 
strength of the interactions made by (-)-hosiene, strychnine and N-methylbicuculline may contribute 
towards better detection. For example, the binding of (-)-hosieine to AcAChBP closely resembles the 
orientation of (-)-nicotine, however, the number of potential hydrogen bonds increases from two to four 
and the number of residues that interact by van der Waals interactions is increased by three (Figure 3.8). 
 
 
3.6 Comparison with published data 
Comparison of the data previously reported in the literature may validate further the use of the three 
biophysical techniques for the characterisation of AcAChBP ligands. Unless stated otherwise data were 
extracted from CHEMBL (213). Due to the lack of KD values, other parameters calculated from different 
assays were utilised. These parameters include IC50, Ki and EC50 values. To calculate an IC50, a 
displacement assay is conducted on physiologically relevant cells, which produce the receptor of interest 
or using recombinant protein. In this type of assay a known ligand, normally radiolabelled, is in 
competition with the ligand of interest for the binding site. The effect of competing out the labelled 
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Figure 3.8 Schematic diagrams of ligand interactions with AcAChBP and GBP. (A) AcAChBP:(-)-nicotine, 
(B) AcAChBP:(-)-hosieine, (C) AcAChBP:strychnine and (D) GBP:N-methylbicuculline complexes. Ligands 
are shown in sticks with purple bonds, residues that participate in hydrogen bonding interactions are 
shown in sticks with orange bonds. Atoms are coloured: oxygen (red), nitrogen (blue) and carbon (black). 
Hydrogen bonds are shown as green dashed lines and atoms or residues that are involved in hydrophobic 
interactions are marked with red semi-circles. Water molecules appear as blue circles. The figures were 
made in LigPlus (212). 
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ligand is plotted against concentration (214). An IC50 is the concentration of an inhibitor where the 
response is reduced by half of the maximum. From this value, a Ki can then be calculated if the affinity 
of the labelled ligand is known (215). An EC50 is the effective concentration of a compound at half the 
maximal response (215). The EC50 is similar to IC50 and is dependent on the effect of the compound on 
the receptor. 
As the archetypal ligand of nAChR, (-)-nicotine has a lot of binding data available, anatoxin has less and 
anatabine only has one source. Data relevant to the three ligands are dependent on the organism, 
receptor subtype and labelled ligand used. AChBP is a surrogate protein for nAChRs and shares the most 
similarity with the α7 subtype (216). Due to this, data for AChBP (Ls and Ac) and the α7 subtype are 
considered. IC50 values for (-)-nicotine range from 8-21 µM (217,218), whereas Ki values are between 
0.2-4 µM (217,219-226) and values of 23-91 µM are determined for EC50 (227-230). All values for IC50 
and Ki presented here have used a labelled α-bungarotoxin as the competitive ligand for the assays. 
Values of Ki for AChBP are similar between the two homologues (Ac and Ls), 0.08-0.6 µM (231-234). 
The KD values (0.4-2.3 µM) from the three biophysical techniques, in comparison with this data, fit well 
with Ki values for α7 and AChBP. This suggests that the affinity which was measured by all three 
techniques utilised is meaningful and representative of the literature data. The comparison also 
supports the use of displacement assays and the calculation of Ki values from the data, as a comparable 
technique. IC50 and Ki values for anatoxin competition with α-bungarotoxin at α7 receptors ranged 
between 0.09-1.14 µM and 0.004 µM, respectively (226,235,236). These data demonstrate that 
anatoxin is of similar potency to nicotine. The KD values determined (0.1-0.3 µM) fit with this 
observation and with the literature values. As previously stated, not much research has been 
conducted on the binding of anatabine, therefore only one study demonstrated an average EC50, for 
both enantiomers, of 61 µM (194). This is not comparable with KD values, as is observed for the 
comparison between nicotine EC50 and KD. 
 
 
3.7 Consideration of alternative techniques to study AcAChBP-ligand interactions 
In addition to the studies reported above, four other techniques to characterise ligand binding properties 
were considered and preliminary data generated. These methods are NMR, BLI, and two fluorescence-
based approaches to study the influence of a ligand on protein stability. 
NMR was used for the preliminary screening of a compound library against AcAChBP, seeking to identify 
ligands (Chapter 5.2). The technique has also been developed further to quantify how strong a 
compound binds to the protein of interest (237). This method was being trialled, however, due to time 
restraints was not completed. 
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Similar to SPR, BLI uses biosensors and measures changes in interference patterns, caused by the 
binding of molecules (238). The technique was problematic for the analysis of molecules < 300 Da, as 
any changes were in the range of the background noise. A shift in the interference pattern is 
dependent on a density change on the biolayer, and due to the size of the compounds tested the signal 
may not be sufficient (239). Possibly due to the alternative method used in SPR to measure binding, 
this technique may be more effective at detecting the small changes occurring in intermolecular 
associations. One study analysed the binding of high affinity monoclonal antibodies to a target, on four 
biosensor platforms. Problems with noise and data reliability for BLI were reported in comparison with 
SPR (240). This study suggests experimental procedure, which may be linked to sensitivity leads to 
differences between SPR and BLI. Therefore, BLI may not be the most suitable method for screening 
small molecules, unlike SPR, and similar to ITC should be used for validation of improvements to drug-
like compounds. 
DSF and nanoDSF measure changes in fluorescence upon a temperature increase, which is an indicator 
of protein stability (117,241). Binding affinity could be deduced from these techniques by measuring the 
change in fluorescence upon increasing ligand concentrations. However, due to the stability of AcAChBP 




Three biophysical techniques, WF, ITC and SPR, have been used to measure the affinity of several ligands 
for AcAChBP and GBP. The data presented display a level of agreement amongst these three techniques. 
Larger compounds showed good agreement between WF and ITC results, this may be due to additional 
interactions formed and their respective strength. Comparison of the recorded KD values and literature 
parameters suggested there was a good agreement, particularly for nAChR α7 and AChBP. Any of the 
three techniques could be appropriate to support compound screening and subsequent validation of 
potential ligands. Nonetheless, WF would be preferential due to small sample consumption and ease of 
use. 
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4. Characterisation of strychnine and N-methylbicuculline interacting with 
AcAChBP and GBP 
 
4.1 Introduction 
Receptor-specific chemical tools have been used for the identification of CNS regions (242), as well as to 
assess the function of individual channel types (59). The most well-known chemical tools for the 
inhibitory receptors, GlyR and GABAAR, are strychnine and bicuculline respectively. 
The alkaloid strychnine is the archetypal antagonist of GlyR, with high affinity for homomeric (KD 50 nM 
(243)) and heteromeric (Ki 210 nM (244)) receptors. In the GlyR homomeric receptor, it has been 
shown to inhibit pore opening by preventing the necessary conformational changes needed, upon 
ligand binding. Predominantly, it carries out this role by stopping the flexible loop C from closing 
(Chapter 1.1.2.3) (25). 
Bicuculline is the exemplar ligand for GABAAR. In the past, it was utilised to specifically recognise 
GABAARs, however, data have emerged suggesting it is a promiscuous ligand. Not only does it bind to 
GABAAR (IC50 2.7 µM) (245), but it has been shown to interact with nAChR (IC50 0.8 µM) (246), 5-HT3R 
(IC50 20 µM) (247), GlyR (IC50 300 µM) (248) and a small-conductance calcium-activated potassium 
channel, which is located at the synapse (249). Two recent studies have provided structural data of the 
interaction between bicuculline and GABAAR (29,33), however, no data has been published for the other 
receptors. 
The interactions of strychnine and N-methylbicuculline with AcAChBP and GBP have been investigated 
by biophysical and structural techniques. These data provide new insights into the nature of binding to 
other receptor types. Data from these studies could also inform the use of GBP as a model for 
heteromeric GlyR. Work presented here contributed to two publications, Dawson et al. (75) and Jones 
et al. (211). 
 
4.2 Deducing the binding affinity of strychnine with AcAChBP and GBP using ITC and WF 
The interaction between strychnine and both GBP and AcAChBP was investigated using two biophysical 
techniques, WF and ITC. WF data were collected by exciting (280 nm) the aromatic residues, specifically 
a tryptophan (W164) in the orthosteric binding site and measuring emissions between 300-400 nm. 
Strychnine was titrated into the sample and the effect on fluorescence was measured. The 
measurements resulted in a KD of 0.155 ± 0.007 µM for strychnine with AcAChBP, which is consistent 
with previously reported data (0.04 and 0.02 µM by competitive binding assays and stopped-flow 
spectrofluorimetry, respectively (59,66)). After extensive optimisation of the WF experiments with GBP 
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a KD of 26.6 ± 0.5 µM was calculated. This value indicates a lower affinity when compared to other data 
for homomeric GlyR α1 (0.05 and 0.14 µM by radioligand saturation and ITC, respectively (250)) and α3 
(0.04 and 0.05 µM by SPR and ITC, respectively (24)). To further investigate the binding, ITC experiments 
were conducted. These took a longer time to optimise than WF assays, due to the need to balance the 
need for a sufficient heat change per titration point and saturation of binding sites. However, 
consistent data were recorded (Table 4.1). 
 
Table 4.1 Binding data for the interaction of strychnine with AcAChBP and GBP. Mean thermodynamic 
parameters are derived from ITC as well as dissociation constants: KD1 from ITC and KD2 determined from 
fluorescence measurements. The standard error for each measurement is given (n=3). 
 
 
Figure 4.1 ITC data for strychnine binding GBP and AcAChBP. Example isotherms (A, B) and curves with 
the best fit (C, D) are shown for GBP (A, C) and AcAChBP (B, D). In the examples, a baseline deduction 
has been applied. All data have had the relevant controls (buffer-buffer, buffer-protein, ligand-buffer) 
deducted. 
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Figure 4.2 Strychnine binding monitored by WF. A plot of the mean percentage change versus 
concentration and example traces obtained from titrations, starting with no ligand (blue) to maximum 
ligand concentration (cyan) is shown for GBP (A, B) and AcAChBP (C, D). Standard error bars are behind 
each data point (n=3). 
The ITC derived KD values are consistent with WF data. AcAChBP has an ITC value of 0.07 ± 0.02 µM and 
WF KD of 0.155 ± 0.007 µM. Whereas GBP has an ITC KD of 28.8 ± 3.2 µM and a WF value of 26.6 ± 0.5 
µM. This difference in KD between the two proteins is most likely due to the substitutions made to 
AcAChBP to form GBP which, potentially could disrupt binding interactions of strychnine with the 
protein. 
As well as KD, the ITC data provides a thermodynamic profile of binding. For both proteins, strychnine 
has an N of less than one. This suggests that not all binding sites are filled, 50% for AcAChBP and 60% 
for GBP. This contrasts with ITC measurements made with GlyR α3, which show an N of 1, therefore 
supporting a 1:1 interaction. However, these experiments were conducted in a different buffer (PBS 
compared to Tris) (24). The ΔH for strychnine binding to the two proteins is similar, therefore suggesting 
that they may make similar interactions. Due to substitutions in GBP, if similar interactions are being 
made this suggests that strychnine binding is driven by van der Waals interactions instead of specific 
hydrogen bonds or hydrophobic interactions with regions of the pocket. A difference between the 
proteins binding strychnine is the ΔS. AcAChBP has a favourable ΔS, whereas GBP has an unfavourable 
change. When calculated, ΔS is 0.006 kcal mol-1 K-1 for AcAChBP and -0.004 kcal mol-1 K-1 for GBP. One 
factor that contributes to entropy is SASA. As previously calculated (Chapter 3.5), the total SASA for 
Chapter 4 
59 | P a g e 
 
 
strychnine is about 450 Å2, when binding to AcAChBP it loses 36.3 ± 1.7% of the accessible surface, 
whereas binding to GBP it loses 44.1 ± 5.1%. This could explain the small variation in ΔS for ligand 
binding to the two proteins, however, other factors may also be involved. The difference observed 
between the change in enthalpy (-7.4 ± 1.1 kcal mol-1) and entropy (1.3 ± 1.1 kcal mol-1) for 
GBP:strychnine is comparable to that measured for GlyR α3 by Huang et al., ΔH of -16.3 kcal mol-1 and   
–TΔS of 6.4 kcal mol-1 (24). 
 
4.3 Comparison of AcAChBP: and GBP:strychnine crystal structures 
Two structures of the AcAChBP:strychnine complex have been reported (59,75). Superimposing these 
structures indicates a high degree of similarity (RMSD 0.5 Å). The ligand positions are preserved and 
residues in the orthosteric pocket display only slight differences in orientation, possibly due to flexibility 
of individual amino acids or different refinement strategies. Due to these similarities, only one structure 
was required for direct comparison to investigate AcAChBP:strychnine binding. After inspecting the 
maps and due to similarities in resolution and chain completeness the in-house structure was chosen 
(PDB code: 5O8T). Strychnine binds surrounded by the aromatic cage residues Y72, W164, Y205 and 
Y212, which contribute van der Waals interactions (Figure 4.3). Other residues also contribute van der 
Waals interactions including T53, Q74, Y110, M133, I135, V165, D181, S184, S206, C207 and C208. One 
of the tertiary amines makes a hydrogen bond with the MC of W164. This amine is likely protonated, 
with a pKa of 8.3 (251). Due to the protonation of this amine, the resultant cation also forms an 
interaction with the π ring of the W164. This interaction is similar to that observed for other ligands of 
AcAChBP including nicotine. The carbonyl of strychnine is solvent-accessible, which can lead to water-
mediated MC interactions. 
A comparison of the AcAChBP:strychnine and GBP:strychnine complexes shows that, although 
positioned in the orthosteric site as expected, in most cases the ligand adopts different orientations. The 
five GBP:strychnine binding sites were superimposed to compare the position of the ligand and pick a 
representative chain. Chain B will be used as an exemplar for comparison as it is representative of the 
other strychnine orientations. In chain A there is a small difference in ligand orientation compared to 
chain B (RMSD 0.3 Å). One binding site of the GBP:strychnine complex has been modelled with two 
poses of strychnine. One of the ligands adopts an orientation similar to strychnine in AcAChBP and the 
other is similar to the orientations found in the other binding sites. The similar strychnine orientation to 
AcAChBP in GBP could be accommodated by a different rotamer of Y212, which is also present in this 
binding site and clashes with the example orientation. The exemplar orientation has rotated around 
90°, compared to AcAChBP:strychnine, and is now positioned with the indole group interacting with 
loop C and the ether directed towards S135. A reason for the different orientation would be the 
addition of polar residues (E162 and R74) directed into the pocket (75). These amino acid substitutions 
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would produce a clash with the orientation of strychnine as observed in the AcAChBP:strychnine 
complex. Analysis of the GBP:strychnine complex and comparison with the AcAChBP:strychnine 
structure indicates both conserved interactions (Y72, M133, W164, V165, Y205 and Y212) and different 
(R74, S135, E162, S163, Y166, S167, T208, E210 and P211) van der Waals interactions (Figure 4.3). Due 
to the change in orientation of strychnine, the tertiary amine no longer forms the MC hydrogen bond 
or π-cation interaction. Instead, this amine forms a water-mediated hydrogen bond with MC S163 and 
Y166. This interaction also links to other water molecules and residues setting up a stabilising hydrogen 
bonding network. Potentially, the loss of the π-cation interaction, which is important for binding to 
AcAChBP (35), leads to the reduced affinity of strychnine for GBP. 
 
 
Figure 4.3 Strychnine bound in the orthosteric site of (A) GBP (PDB code: 5OBG) and (B) AcAChBP (PDB 
code: 5O8T). Strychnine (silver for GBP and yellow for AcAChBP) is shown bound surrounded by 
important residues of the principal-(+) (cyan) and complementary-(-) (magenta) subunits. Oxygen (red), 
nitrogen (blue) and sulfur (yellow) atoms are represented as well as a water molecule (blue sphere). 
Potential hydrogen bonds are shown as dashed lines. 
 
4.4 Are interactions of AcAChBP: and GBP:strychnine representative of the interactions in the 
physiologically relevant receptors, GlyR and nAChR? 
The sequence alignment in Figure 4.4 was constructed to compare residue differences between 
AcAChBP-nAChR and GBP-GlyR. 
 
4.4.1 GlyR β+α 
The sequence alignment of GBP, GlyR α1 and GlyR β shows that all but one residue are conserved at the 
heteromeric interface. E210 on loop C is not conserved, however, removal of this amino acid in the native 
receptor should not affect binding as it does not contribute any specific interactions. Comparison of the 
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Figure 4.4 Sequence alignment of the important binding loops. The principal-(+) and complementary-(-) 
subunits of AcAChBP, GBP, nAChR α7, GlyR α1, GlyR β, GABAAR α1, GABAAR β3 and GABAAR ρ1 are 
compared. In red are residues of AcAChBP which were substituted to form a heteromeric GlyR 
interface in GBP. The physiological interface of GlyR and GABAAR are shown in bold. In blue are 
residues that may prevent N-methylbicuculline binding GABAAR ρ1. 
 
principal subunit (loops A-C) binding site residues also demonstrates that loop C is the major difference 
between heteromeric (β+α-) and homomeric interfaces (α+α-). 
 
Two GlyR:strychnine complexes have been reported. These are the homomeric α1 and α3 receptors 
(24,25). The binding sites of these two homomeric structures are similar with slight alterations of residue 
orientation. Strychnine in these sites is also bound in a similar position. Comparing the structures of 
these homomers to GBP allows for the identification of conserved residue positions in the binding site, 
which supports the observations from the sequence alignment. However, even though there is a high 
conservation of residues, a different orientation of strychnine is adopted. This is emphasised by 
differences in affinity of strychnine with GBP (26.6-28.8 µM, Table 4.1) and the homomeric GlyR (0.04-
0.14 µM (24,250)). One reason that may cause this change is due to residue differences, which make up 
the flexible loop C. GBP substitutions model the heteromeric GlyR C loop (KGTG) whereas the 
homomeric loop is different (NTG). This difference extends loop C of GBP, and the incorporation of a 
second glycine may lead to a more flexible loop able to accommodate the different orientation of 
strychnine observed. In the GlyR homomer structure, the C loop sits tightly closed against the pocket 
constraining the orientation of the ligand (Figure 4.5). Potentially, due to the flexibility of loop C in GBP, 
similar close interactions with strychnine cannot be formed possibly leading to the lower affinity 
observed. 
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Figure 4.5 Differences between strychnine bound to GBP and GlyR. (A) A schematic of strychnine bound 
in the GBP binding pocket and the interactions it makes as seen in Figure 4.3A. The comparable residues 
in GlyR are shown in green. (B) Strychnine (yellow) bound in the homomeric GlyR (PDB code: 5CFB) 
orthosteric pocket. Residues (green) and the alternate orientation of strychnine in GBP (silver) are 
shown. Atoms are coloured as in Figure 4.3. 
 
4.4.2 nAChR α7 
The sequences of AcAChBP and nAChR α7 were compared. As in GBP:strychnine binding, most of the 
interactions with the ligand are MC van der Waals, therefore substitution does not have a large effect. 
Important interactions are potentially maintained in the sequence of α7, primarily the MC hydrogen 
bond and π-cation between strychnine and W164. No structures are available with strychnine bound to 
nAChRs for comparison. Therefore, based only on sequence data it can be suggested strychnine would 
bind in a similar orientation. However, data from competitive binding assays suggest that there is a 
difference between Ki values for AcAChBP (0.04 µM, (59)) and nAChR α7 (5.4-6.9 µM (252)). This suggests, 
similar to GBP and GlyR, other factors are in effect when strychnine binds to the native nAChR α7. 
 
4.5 Deducing the binding affinity of N-methylbicuculline with AcAChBP and GBP by biophysical 
techniques 
Bicuculline has a half-life of 45 minutes at physiological pH (253), therefore the more stable N- 
methylbicuculline was used in this study (254). N-methylbicuculline differs by the addition of a methyl 
group on N7, which generates a cationic species. Due to the pKa of bicuculline (14.7), the N7 position 
would be protonated, therefore a cation would also exist for the original compound. Firstly, WF was 
utilised to elucidate the affinity for N-methylbicuculline with GBP and AcAChBP. Optimisation of each 
titration was conducted to find the ideal concentration of titrant, which differed between proteins. The 
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experiments resulted in KD values of 1.24 ± 0.04 µM and 8.7 ± 0.5 µM for AcAChBP and GBP 
respectively. Using these values to guide experimental design, ITC experiments were conducted. The 
optimisation was aided by monitoring the c value and maintaining it between 1-500, the optimal range 
(199). Due to the weak signal obtained from N-methylbicuculline titrations with GBP, extensive trialling 
of experimental conditions was required to obtain useable data. The final concentration of N- 
methylbicuculline used was 2 mM, which also gave a final DMSO concentration of 2%. GBP has been 
shown, by nanoDSF data, to be stable up until 2.5% DMSO (Chapter 2.4.5). Even after extensive 
optimisation, the data were not ideal due to relatively low enthalpic input (-0.4 ± 0.1 kcal mol-1). 
 
Table 4.2 Binding data for the interaction of N-methylbicuculline with AcAChBP and GBP. Mean 
thermodynamic parameters are derived from ITC as well as dissociation constants: KD1 from ITC and KD2 
determined from fluorescence measurements. The standard error for each measurement is given (n=3). 
The interaction between GBP and N-methylbicuculline is entropically driven (-TΔS, -5.9 ± 0.3 kcal mol-1) 
with a KD of 29.6 ± 10.0 µM. For the interaction between AcAChBP and the ligand, similar contributions 
from ΔH (-4.0 ± 0.4 kcal mol-1) and -TΔS (-3.3 ± 0.6 kcal mol-1) are noted and the KD is 4.7 ± 1.6 µM. The 
KD values determined by ITC are comparable with the values derived from WF. Calculation of the SASA 
lost for N-methylbicuculline binding to GBP is 43 ± 2%. As the AcAChBP:N-methylbicuculline has a less 
favourable change in entropy it could have a higher percentage of SASA lost leading to more interactions 
and an improved enthalpy change. However, a higher resolution structure of the AcAChBP:N-
methylbicuculline complex than reported below would be required to confirm this hypothesis. As well 
as the differences in affinity and thermodynamic parameters, there are differences with N, the molar 
ratio of ligand to target. N-methylbicuculline should bind in a 1:1 relationship, the ligand to the binding 
site, although for the two proteins this is different. For GBP N is around 2, which suggests that two 
molecules of N-methylbicuculline may bind per subunit, however, due to difficulties in data acquisition 
a full titration curve could not be determined, which means N may not be accurate. The possibilities exist 
that there is a second binding site, or that a second ligand binds at the orthosteric site, or aggregation 
of the ligand could be complicating the study. For example in the GBP:strychnine crystal structure, one 
pocket contained two molecules of the ligand (59). Conversely, AcAChBP has an N of 0.8, which 
suggests that 80% of the binding sites are filled. This is consistent with other data reported for 
AcAChBP (N of 0.6 for LsAChBP:nicotine and 0.5 for LsAChBP:carbamylcholine (35)) that show an N of 1 
is not achieved for binding. Yet, there is no evidence of cooperativity or allosteric effects. 
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Figure 4.6 ITC data for N-methylbicuculline binding GBP and AcAChBP. Example isotherms (A, B) and 
curves with the best fit (C, D) are shown for GBP (A, C) and AcAChBP (B, D). In the examples, a baseline 




4.6 Crystal structure of GBP:N-methylbicuculline 
The crystal structure of the GBP:N-methylbicuculline complex was obtained at a resolution of 2.4 Å, with 
one molecule of N-methylbicuculline in each of the binding pockets. In chains B, C and E the residues 
K206GT and in chain D the residues G207T could not be modelled. This is due to diffuse density owing 
to the flexibility of loop C, which is in keeping with its function (25). In certain places, the density was 
clear enough to model the glycosylation of N91 (chains B, D and E) and place a well-ordered chloride ion 
(chains A-E, B-factor 37-58 Å2). It was noted there was one orientation of the ligand, however, there were 
two slightly different poses. For brevity, the exemplar molecules will be considered here. Pose I comes 
from chain B, this has an average B-factor of 67 Å2 and a real space correlation coefficient (RSCC) of 0.90. 
Pose II is from chain A with a B-factor of 97 Å2 and a RSCC of 0.88. B-factors infer the degree of error in 
the placement of an atom, the higher the value the less certain, as is seen in more flexible regions. RSCCs 
are an indicator of ligand fit to electron density, 0.8 and above is considered a good fit, below 0.8 
suggests a degree of caution be exercised when considering this part of the structure. From these values 
it can be inferred that both poses fit the electron density well, however, there is less order for pose II, 
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Figure 4.7 N-methylbicuculline binding monitored by WF. A plot of the mean percentage change versus 
concentration and example traces obtained from titrations, starting with no ligand (blue) to maximum 
ligand concentration (cyan) is shown for GBP (A, B) and AcAChBP (C, D). Standard error bars are behind 
each data point (n=3). 
 
4.6.1 Pose I 
Pose I (Figure 4.8A) is adopted in three of the five binding sites. Due to the presence of six oxygen 
atoms on N-methylbicuculline there is the possibility of multiple hydrogen bonds. The isoquinoline 
motif has two oxygen atoms in the dioxolo group, one of these makes an interaction with Nε of R74 
(3.3 Å), whereas the other is solvent accessible. The dioxolo group on the phathlide forms two hydrogen 
bonds, one with R96 (3.4 Å) and one with the protonated E210 (3.1 Å). The carbonyl and oxygen of the 
furan ring coordinate a well-ordered water molecule (B-factor 31 Å2), this is then coordinated by the 
MC carbonyl of W164 and another well-ordered water (B-factor 31 Å2). Superimposing this structure 
with AcAChBP:nicotine complex indicated that the second water was conserved in both structures. A 
water-bridged network of hydrogen bonds is commonly reported with AcAChBP structures. 
A key interaction noted is the cation-π interaction with W164. This cation also sits in an electron-rich 
environment produced by Y72, E162, W164 and Y212. The cation-π interaction is a consistent feature of 
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other ligands that interact with AcAChBP and is a major contributor to binding. Other residues including 
F53, Y72, V125, M133, S135, V165, Y166, S167, Y205 and Y212 all form van der Waals interactions with 
the ligand (Figure 4.8). Of these Y72, W164, Y205 and Y212 make up the aromatic cage, which is a 
defining feature of the pLGIC family. 
 
4.6.2 Pose II 
Pose II is slightly different to pose I with a rigid body rotation around N7. This may be due to a 
combination of crystallographic disorder in the structure and the flexible nature of the pLGIC binding 
site. There is conservation of van der Waals interactions in the two poses but details of hydrogen bonding 
change (Figure 4.8). For the isoquinoline motif, the hydrogen bond between the dioxolo group and R74 
is maintained (3.2 Å), as is the exposure to the bulk solvent of the other oxygen atom. Due to the 
rotation, the carbonyl and furan oxygen atoms no longer interact with the well-ordered water, instead, 
the carbonyl forms a hydrogen bonding network with a dioxolo oxygen atom, Y212, V165 and a 
different water molecule (B-factor 42 Å2). Y212 can now make this hydrogen bond due to a rotameric 
shift, like Y205, which accommodates the move of N-methylbicuculline. N7 of the isoquinoline motif is 
still maintained in a similar location as in pose I, which makes a cation-π interaction with W164. Van der 
Waals interactions are similar to those described for pose I. 
 
4.7 Comparison of the GBP:N-methylbicuculline complex with the inhibitory pLGICs, GlyR and 
GABAAR 
4.7.1 GlyR 
The model of GBP:N-methylbicuculline complex was compared to the model of the full length 
homomeric GlyR. After sequence and structural alignments, key residues involved in the binding of N- 
methylbicuculline in GBP are conserved in the GlyR α3 homomer (Figure 4.4). Of the twelve residues, 
five are strictly conserved (F53, R74, E162, S135 and Y205) and four are homologous (Y72, M133, W164 
and Y212). This leaves three residues that are not conserved, firstly, E210 is a deletion in the sequence 
alignment, however, it contributes a hydrogen bond to the ligand in the complex. Nonetheless, a 
similar interaction could be formed with T208 in GlyR. R96E and V125R should be considered in tandem, 
the glutamic acid is pointing away from the binding site, therefore does not have a direct effect, 
however, it does form a hydrogen bond with the arginine, which pulls the basic residue into a position 
similar to that occupied by R96 and so could interact with N-methylbicuculline. This comparison 
demonstrates that GBP is consistent with the GlyR model and could be representative of N- 
methylbicuculline binding in full length native heteromeric receptors. 
Chapter 4 





Figure 4.8 Representation of N-methylbicuculline bound to GBP. Two similar poses are observed in the 
orthosteric binding site (PDB code: 5OBH). (A) Pose I (silver) is in the binding site made up of the principal 
(cyan) and complementary (magenta) subunits. (B) Pose II (cyan) is in the binding site made up of the 
principal (yellow) and complementary (cyan) subunits. Atoms are depicted as in Figure 4.3. Polder (255) 
omit Fo-Fc maps of (C) pose I and (D) pose II are shown. Maps were calculated in Phenix (256) then 
normalised in Coot. The maps are contoured at 5σ. Atoms are depicted as in Figure 4.3. 
 
4.7.2 GABAAR 
After comparing the GBP:N-methylbicuculline model with GlyR, it was decided to compare it to GABAAR, 
which was previously thought of as the archetypal receptor for this ligand. Two structures show 
bicuculline binding to the heteromeric αβγ GABAAR, by cryo-EM (29,33). Superposition of these 
structures themselves led to the observation that they are comparable (RMSD 0.5 Å). As such, only one 
receptor will be used for comparisons (PDB code: 6HUK). The structure shows one bicuculline molecule 
Chapter 4 
68 | P a g e 
 
 
bound in each of the two β+α- heteromeric binding sites (29). Upon inspecting the maps and calculation 
of the RSCCs of these two molecules (0.84 and 0.81), it was decided that they are representative of 
binding and comparable to the GBP:N-methylbicuculline complex. 
 
Figure 4.9 Differences between N-methylbicuculline bound to GBP and GABAAR. (A) A schematic of N- 
methylbicuculline bound in the GBP binding pocket and the interactions it makes as seen in Figure 4.8A. 
The comparable residues in GABAAR are shown in green. (B) Strychnine (yellow) bound in the 
heteromeric GABAAR (PDB code: 6HUK) orthosteric pocket. Residues (green) and the alternate 
orientation of N-methylbicuculline in GBP (pose I, silver) are shown. Atoms are coloured as in Figure 4.3. 
Firstly, a sequence and structural alignment were conducted. As with GlyR, this showed that many of the 
residues important for N-methylbicuculline binding in GBP are conserved in GABAAR. Of the 13 residues, 
five are strictly conserved (F53, R74, R96, E162 and Y212) and five are homologous (Y72, M133, S135, 
W164 and Y205) (Figure 4.4). This leaves three residues that are not conserved (E210G, T108Y and 
V125R). Similar to GlyR, the substitution E210G (this is a deletion in the sequence alignment) does not 
affect the binding site. The T108Y, which does not have a role in GBP, adds extra aromaticity to the 
negatively charged pocket, in which N7 binds. A key difference between GBP and GABAAR is the V125R 
substitution, the arginine, in its current orientation forms a hydrogen bond with either the MC of G183 
or the side chain (SC) of Y230 (Figure 4.9). This residue provides a steric block, preventing pose I of N- 
methylbicuculline binding GBP from being adopted in the GABAAR binding site. Due to this orientation 
not being feasible, another is adopted. This different orientation is established by a rotation, which 
maintains the isoquinoline motif in a similar position as in GBP. The position of N7 is also retained, within 
1 Å, therefore conserving the cation-π interaction. Even though rotated, the dioxolo group of the 
isoquinoline motif forms a hydrogen bond with R94, which is analogous to R74 in GBP. In the new 
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orientation, a variety of van der Waals interactions are also established. No water molecules are 
included in the cryo-EM structure, therefore additional hydrogen bonds through water-mediation are 
not described. Due to the flexibility of the pLGIC ligand binding pockets and the number of interactions 
N-methylbicuculline can make, leads to its promiscuous activity across the protein family. Even though 
the orientations observed are different, N-methylbicuculline has a preferred conformation, as is seen 
by the overlay of pose I with pose II or the GABAAR bicuculline (Figure 4.10). In comparison, the overlay 
of pose I with the crystal structure from the CCDC database demonstrates the flexibility bicuculline can 
adopt. 
The GABAAR structure and publications raise an issue in the use of bicuculline as a chemical tool for the 
study of pLGICs. The paper reports that N-methylbicuculline is used, however, the structure contains 
bicuculline. Due to differences in potency (257), it is important to know which compound was used so 
that comparisons can be conducted correctly. 
 
 
Figure 4.10 Superpositions of N-methylbicuculline and bicuculline. (A) A superposition of N- 
methylbicuculline pose I (silver) and pose II (cyan) from the complex with GBP. (B) Superposition of N- 
methylbicuculline pose I from GBP (silver) and bicuculline (yellow) from GABAAR (PDB code: 6HUK). (C) 
N-methylbicuculline pose I from GBP (silver) superposed on the single crystal structure of bicuculline 
from the CCDC database (code: Bicucul01, raspberry). For A and B the superpositions were calculated in 
Coot with the LSQ function using the GBP complex as the reference structure. In (C) the Superpose 
Ligands function in Coot was used. 
 
 
4.7.3 GABA ρ receptors 
GABAA ρ receptors, otherwise known as GABAC receptors (GABACR) are insensitive to bicuculline. Due 
to a lack of structural data on these proteins, insights into the reasons why rely on mutational 
studies. The substitutions Y127S, F159Y and F261YS_VF in GABAA ρ were key for the sensitivity of the 
receptor to bicuculline (258). These residues gave the largest increase in potency and by looking at the 
GABAAR structure the reasons can be rationalised. The Y127S substitution opens space behind R94 
allowing movement in this residue and contributes van der Waals interactions to the binding site. The 
F159Y substitution adds a hydroxyl group to the binding site, which provides one of the interactions  
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with N7 of bicuculline and also forms a hydrogen bond to E202, which could stabilise this key residue, 
essential for GABA binding. Lastly, the tripeptide substitution to a dipeptide removes extra bulk from the 
binding site, allowing room for bicuculline to bind. In addition to these residues, from the analysis of 
the GBP:N-methylbicuculline structure and comparison to GABAAR models, the substitutions A229W 
and F73Q may also play a role. A229W, on loop C, adds extra bulk into the binding site therefore it may 
inhibit bicuculline binding. F73 is a conserved residue across GBP, GlyR and GABAAR, the substitution to 
Gln would remove the aromaticity and may direct a polar group towards the binding site. 
TPMPA (Figure 4.11) is a GABACR specific antagonist. Comparison of this ligand to bicuculline suggests 
they share some chemical similarities. The pKa of TPMPA is 9.9 (213), therefore should be protonated 
upon binding. The protonated amine should make a π-cation interaction which is maintained by 
bicuculline and the proteins it binds. The phosphinic acid group (pKa 3.5 (213)) is perhaps then able to 
form hydrogen bonding networks. However, the size comparison between the two molecules is 
different, TPMPA (MW 161 Da) is a fraction of the size of bicuculline (MW 367 Da). This emphasises the 




Figure 4.11 Structure of the GABACR antagonist TPMPA. 
 
4.8 Low resolution crystal structure of a AcAChBP:N-methylbicuculline complex 
A preliminary low resolution (2.9 Å) structure of the AcAChBP:N-methylbicuculline complex was solved. 
Two pentamers make up the asymmetric unit with ten orthosteric sites. N-methylbicuculline was 
modelled into density observed in three of the pockets (associated with subunits A, D and J). The N- 
methylbicuculline molecule in chain D will be described as it possesses the lowest B-factor (61.5 Å2) and 
best RSCC (0.88) (Figure 4.12), in comparison to molecules in chain A (B-factor 95.1 Å2 and RSCC 0.78) 
and J (B-factor 73.9 Å2 and RSCC 0.85). The ligand does not make any hydrogen bonds, instead, it forms 
a variety of van der Waals interactions with residues from both the principal (Y110, W164-Y166, Y205, 
C207, C208, E210 and Y212) and complementary (T53, Y72, Q74, R76, M133, I135 and D181) subunits  
(Figure 4.12A). Interestingly, the cation on N7 is positioned closer to Y110, instead of W164, which is 
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observed in the GBP:N-methylbicuculline complex. The cation sits in the electronegative pocket 
generated by Y110, W164 and Y212. One key difference between the GBP:N-methylbicuculline and 
AcAChBP:N-methylbicuculline models is the amino acid that occupies the adjacent position to W164. In 
GBP, this residue is E162, whereas in AcAChBP it is Y110. The different orientation adopted by N-
methylbicuculline in the AcAChBP model may be due to the repositioning of Y110 generating more 
space in the pocket, therefore the compound can bind deeper. A comparison between N-
methylbicuculline bound to AcAChBP and the other two proteins (GBP and GABAAR) demonstrates a 
different orientation is adopted in each (Figure 4.12B). This clearly illustrates the promiscuous binding 
capabilities of N-methylbicuculline and the pLGIC family’s binding site flexibility to accommodate it. 
 
Figure 4.12 N-methylbicuculline binds differently in the AcAChBP orthosteric binding site. (A) N- 
methylbicuculline (purple) is in the binding site made up of the principal (cyan) and complementary 
(green) subunits. (B) An overlay of the bicuculline molecules from AcAChBP (purple), GBP pose I (silver) 
and GABAAR (yellow) after the principal subunits for each protein were superimposed (SSM) in Coot. 
Atoms are depicted as in Figure 4.3. 
 
4.9 Summary 
An analysis of the interactions between two key ligands of the inhibitory pLGICs and the model proteins, 
AcAChBP and GBP, have been presented. The data suggest that different orientations of both strychnine 
and N-methylbicuculline can be adopted in the orthosteric binding sites of these proteins. In the absence 
of a GlyR heteromeric structure, GBP provides insights into how these ligands may interact with the 
receptor. Even though these compounds were utilised as receptor-specific chemical tools in the past 
they are promiscuous ligands due to the number of interactions they can form and the flexibility of the 
orthosteric binding site of the pLGIC family. 
Chapter 5 




5. A screening campaign to identify new ligands for GlyR and nAChR, 
utilising the GBP and AcAChBP surrogates 
5.1 Introduction 
Ligand screening is the starting point for many drug discovery projects where the objective is to find new 
chemical entities that interact with a target of interest. The number of compounds that can be screened 
has increased due to improvements in the detection of binding events and throughput (259). A chemical 
library can range from a few hundred compounds to a few million (85). Ruddikeit et al. published data on 
all the possible compounds that could be screened starting from one atom up to 17, using C, N, O, S and 
halogen atoms. In total their database consists of 166 billion compounds (260). From this example, the 
enormity of chemical space is observed and the potential for new ligands. 
In the past, the rule of five was utilised as a set of parameters to select ligands to develop into drugs. 
These parameters are a list of chemical properties that are associated with increased absorption and 
permeation of orally bioavailable drugs and includes (261): 
• MW of ≤ 500 Da 
• Hydrogen bond donors (HBD) ≤ 5 
• Hydrogen bond acceptors (HBA) ≤ 10 
• A logP of ≤ 5 
 
With the advent of new libraries of small molecules, a new paradigm was initiated in drug discovery that 
has led to the development of many new lead compounds (262). A new set of parameters were defined 
for these compounds following the rule of three (263): 
• MW < 300 Da 
• HBD ≤ 3 
• HBA ≤ 3 
• ClogP ≤ 3 
• Rotatable bonds (RotB) ≤ 3 
• Polar surface area ≤ 60 
 
Due to the small size of the molecules, fewer interactions are predicted to be made, therefore more hits 
should be returned after the screening of a library. This outcome is linked with the increased ligand 
efficiency that small molecules possess in comparison to larger compounds thereby making them superior 
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starting points for extension (264). The small molecule libraries were also advantageous as more of 
chemical space could be sampled, in smaller collections (265). 
Various biophysical techniques have been employed to conduct these screens, including SPR, X-ray 
crystallography and NMR (85,86,266). 1H NMR allows for a flexible screening platform and is conducted 
in solution, therefore the native environment for binding interactions (93). It offers methods to detect 
ligand binding and for the calculation of affinity, by measuring the differences of one of three reported 
parameters, chemical shift, linewidth and intensity (88). However, as many compounds, proteins, buffers 
and reagents contain hydrogen, the complexity of a 1H NMR spectrum limit its use (267). 19F NMR, 
relative to 1H, is a more recent screening platform, which is still being improved (268). Fluorine is not 
present in the repertoire of natural amino acids from which proteins are synthesised, therefore can be 
incorporated into potential ligands and so provides a label for NMR-based screening methods (269). The 
19F NMR spectra are therefore simpler than 1H spectra due to fewer fluorine environments and the lack 
of coupling (267). Taking these factors into account 19F NMR can provide a simpler platform for screening. 
Another method for screening large compound libraries is computational docking (270). For docking, 
programmes mostly differ by what is defined as flexible (either the protein, ligand or both) and if a 
structure is available. Upon docking, the programmes can predict parameters, including how a compound 
binds to a target and what interactions it makes (271). Due to the speed and large quantity of data that 
docking can generate, dependent on computational resources, it can be utilised to inform and 
complement experimental methods (272). 
Due to the essential role of GlyR and nAChR in human biology, modulation of these receptors is important 
to overcome relevant diseases, or for pain control and anaesthesia (228,273). The identification of new 
chemical matter that binds to GBP and AcAChBP will be discussed, utilising both experimental and 
computational approaches. Using small molecule libraries, data from potential ligands will be collated to 
identify important ligand-protein interactions that could be used for compound development. These 
interactions will be compared to the physiologically relevant receptors to ascertain the validity of using 
GBP as a surrogate for GlyR and to provide information for nAChR ligand development. 
 
5.2 NMR screening using an in-house compound library 
The Drug Discovery Unit (University of Dundee) provided access to a library of 435 fluorine-containing 
compounds specifically assembled for screening by 19F NMR. The library constituents were selected based 
on low mass, high solubility and potential for chemical modification (274). The library was screened 
against AcAChBP and GBP. In these screens, we sought to identify new potential ligands, but the screening 
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also afforded the first opportunity to test this compound library and the 19F NMR approach with two 
targets. Cocktails of nine to ten compounds were used, due to the simplicity of the 19F spectra, which 
increased the throughput of the screen. 
In 1H NMR, large protein molecules tumble slowly (nanoseconds), resulting in fast relaxation and broad 
peaks in the spectrum (~100 Hz). However, as there are no fluorine atoms present on the protein these 
peaks are not detected in 19F NMR. The small compounds, relative to the protein, tumble fast 
(picoseconds) leading to slow relaxation and sharp peaks (~1 Hz). If a potential ligand binds to the protein, 
it will adopt the relaxation of the protein leading to peak broadening (95). If the concentration of all the 
compounds in the cocktail are the same, the difference in peak intensity leads to the identification of 
binders. However, errors in compound concentration could occur due to evaporation of the solvent, 
precipitation of compounds and transfer of compounds from storage to the experimental setup. Owing 
to these potential errors, the peak intensities cannot be directly compared. Instead, competition assays 
can be carried out using a known ligand as a competitive binder. Upon the addition of this molecule to 
the NMR sample, it out competes any small molecule that may have bound, leading to an increase in peak 
intensity for the specific compound. For the described work in this thesis, strychnine was used, which has 
a known affinity for the two proteins, AcAChBP (KD 70-160 nM) and GBP (KD 27-29 µM, Chapter 4.2). 
Using strychnine also allows for the identification of compounds that interact with the orthosteric 
binding site and not with other potential pockets. Compounds were screened at 30 µM, therefore an 
excess of strychnine was used (500 µM) to account for any molecules that had similar affinities. 
In total 93 compounds were identified for the two proteins using the technique. Specifically, 21 and 59 
unique compounds were identified for GBP and AcAChBP respectively. An additional 13 compounds were 
identified as binding both proteins. An example of a potential compound binding is shown in Figure 5.1. 
This demonstrated that the fluorinated compound library could be screened by NMR and lead to hit 
identification. 
 
5.3 Substructure analysis of the NMR hits seeking to determine similarities 
To understand what type of compounds may bind to the proteins, and to seek out any common features 
a substructure analysis was conducted on the hits using the Molsoft ICM software (175,176). Compounds 
for the specific proteins were clustered based on similarities in their 2D structure by the unweighted pair 
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Figure 5.1 A comparison between four example 19F spectra, with (red) and without (blue) strychnine, a 
competitive inhibitor of AcAChBP and GBP. The spectra have been shifted so differences can be observed. 
A) Shows an increase in signal intensity of the red peak compared to the blue peak which shows small 
molecule binding in the orthosteric binding site of GBP. B) Shows no difference in intensity therefore no 
binding of the compound is inferred for AcAChBP. 
group method with arithmetic mean (UPGMA) algorithm. An arbitrary cluster threshold of 0.75 was used 
for both compound sets to limit the number of compound series produced, the distance between nodes 
indicates the level of similarity. Using the atomic property fields (APF) alignment method, the basic 
substructures could be identified. The APF tool identifies common physiochemical properties including 
lipophilicity or hydrogen bonding groups. It uses these properties to overlay the compounds by 
similarities, over many iterations (275). For the GBP hits, 34 compounds (21 unique and 13 non-specific) 
could be subdivided into five series with three unclassified molecules (Figure 5.2). AcAChBP has a larger 
number of hits (59 unique and 13 non-specific) and these could be divided into seven series with four 
unclassified (Figure 5.2). 
A range of potential substructures for the GBP hits were identified. All substructures consisted of a five- 
or six-membered ring, either aromatic or alkyl. Each ring possessed a hydrogen bond acceptor, donor or 
both as a substituent or incorporated into the ring itself. A comparison to AcAChBP substructures found 
similar patterns, although slightly different groups. Perhaps due to conserved interactions with a few 
common residues shared between the protein binding sites, or adoption of similar orientations when 
bound. Differences in interactions are discussed later (Chapter 5.5.7.3), and these should be highlighted 
to develop an understanding of specificity. 
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Figure 5.2 NMR small molecule screen hits clustered by structural similarities, using a generic cut-off of 
0.75. The scale is indicative of compound similarity based on the common substructure. Each colour 
represents a different series, with the common structure of each detailed in the table and an example is 
given. A) AcAChBP 72 hits and B) GBP 34 hits. 
A follow-up BLI assay was trialled for the 93 compounds however, a sufficient signal to measure binding 
was not achieved. The assay was conducted using strychnine binding as a positive control and compounds 
binding to TEV protease as a negative control. After the first attempt, experiments were optimised utilising 
the control compound, strychnine. A second assay was conducted with the hit compounds, however, 
similar results were observed. Due to the lack of available material, no further experiments could be 
performed. Due to this reason, a subset of seven compounds were selected based on the substructure 
analysis and availability for further experimentation. Two compounds from two series and an unclassified 
molecule were chosen for AcAChBP. Three compounds from different series were chosen for GBP. One 
compound that interacts with both proteins was also chosen, for comparative purposes (Table 5.1). 
 
 
Table 5.1 Seven NMR compounds chosen to characterise further, showing the number, chemical 
structure, protein to which it is predicted to bind and the assigned compound series (Figure 5.2). 
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5.4 Attempted measurement of compound binding and calculation of affinity 
Experiments were attempted to deduce the affinity of the compounds for their relevant proteins. Firstly, 
WF assays were considered. Due to the potential that the compounds themselves had intrinsic 
fluorescence each was tested (276). These data showed that all but one of the compounds were 
fluorescent in the relevant emission range (300-400 nm). For compound 1d, binding data were collected 
leading to the measurement of a KD of 359 ± 4 µM and 393 ± 5 µM for AcAChBP and GBP, respectively 
(Figure 5.3). Owing to the intrinsic fluorescence of the other compounds, this technique could not be 
used to measure their binding. SPR was also tested due to its common use in screening (185) however, a 
complete curve was not measured. Potentially, non-specific binding of the small molecules to the protein 
could have led to an incomplete curve due to changes in sensitivity or data analysis (277,278). 
Optimisation of these experiments was underway, testing new protein preparations and increasing the 
concentration of the compounds nonetheless, these were not completed due to time constraints. Initial 
ITC experiments demonstrated that standard methods, as conducted previously, were not able to 
elucidate KD values of the small molecules. ITC has been shown to have a maximal threshold for the 
measurement of KD values less than 250 µM (279). 
Crystallisation trials were attempted with the seven selected hits from the NMR screen and the relevant 
proteins (GBP or AcAChBP). Small crystals were obtained from sitting drop plates for multiple conditions. 
Initial diffraction data were collected and allowed for the selection of conditions for optimisation. 
However, due to time constraints optimisation was not completed and further data were not collected. 
 
5.5 Computational docking of small molecules 
Due to the ongoing optimisation of crystallisation of the protein-small molecule complexes, 
computational docking was conducted to investigate how they might bind to the relevant proteins. The 
docking could suggest information about the orientation of and interactions a compound would make 
when binding to the protein. This information could then be used in combination with experimental 
methods to develop molecules into drug-like compounds. However, these are only predictions and 
caution should be taken when interpreting the results. 
 
5.5.1 Selecting GBP and AcAChBP models for docking simulations 
There are three GBP structures currently available in the PDB: complexes with glycine (resolution: 2.6 Å, 
PDB code: 5OAN), strychnine (resolution: 2.0 Å, PDB code: 5OBG) and N-methylbicuculline (resolution: 
2.4 Å, PDB code: 5OBH). The Molsoft 4D docking tool was used to prepare a model of each structure and 
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Figure 5.3 Binding of small molecule 1d monitored by WF. Example traces obtained from titrations, 
starting with no ligand (blue) to maximum ligand concentration (cyan) and a plot of the mean 
percentage change versus concentration is shown for AcAChBP (A, B) and GBP (C, D). Standard error bars 
are behind each data point (n=3). 
 
to align the binding sites; this accounts for conformational flexibility in the binding site ((280), Chapter 
2.5.2). The compounds were then screened against each binding site in a single docking experiment. This 
identified the structure that forms the most favourable interactions with the compounds (280). Results 
from this docking suggested that all compounds preferentially bound to the GBP:strychnine structure. 
This structure was utilised for all further GBP computational docking experiments. Various structures 
were available for AcAChBP with different ligands bound. However, 4D docking is most useful when 
structures with conformational changes are used (281), therefore three were chosen based on the ligand 
present, the resolution and analysis of the binding sites. The structures containing the compounds 
nicotine and strychnine were selected as they are well-documented ligands of nAChR. Also, these 
models would provide templates of both agonist and antagonist bound pockets, which differ in protein 
conformation. An apo structure was also deemed necessary as this could provide another alternate 
conformation of the pocket. Comparison of apo structures led to the identification of 2Y7Y as a good 
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model due to density fit and chain completeness. Again, 4D docking was conducted and two structures 
were selected based on what structure compounds preferentially bound: AcAChBP:apo (resolution: 
1.9 Å, PDB code: 2Y7Y) and AcAChBP:nicotine complex (resolution: 2.2 Å, PDB code: 5O87). These two 
structures would allow for the deduction of differences in binding of a compound when interacting with 
an open, compared to a closed pocket. 
 
5.5.2 Controls for docking simulations 
Before initiating any docking simulations, the relevant ligands for the crystal structures utilised were re- 
docked. The compounds strychnine and nicotine were used for this purpose. For the GBP structure, no 
waters were included in docking as none contribute to strychnine binding. Upon binding strychnine to the 
pocket, an ICM score of -14.6 was achieved. This is the baseline score, which other compounds docked in 
this structure can be compared. A comparison between the re-docked strychnine molecule and the ligand 
in the original structure were in good agreement (Figure 5.4A). The ligand mostly makes van der Waals 
(VDW energy, -33.3 kcal mol-1) interactions (Appendix B). 
 
 
Figure 5.4 Docking controls. Images showing the consistency in original (yellow) and re-docked (green) 
compounds for docking simulation controls. A) GBP:strychnine (PDB code: 5OBG), largest difference 
1.4 Å and B) AcAChBP:nicotine (PDB code: 5O87), largest difference 0.3 Å. 
 
Nicotine was docked into both the AcAChBP structures. Docking into the AcAChBP:apo structure was first 
conducted without any waters present. Nicotine was docked in a completely different orientation (Figure 
5.5A) compared to the AcAChBP:nicotine structure. A highly-ordered water is present in most structures 
and is important for ligand binding (75), as seen in Chapter 3.4.2. With this water present, the docked 
nicotine molecule was in a similar orientation as observed in the AcAChBP:nicotine structure and an ICM 
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score of -23.6 was predicted. This water molecule was kept for both docking simulations. After re-docking 
nicotine into the AcAChBP:nicotine structure, a comparison of the re-docked ligand and original nicotine 
molecule were in good agreement (Figure 5.4B). The ICM score for the re-docked nicotine was -28.4, 
which gives a baseline for future docking. There is a difference between the scores of nicotine binding to 
the two AcAChBP structures potentially due to the interactions being made. In the AcAChBP:nicotine 
structure, the pocket is smaller (189 Å3), than AcAChBP:apo (240 Å3). The smaller pocket is probably due 
to the closing of the flexible loop C and may make more interactions as is observed in the difference 
between VDW energies (-16.4 to -23.5 kcal mol-1, Appendix B). 
 
5.5.3 Docking of the GBP NMR hits to predict binding interactions 
The orthosteric pocket of GBP was determined to have a volume of 600 Å3. Due to the conformation of 
the protein, the pocket extended beyond the cavity surrounded by the aromatic cage. For docking 
simulations, only the top part of the pocket, incorporating loops A-F, was utilised. In GlyR, strychnine is 
an antagonist and inhibits global conformational changes and pore opening (25). In a potentially similar 
manner, the binding pocket of GBP:strychnine should be an open conformation. Experimentally, upon 
small molecule binding the pocket may close, due to the size of the compounds, increasing the number 
and/or strength of interactions formed. This means that binding scores may be improved due to 
conformational changes not observed in the virtual screening. Protein flexibility was trialled, selecting five 
residues of the highly flexible loop C. However, the docking was computationally expensive, in 
comparison, to without protein flexibility. Due to this reason, this type of docking was not investigated 
further. 
The hits identified as potential ligands for GBP (1a, 1b, 1c and 1d) are predicted to bind in two different 
orientations classified here as pose 1 (1a and 1b) and pose 2 (1c and 1d). The pose 2 compounds bind to 
one side of the binding pocket, which is made up of the residues of the principal subunit. From a 
comparison of the compounds bound in the orthosteric pocket (Figure 5.6A), similarities can be observed. 
The compounds consist of a six-membered ring (either piperazine or morpholine) and a fluorinated group; 
joined by an aliphatic linker with an oxygen-containing functional group. The six-membered ring occupies 
the top of the pocket making van der Waals interactions with T208 and E210, as well as MC of W164- 
S167. The fluorinated group is positioned at the bottom of the pocket between E162, Y205 and Y212, 
potentially making hydrophobic interactions. Due to the added flexibility of the linker of 1c, the hydroxyl 
group is predicted to make a weak hydrogen bond with S163 (2.1 Å). It is worth reiterating that there is a 
difference in hydrogen bonding distances between the docking models and crystal structures due to the 
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Figure 5.5 Images of nicotine bound in (A, B) AcAChBP-apo (PDB code: 2Y7Y) or (C) AcAChBP-nicotine (PDB 
code: 5O87). A) Shows nicotine binding in the AcAChBP-apo pocket without the key water molecule 
present. Comparison of (B) and (C) shows that the re-docked nicotine molecule (yellow) with the water 
present in the apo pocket matches the original (silver) in the AcAChBP-nicotine structure. 
 
addition of hydrogen atoms (Chapter 2.5.2). The hydrogen bond with S163 contributes to the 
compounds hydrogen bonding (HBond) energy of -2.1 kcal mol-1, as well as other weak interactions. 
 
Compound 1d has a higher hydrophobic interaction energy (Hphob, -4.5 kcal mol-1) than 1c (-3.9 kcal 
mol-1), this is probably due to the fluoro-phenyl group. The major contributor for binding is van der Waals 
interactions for both compounds. 1d makes more interactions with a VDW energy of -21.5 kcal mol-1, 
perhaps due to its planarity and rigidity, it can bind deeper in the pocket. As such 1d has a better ICM 
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score (-12.0) compared to 1c (-10.5) however, these are less than the score for strychnine (-14.6). This 
possibly suggests that these compounds are weaker binders. This difference between the ICM scores of 
the compounds and strychnine may be due to the greater size and the number of interactions strychnine 
makes, therefore increasing affinity. However, it has been noted that larger compounds have a low 
ligand efficiency in comparison to smaller molecules as not every atom plays a role in binding 
interactions (282). 
The pose 1 compounds have the best binding scores (-16.2 to -16.9 for 1a and 1b), therefore would 
probably bind more efficiently to the protein. They also have a higher score than strychnine, so should 
make equally efficient interactions. Comparing the chemical structures, the two compounds are distinctly 
different. 1b is more flexible with a RotB score of 5, whereas 1c is planar with a RotB of 2. Even though 
there are chemical differences they bind to GBP in a similar orientation. They bind across the pocket 
making interactions with both the principal and complementary subunits. Both compounds are predicted 
to make a hydrogen bond with S135 however, these are estimated to be of different strengths. Possibly 
due to the potential to interact with more residues, the interaction scores are better for pose 1 
compounds, in comparison with pose 2. Comparable to the pose 2 compounds, the fluorine groups of 
pose 1 compounds occupy a similar region between Y205 and Y212. As well as hydrogen bonding, the 
pose 1 compounds have an increased hydrophobic interaction. 1b has the highest Hphob energy (-5.7 kcal 
mol-1). Perhaps this is due to the addition of extra hydrophobic groups such as the methyl and 
cyclobutane. A variety of van der Waals interactions are also made with R74, M133, W164-167, E162, 
Y205, T208, E210 and Y212, giving an average predicted energy of -20.0 kcal mol-1 for both pose 1 
compounds. 
 
5.5.4 Docking of AcAChBP NMR hits to identify differences between apo and closed states 
A closed ligand-bound and an apo structure were selected as templates for the docking calculations. A 
comparison between the docking outcomes to both structures may suggest if there are any major 
differences between the open and closed states. 
Firstly, compounds (2a, 2b, 2c and 1d) were docked to the AcAChBP:nicotine structure. All four 
compounds bind in a similar orientation to each other, close to W164. This is possibly due to the smaller 
pocket size and steric restrictions. Unlike GBP, the AcAChBP binding pocket is restricted by the presence 
of Y110 and the Cys loop (C207-C208). The fluorine-containing groups occupy comparable positions 
between M133 and V165, possibly contributing to hydrophobic interactions. The lower portion of the 
compounds are either small or planar making interactions with Y110, Y205 and Y212. From the 
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predicted binding energies the main interactions are hydrophobic and van der Waals. All the ICM scores 
(-6.2 to -13.0) for the compounds are below that of nicotine (-28.4). This is potentially because the 
compounds appear to lack the capacity to form the hydrogen bonding contributions to binding that 
nicotine possesses. Also, these compounds are lacking the π-cation interaction, which has been 
highlighted in Chapter 3 as important for binding to AcAChBP. 
The same compounds were next docked into the apo structure. All four ligands were orientated 
differently, in comparison to the poses predicted using the AcAChBP:nicotine structure as a template, 
most likely due to the extra space in the pocket. The extra space has possibly also led to fewer interactions 
being formed for most of the compounds, noted by the predicted energies. This also affects the ICM scores 
for 2a (-8.4) and 2b (-6.8), which have deteriorated. However, the scores for 1d and 2c have improved. 
The score for 1d (-16.1) is still lower than the value for nicotine (-23.6), but 2c (-22.9) is comparable. This 
compound (2c) is larger (MW 253 Da) than the others (MW 167-208 Da) and can spread out in the space 
provided. Owing to this, favourable interactions appear to have been made with Q36, Y53, Y91, W145, 
S165, Y186 and Y193. Hbond energy (-4.8 kcal mol-1) contributes to the binding score with two optimal 
interactions that can be seen in Figure 5.6C. Hphob (-4.8 kcal mol-1) and VDW (-21.2 kcal mol-1) energies 
also contribute more, in comparison to nicotine binding (Appendix B). 
 
5.5.5 Maybridge rule of three library screen to find new ligands 
The availability of libraries containing large numbers of molecules, displaying diverse structures and the 
relative ease of computational docking calculations can inform structure-driven compound design 
approaches. The Maybridge rule of 3 diversity set of 2,000 compounds (Maybridge.com, (263)) is available 
in a relevant format and was deemed appropriate to computationally screen against GBP and AcAChBP 
using the same approaches employed with the NMR hits. For each protein, all 2,000 compounds were 
screened at a thoroughness of 3, sampling racemic centres. Again, various conformations of each 
compound are deduced. A selection of the conformations are then screened against the pocket in 
different orientations and locations. The best scoring conformation, based on the interactions it makes is 
presented in the hit list (176). The same protein structures for the NMR hits were used for screening this 
library. After docking, the top 50 hits were ranked by ICM score and separated into series by substructure 
similarity. This was carried out to observe any related characteristics that bind these proteins. The top ten 










Figure 5.6 Selected hits from the NMR screen (Table 5.1) docked into the relevant target. A) GBP (PDB code: 5OBG), B) AcAChBP:nicotine (PDB 
code: 5O87) and C) AcAChBP:apo (PDB code: 2Y7Y). Small molecules (coloured, sticks) are shown bound in the orthosteric binding pocket of the 
protein (silver, ribbon). Residues (silver, sticks) important for binding are shown and labelled. Key atoms are coloured hydrogen (white), oxygen 
(red), nitrogen (blue), sulfur (yellow) and fluorine (pale yellow). Hydrogen bonds are shown as coloured spheres using size to indicate the 















5.5.5.1 GBP Maybridge library hits – how do they bind? 
The top 50 compounds predicted to bind GBP were classified into seven series by common substructure 
(Figure 5.7). One compound could not be classified into any series and does not share the common 
aromatic ring. There is a variation in ICM scores for the small molecules between -22 to -29 (Figure 5.7C), 
which are all higher than the ICM score for strychnine binding to the same protein (-14.6). This supports 
the use of small molecules in screening as they make specific, favourable interactions and may have a 
higher ligand efficiency in comparison to larger compounds. The top ten compounds (red boxes) are from 
different series ranging from 1-6 and the predicted binding energies are shown in Appendix B. 
The common substructure for series 1 is shown in Figure 5.7. The three compounds of the top ten that 
are in this series are 3a, 3b and 3c. Two of the compounds (3a and 3b) are similar differing only in the 
position of the ether group. The fact that both these compounds were high-ranking hits may suggest that 
the common substructure is important for binding. A comparison of the predicted binding pose showed 
that they occupy a similar footprint in the binding site of GBP. As such they make comparable interactions, 
which are shown in their binding energies: Hbond (-5.3 to -5.4 kcal mol-1) and Hphob (-4.8 kcal mol-1). 
There is a difference in the VDW energy (-21.4 to -23.2 kcal mol-1), which is possibly due to the difference 
in the ether group placement. This difference leads to a positional change of the phenyl ring and possibly 
increased interactions with the MC of V165-S167 for 3b. Due to this difference, the ICM scores are 
dissimilar (-29.4 for 3b and -25.9 for 3a) however, these are both still regarded as good hits. The third 
molecule (3c) also shares the presence of a carboxylic acid group. For the other two compounds, this 
group is predicted to interact with the R74 SC and is conserved by other top ten compounds. However, 
perhaps due to the rigidity (RotB 2, compared to 4 for 3a/b), 3c occupies a different position in the binding 
site. As such there are differences within the binding energies compared across the three compounds: 
Hbond (-4.7 to -5.4 kcal mol-1) and VDW (-17.5 to -23.2 kcal mol-1). Conceivably, the difference in 
orientation could cause a change in van der Waals interactions and lower the ICM score for 3c (-26.6). 
As well as the common series substructure, the two compounds (3d and 3e) in series 2 also share other 
similarities. Both compounds consist of two phenol groups connected by a one-atom linker. The 
differences between these compounds are the position of one of the hydroxyl groups on a phenyl ring 
(ortho or para) and the linker atom (carbon or sulfur). The main difference is observed for the predicted 
VDW energy (-23.3 to -24.5 kcal mol-1). This may be due to the additional interaction with R74 and/or due 
to the size of the linker atom (atomic radius S 1.8 Å and CH2 2.0 Å). Even with these structural differences 
both compounds are positioned similarly in the binding site and have comparable ICM scores (-25.2 to 
-25.7). 
 








Figure 5.7 Analysis of the top 50 Maybridge screening hits for GBP (PDB code: 5OBG). A) All 50 compounds clustered by common substructure 
(different colours), using a 0.75 cut off. B) Table of the common substructures of each series in (A) and an example. C) Comparison of ICM score 
(x-axis), hydrogen bonding (y-axis), van der Waals (colour) and hydrophobic interaction (size) energies for the top 50 hits. The top ten compounds 



































Figure 5.8 Top ten GBP hits from the Maybridge screen docked to GBP (PDB code: 5OBG). The same colour scheme and depiction as used in 
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Even though there is a similar substructure for series 3, the two compounds in the top ten bind in different 
positions. Due to their small size, they only bind predominantly to one subunit, either principal (3f) or 
complementary (3g). The two compounds make a variety of different interactions observed in the models 
and the predicted energies (Hbond -5.8 to -7.6 and VDW -8.4 to -17.3). Compound 3f is predicted to bind 
similar to series 2 compounds and makes an additional hydrogen bond with the MC of S163. Compound 
3g is oriented in a similar position to the thiazole of 3c interacting with R76. However, 3g occupies a 
position higher in the pocket towards R96 and V125. The ICM scores for both compounds are comparable 
(within 0.3), which may suggest that increased hydrogen bonding energy of 3g may compensate for its 
low van der Waals energy. 
The remaining three compounds are from three different series: 3h (series 4), 3i (series 5) and 3j (series 
6). They are all predicted to occupy a similar position to series 1 compounds, and form interactions 
observed by other molecules of the top ten. Of note, 3j has the highest Hphob (-7.0 kcal mol-1) and VDW 
(-25.4 kcal mol-1) interaction energies. Similar to strychnine this is probably due to the size of the 
compound (MW 282 Da) in comparison to the others (MW 138-227 Da). However, again like strychnine, 
the extra size does not increase its ICM score (-25.7), which suggests low ligand efficiency. 
Computational docking of the Maybridge library to GBP led to the identification of several small molecules 
that bind in the orthosteric site. Structural similarities between the compounds provide clues about which 
chemical features might be important for binding. Specific protein-ligand interactions were identified 
from comparisons of these compounds. This information could be coupled with other docking and 
experimental analyses to inform compound development. 
 
5.5.5.2 Computational docking of the Maybridge library to AcAChBP:nicotine 
The top 50 hits for AcAChBP:nicotine structure could be classified into six series with five compounds not 
fitting into any of the groups (Figure 5.9). The top ten compounds have an ICM score range of -23.0 to 
-29.6, which is comparable to the nicotine value of -28.4. These compounds are from four of the six 
series with one unclassified molecule. 
All of the top ten compounds are mostly planar with limited flexibility (RotB 0-2). All compounds are 
predicted to bind in a similar position to nicotine in the AcAChBP:nicotine pocket and make an interaction 
with the well-ordered water molecule (Chapter 3.4.2). 
There are three compounds from series 1 in the top ten. As well as the common substructure, these 
specific examples all have an amine group that extends between M133 and V165. For two compounds (4a 
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and 4b) this amine group makes the hydrogen bond with the key water molecule in the binding site. For 
4c and 4b, the nitrogen atom in the ring would form a hydrogen bond with this water. For each of the 
three compounds, the phenyl group is positioned within the aromatic cage formed by Y72, W164, Y205 
and Y212 (Chapter 1.1.2.2). Compounds 4a and 4c are similar when comparing ICM scores (-25.6 to          
-26.5), however, the main difference is the VDW energy (-23.5 to -25.0 kcal mol-1). This is due to 4a 
extending towards Y110 and making more interactions. 4b has the highest ICM score (-29.6), possibly 
due to the highest Hbond energy (-9.3 kcal mol-1). This is due to the variety of hydrogen bonds it makes 
to Y212, MC M133 and a potential bidentate interaction with the water molecule. 4d is the only 
compound from series 2 featured in the top ten. This compound shares many of the interactions 
previously discussed in series 1. As such it has a comparable ICM score (-25.4) to 4c (-25.6). 
Series 3 comprises four of the top ten compounds. The substructure of these four compounds is almost 
identical thus they make similar interactions. The carbonyl substituent of all four molecules makes a 
strong (1.5-1.6 Å) hydrogen bond to the water molecule. A hydrogen bond is also potentially formed with 
Y212. The Hbond (-4.9 to -5.1 kcal mol-1) and Hphob (-3.9 to -4.0 kcal mol-1) energies, for the four 
compounds, are similar. Nonetheless, the VDW energy for compounds 4e and 4f (-24.1 to -24.9 kcal  
mol-1) are better than the other two compounds, 4g and 4h (-21.4 to -21.6 kcal mol-1). This suggests that 
either the ester and/or chlorine substituents for the two former compounds generate more favourable 
interactions. 
The remaining compounds are 4i (series 6) and 4j (unclassified). Both compounds form interactions 
already discussed (Figure 5.10). Of note is 4i, which is comparable to 4a, as it extends towards Y110 and 
makes more interactions leading to an increase of the VDW energy (-26.7 kcal mol-1) and ICM score (-27.5) 
in comparison with other compounds (Appendix B). 
In summary, the ten planar compounds docked as potential ligands into the AcAChBP:nicotine complex 
all share common features as well as with nicotine, which suggests similar interactions with the 
template. One of the main interactions with the well-ordered water molecule that nicotine makes is 
conserved by all the compounds. However, it may prove difficult to treat these compounds as templates 








Figure 5.9 Analysis of the top 50 Maybridge screening hits for AcAChBP:nicotine (PDB code: 5O87). A) All 50 compounds are clustered by common 
substructure (different colours), using a 0.75 cut off. B) Table of the common substructures of each series in (A) and an example. C) Comparison 
of ICM score (x-axis), hydrogen bonding (y-axis), van der Waals (colour) and hydrophobic interaction (size) energies for the top 50 hits. The top ten 

















Figure 5.10 Top ten AcAChBP hits from the Maybridge screen docked to AcAChBP:nicotine (PDB code: 5O87) using Molsoft ICM. The same colour 
















5.5.5.3 Different Maybridge compounds are predicted to bind AcAChBP:apo 
In comparison to hits for the AcAChBP:nicotine complex, the top 50 hits for the apo structure were 
classified into eight series with one outlier (Figure 5.11). Like hits for GBP (RotB 2-4), there are flexible 
groups (RotB 2-6) within each of the series. The top ten ICM scores range from -22.2 to -26.2, which is 
comparable to the value for nicotine binding of -23.6. The top ten compounds, which are dissimilar to 
compounds that are bound to AcAChBP:nicotine, come from four different series. 
Four compounds from the top ten come from series 1 and three of them are the highest-ranking hits (ICM 
scores -25.2 to -26.2). These three compounds (5a, 5b and 5c) are also homologues with one change (CH3, 
Cl or F). The fourth compound is the lowest ranking of the top ten. The three homologues occupy identical 
positions within the binding site, similar to nicotine. A strong hydrogen bond is made between the 
carbonyl and water (1.9-2.0 Å). The chemical differences between the compounds only affect the VDW 
energy (-20.5 to -21.8 kcal mol-1). This is probably due to a change in the size of the substituents and 
interactions made; methyl (VDW radius 2.0 Å) and chlorine (VDW radius 1.8 Å) groups are larger than 
fluorine (VDW radius 1.5 Å) which is more similar to hydrogen (VDW radius 1.2 Å) (283). The other 
compound (5d) takes up a different position binding in a cavity between loop C and the principal subunit. 
Here, the VDW (-24.5 kcal mol-1) and Hphob (-5.1 kcal mol-1) energies are higher than the other three 
compounds (Appendix B). The Hbond energy is also higher for 5d (-4.2 kcal mol-1). It makes one hydrogen 
bond between the nitrogen of the pyridine ring and Y186, but perhaps due to tight binding in the cavity, 
weaker interactions can be made. Even though it seems this molecule makes more interactions, the ICM 
score is lower (-22.2) possibly due to other factors considered to calculate the score e.g. desolvation 
energy. 
The three compounds: 5e (series 3), 5f (series 3) and 5g (series 2) are predicted to bind in a similar position 
to nicotine and interact with the key water molecule. The compounds also extend towards Y91 forming 
additional interactions. Due to the similarities, all three compounds have comparable ICM scores (-23.4 
to -23.5), Hbond (-3.0 to -3.3 kcal mol-1), Hphob (-5.1 to -5.8 kcal mol-1) and VDW (-21.8 to -23.4 kcal mol-1) 
energies. 
The final group of compounds to be discussed is series 6, with three compounds in the top ten. Similar to 
series 2, the compounds occupy the cavity between loop C and the principal subunit. Two compounds (5h 
and 5j) are homologues with a chlorine atom being the only difference. The acetamide substituent 
makes three MC hydrogen bonding interactions (S144, I152 and I194) leading to a similar Hbond energy 
(-7.5 kcal mol-1). The presence of the chlorine improves the VDW (-21.1 to -22.4 kcal mol-1) energy, 
 






Figure 5.11 Analysis of the top 50 Maybridge screening hits for AcAChBP:apo (PDB code: 2Y7Y). A) All 50 compounds clustered by common 
substructure (different colours), using a 0.75 cut off. B) Table of the common substructures of each series in (A) and an example. C) Comparison 
of ICM score (x-axis), hydrogen bonding (y-axis), van der Waals (colour) and hydrophobic interaction (size) energies for the top 50 hits. The top ten 



































Figure 5.12 Top ten AcAChBP hits from the Maybridge screen docked to AcAChBP:apo (PDB code: 2Y7Y) using Molsoft ICM. The same colour 
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leading to an enhanced ICM score of -24.2, compared to -22.4. 5i has two differences, compared to 5h, 
a carbonyl instead of an ether and an additional tBu substituent. Due to the addition of the carbonyl the 
Hbond energy decreases (-7.4 kcal mol-1). However, the addition of the tBu group improves the Hphob 
(-4.0 kcal mol-1) and VDW (-23.0 kcal mol-1) energies, which places 5i equivalent in ICM score to 5j        
(-24.1 to -24.2). Consequently, this suggests that the additional substituents on the phenyl ring are 
needed to improve binding. 
From this set of compounds, there are two main sites of interaction in the apo binding pocket: 1) similar 
to nicotine in proximity to W145 and 2) in the cavity between loop C and the principal subunit. Similar 
to nicotine binding, the compounds that bind in position 1 make contacts with the key water molecule, 
after that most other interactions are hydrophobic or van der Waals. For position 2, the orientation of 
the ligand may be stabilised by a few hydrogen bonds with MC groups and close interaction with other 
residues. These observations coupled with those from the closed pocket screen could be used to inform 
ligand design against AcAChBP and in the long term nAChRs. 
 
5.5.6 Validation of computational screening via KD determination 
The highest ranking compounds, 3b and 4b, from the computational screen with GBP and 
AcAChBP:nicotine were obtained to validate the results. Compounds from the screen with AcAChBP:apo 
could not be acquired due to availability. Similar to the NMR compounds, WF was conducted to 
determine KD values. The intrinsic fluorescence of each compound was first checked. 4b was identified 
as fluorescing in the relevant range, whereas 3b did not. WF experiments with 3b gave a KD of 237 ± 5 
µM (Figure 5.13). Due to time constraints, no other biophysical assays could be conducted. Comparing 
the KD and ICM score for 3b may allow for the prediction of the affinity of other docked compounds i.e. 
similar ICM scores may relate to mid micromolar affinity.   
 
 
Figure 5.13 Binding of small molecule 3b to GBP monitored by WF. An example trace obtained from 
titrations, starting with no ligand (blue) to maximum ligand concentration (grey) (A) and a plot of the 
mean percentage change versus concentration (B) are shown. Standard error bars are behind each 
data point (n=3). 
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5.5.7 Are there differences between the hits for different proteins? 
For GBP and AcAChBP, 14 and 24 new small molecules have been identified respectively that potentially 
bind in the orthosteric pocket. A comparison of the molecules may elucidate structure-ligand binding 
relationships that could be combined with experimental methods to aid in the design of new drug-like 
compounds. 
 
5.5.7.1 Comparison of NMR and Maybridge small molecule hits 
As previously modelled in GBP NMR hits, there are two positions where compounds are predicted to 
bind, pose 1 and pose 2. This observation was also noted in the Maybridge top ten hits for GBP. Seven 
out of the ten compounds sit across the binding site in pose 1. Perhaps a key difference is the presence 
of a large phenyl group for the Maybridge compounds which may make more interactions with the 
principal subunit. In comparison, the NMR molecules have smaller groups, such as a CF3 or imidazole, 
which could make fewer interactions. Possibly due to these interactions, the Maybridge ICM scores are 
better (-25.1 to -29.4) than the NMR compounds (-10.5 to -16.9). Pose 2 is adopted by compounds 1c, 
1d, 3f and 3i, which make similar interactions. However, possibly due to the rigidity of the phenyl ring, 
in comparison to the flexibility of the morpholine/piperazine groups, the geometry is better to form a 
second hydrogen bond with E210 and increase van der Waals interactions. These interactions could 
explain why the ICM score is better for 3f/3i (-25.1) compared to 1c/1d (-10.5 to -12.0). 
A comparison between the NMR and Maybridge hits derived from screening against the 
AcAChBP:nicotine complex indicates that both sets occupy a comparable position. However, the NMR 
compounds score substantially lower (-6.2 to -13) than the Maybridge set (-25.4 to -29.6). One reason 
for this may be due to differences in interactions with the key water molecule. In the Maybridge set, 
every compound is predicted to make one or two hydrogen bonds with this water. Whereas, for the 
NMR compounds the fluorine group blocks any interaction. 
Two binding positions have been identified for the Maybridge set of compounds interacting with 
AcAChBP:apo. Most compounds are still driven by the interaction with the key water molecule. Perhaps 
due to the lack of this drive to make a hydrogen bond with the water molecule, the compounds from 
NMR make different interactions. Similarly, possibly due to the extra space and lack of constraints, both 
sets take advantage and form new interactions lower in the pocket, towards Y91 (Y110 of 
AcAChBP:nicotine). This opens new areas of the pocket that could be targeted to increase affinity or 
specificity. 
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5.5.7.2 Comparison of AcAChBP:nicotine and :apo hits 
As noted above, all the small molecules bound in the AcAChBP:nicotine structure are orientated 
similarly. This is due to the smaller pocket volume (189 Å3) in comparison with apo (240 Å3). As the pocket 
is smaller the number of van der Waals and hydrophobic interactions can increase. However, the 
potential to make hydrogen bonds is limited by space and orientation. Moving to the apo structure the 
opposite should happen, the potential for van der Waals and hydrophobic interactions decrease and 
hydrogen bonding opportunities increases. This is observed by the presence of two binding orientations 
in apo (previously described). 
The nicotine-like orientation is similar between the AcAChBP:apo and :nicotine structures. A hydrogen 
bond donor or acceptor on, or in, the ring of the hit compounds forms the interaction. In both cases, a 
carbonyl substituent could make a stronger and closer interaction than other groups. Another 
comparable interaction between the two sets of compounds is the position of a ring within the aromatic 
cage of the binding site. The aromatic cage provides van der Waals as well as charge-π and π-π 
interactions. Depending on the size of the ring, the strength of interactions with the aromatic cage will 
possibly be stronger in the AcAChBP:nicotine structure due to proximity. In the AcAChBP:nicotine 
structure, additional hydrogen bonds could be made with residues of loop C, interactions which are 
predicted to strengthen binding. Due to the conformation of loop C in the apo structure, these 
supplementary interactions, generally, cannot be established. The second orientation in the cavity 
between loop C and the principal subunit either cannot be adopted or is unfavourable in the 
AcAChBP:nicotine binding site. This cavity may form similar interactions as in the AcAChBP:nicotine 
pocket, due to size. 
As discussed in Chapter 3.6, AcAChBP provides a surrogate for the nAChR α7 subunit (216). Figure 5.14 
shows a sequence alignment between the two AcAChBP structures used in docking and human nAChR 
α7. The main binding residues, as discussed for compound binding, in AcAChBP are conserved in the α7 
subunit, except for M133. In the α7 receptor there is a substitution, M133Q however, as all interactions 
between the compounds and M133 are by van der Waals these should be maintained. Nonetheless, the 
hydrogen bonding capacity of glutamine needs to be considered as it may affect the binding of the 
compounds. Conservation of the key binding residues suggests that binding interactions should be 
maintained between the two proteins. 
A comparison between known ligands and the compounds will allow for comments on the validity of the 
models generated and may give merit to the interactions observed. Three compounds are shown in 
Figure 5.15, the first two are agonists and the last is an antagonist (284). All three compounds have 
similarities, a carbonyl and an amine group. The carbonyl, similar to some of the compounds probably 
makes contacts with the binding site water molecule. This interaction may be bidentate as with 
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Figure 5.14 Sequence alignment of human nAChR α7, AcAChBP:nicotine (PDB code: 5O87) and 
AcAChBP:apo (PDB code: 2Y7Y). The alignment shows the main principal-(+) and complementary-(-) 
loops for binding. 
compound 4b, due to the proximity of two hydrogen bonding groups. The core structure of antagonist 
SR 16594 is similar to compounds 4b, 4c and 4d. Possibly, the large 8-membered ring prevents the pocket 
from closing. If a similar group was attached to one of the similar three compounds a comparable effect 
may be observed. 
 
 
Figure 5.15 Three ligands of nAChR, used as a comparison to compound hits. Acetylcholine is the 
stereotypical ligand of the receptors, AR-R 17779 is an agonist and SR 16594 (4424) is an antagonist. 
 
Numerous crystal structures of AcAChBP:ligand complexes have been reported, which provides an 
extensive data set (285,286). Comparison between AcAChBP:ligand structures may highlight the 
importance of different interactions. Tubocurarine is a neurotoxin that inhibits the activation of nicotinic 
receptors (59). Similarly, to the predicted orientation of some compounds in the AcAChBP:apo structure, 
it occupies a position between the C loop and W145 however, does not make an interaction with the 
water molecule (PDB code: 2XYT). A KD of 0.5 µM for the AcAChBP:tubocurarine interaction (59), in 
comparison to nicotine binding (0.4-2.3 µM from Chapter 3.2) may suggest that the water-ligand 
interaction is not essential for binding. Several compounds in the apo pocket also do not make this 
interaction therefore, these may provide new scaffolds targeting other parts of the pocket. Likewise, 
tubocurarine, comparable to 2c, sits lower in the pocket making interactions with Q36 and S165. Using 
small groups or long linkers, to avoid antagonistic behaviour, this lower region could be exploited to aid 
in the selection and specificity of agonists. Cytisine is a plant alkaloid and has been used for smoking 
cessation (287). Similar to nicotine, it is a small molecule that interacts with W145 but unlike nicotine, it 
does not form an interaction with the stable water molecule (PDB code: 4BQT). The compounds in 
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the AcAChBP:nicotine binding site occupy a similar position to cytisine however, they make interactions 
with the water molecule as well as loop C residues. This suggests that some of these compounds could 
have a similar affinity to cytisine with AcAChBP (1.6 µM (287)). 
 
5.5.7.3 Comparison of specific protein-compound interactions formed with GBP and AcAChBP 
The binding pocket of GBP is a hybrid, in terms of size, between AcAChBP:nicotine and :apo. There is 
more space and fewer constraints, therefore a variety of interactions can form. This is partly due to the 
substitution of key residues, such as Y110A, but also partly because of the GBP:strychnine complex 
structure used for docking. As previously mentioned, strychnine is an antagonist of the native receptor 
preventing the closing of loop C (25) therefore, it will perhaps also prevent the closing in GBP. 
Several residues in the orthosteric binding site are conserved between the two proteins, namely, Y72, 
W164, Y205 and Y212 which contribute to the aromatic cage. These residues provide general 
hydrophobic and van der Waals interactions. Protein specific substitutions such as Q74R, I135S and 
S206CCP_KGTG provide the specificity for the binding of these small molecules as demonstrated in 
previous sections. Possibly due to these substitutions, the compounds that bind to GBP are not predicted 
to display a similar orientation as the compounds that bind to AcAChBP:nicotine. 
A sequence comparison of GBP and GlyR has been discussed in Chapter 4.4.1 (Figure 5.16). The 
residues thought to be most important for compound binding in GBP are conserved in a β+α- GlyR 
binding site. There are three substitutions, W164F, R76Q and E210 deletion (E210del), which will be 
discussed. W164 provides van der Waals interactions with all the GBP ligands, therefore substituting this 
residue with Phe should not make much difference. The R76Q substitution is only important for the 
binding of two compounds 3g and 3c. This interaction may still be maintained with the substitution 
however, for 3g the other interacting residues, R96 and V165, are also not conserved. Consequently, 3g 
would probably not bind to GlyR. The final substitution is a deletion of E210. This has an impact on several 
compounds, which make a hydrogen bond with this residue including 3d, 3e, 3f, 3i and 3j. If these 
compounds were taken forward this interaction would have to be accounted for and it would have an 
impact on the binding score. However, without this residue (E210) a new pocket becomes available to 
build a molecule towards S167, which is conserved as a threonine in GlyR. 
Various compounds bind to GlyR, including various amino acids, cannabinoids, ions and neurosteroids 
to name a few (288). Comparing GlyR ligands and the compounds identified will potentially show 
common chemical structures and binding modes, as was conducted with the AcAChBP compounds. 
Figure 5.17 shows three competitive ligands of GlyR. The smallest of GlyR ligands are the amino acids 
including glycine and alanine (289). The two ligands, nipecotic acid and quinolinic acid are structurally 
similar to each other and are derivatives of piperidine and quinolone respectively (289,290). The 
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Figure 5.16 Sequence alignment of human GlyR α1 and β with GBP (PDB code: 5OBG). The alignment 
shows the main principal-(+) and complementary-(-) loops for binding. 
quinolinic acid derivative is comparable to 1a, two fused aromatic rings with a carboxylate and CF3 group. 
Consequently, it would be expected that they would similarly interact with the target. The carboxylate 
group of nipecotic and quinolinic acids are also mirrored in some of the Maybridge GBP hits. This group 
can be related to the natural ligand, glycine. The GlyR α3:glycine complex (PDB code: 5VDH) shows that 
the carboxylate of glycine interacts with R65 (291). This is comparable to R74 in GBP, which interacts 
with the carboxylate of some of the hit compounds. There is a difference in size between the natural 
ligand and the other two compounds in Figure 5.17. Nipecotic (MW 129 Da) and quinolinic (MW 
167 Da) acid are smaller than strychnine (MW 334 Da), however, all three compounds are antagonists 
of GlyR (288). Similarities between the acids and the compounds identified from computational 
docking may lead to the conclusion that some of these molecules may also inhibit GlyR. 
 
 
Figure 5.17 Three ligands of GlyR used as a comparison to small molecule hits. Glycine the physiologically 
relevant ligand is an amino acid. Other amino acids have also been shown to bind the receptor. Nipecotic 
acid is structurally similar to the amino acid and is based on piperidine. Quinolinic acid is based on 
quinolone and shares structural similarities with nipecotic acid. 
 
To compare binding modes, structural data are required. For GBP, strychnine, N-methylbicuculline and 
glycine are the only ligands with structural data available in the PDB. As the structure of strychnine and 
N-methylbicuculline have been extensively discussed in Chapter 4 they will not be considered here. 
Glycine bound to GBP (PDB code: 5OAN) is positioned in the centre of the binding site within the 
aromatic cage and mainly makes interactions with the principal subunit (75). This is similar to a subset of 
compounds including 1d, 1c, 3f and 3i. The latter three compounds also make the same hydrogen 
bond, as glycine does, to MC W164. Without more ligands bound to GBP, further validation of 
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compound-protein interactions cannot be conducted. Other ligands bound to GlyR are accessible 
however, these bind in other sites than the orthosteric binding pocket. For example, AM-3607 is a 
candidate potentiator that binds between the extracellular subunits, neighbouring the orthosteric site 
(243). 
 
5.5.8 Compound modification and extension to answer questions and improve binding 
To address some of the issues raised above, example small molecules were modified to investigate the 
effect on binding. The top-ranking compound bound to each protein (GBP, AcAChBP:nicotine and 
AcAChBP:apo) were also modified and extended with various functional groups, to investigate any effect 
on predicted binding. 
 
5.5.8.1 Is the GBP model complete? 
A point previously mentioned, is the deletion of E210 in the heteromeric GlyR. This residue provides a 
hydrogen bond as well as van der Waals interactions with several compounds in GBP. The removal of 
the hydrogen bonding group on a compound was trialled. The 3i Maybridge compound was chosen, the 
hydroxyl was removed, and the molecule was re-docked to the GBP binding site. The removal of the 
group resulted in a Hbond energy decrease of 3 kcal mol-1 and the ICM score decreased from -25.1 to 
-18.6. Therefore, this suggests that the hydrogen bond with E210 was important for binding. 
Substitution of E210 with Gly or Ala led to a similar drop in ICM score however, the Hbond energy was 
maintained between -4.3 and -4.7 kcal mol-1. Due to the replacement of E210 with smaller groups the 
compound was able to re-orientate forming an interaction with T208 instead. This analysis suggests 
that possibly the deletion of E210 from future docking experiments, and perhaps GBP itself, would 
make a more representative binding pocket of the β+α- GlyR orthosteric site. 
 
5.5.8.2 Improving the binding score of a GBP hit 
The top-ranking compound for GBP was 3b with an ICM score of -29.4. Looking at the binding pocket 
there were three potential areas to build into: 1) above towards R96, 2) out towards W164 and 3) back 
between E162 and Y212. There are many sites on 3b where extension could occur, therefore three were 
selected to exploit the pockets identified (Figure 5.18). A screen of 46 common groups per extension 
point was conducted. These common groups were taken from ICM and by analysis of common 
compound substituents (Chapter 2.5.2). The top three of each position are shown in Figure 5.18. A new 
term, VLS score, is used to investigate binding improvement, as this incorporates the effect of additions 
on ligand strain (Chapter 2.5.2). Ligand strain energy is calculated as the difference between the 
bound and free-state and can affect how a compound binds and the affinity to the target (292). 
Therefore, adding groups to a scaffold may increase the strain and cause problems with ligand binding. 
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A baseline VLS score of -24.9 was measured for a hydrogen substituent at each position. Extension 
from position A did not lead to a significant increase in score. However, building from positions B and C 
led to an improved score by 5.6 and 3.2 units. The highest-scoring group of each position was re-
docked, optimised and position combinations were trialled (Chapter 2.5.2). From this analysis, it was 
identified that the ester (position A) and amine (position B) were enough to raise the ICM score to        
-29.4, compared to -24.2 of the optimised unaltered ligand. 
 
Figure 5.18 Extension of the top-ranking GBP small molecule, 3b. Three positions (A, B and C) were 
chosen to exploit different pockets within the binding site (PDB code: 5OBG). The table shows the top 
three groups for each position that gave an improved binding score. 
Interestingly, the incorporation of the cyclopentadiene at position B caused the ligand to take up a 
different orientation within the GBP binding site. This orientation was better than the original with a VLS 
score of -25.7 compared to -25.0. The addition formed a new hydrogen bond between the carboxylic 
acid and Y72, as well as R74. The change could have also increased the van der Waals interactions of the 
compound. This new compound could be further developed to manipulate binding interactions and 
improve predicted affinity. 
 
5.5.8.3 Identifying differences in binding between NMR and Maybridge hits with AcAChBP 
Previously, the potential problem of the fluorine atoms of the NMR compounds interfering with binding 
to AcAChBP:nicotine was noted. To investigate this the CF3 group of compound 2c was removed. Upon 
re-docking of the modified compound to the AcAChBP:nicotine binding pocket, a substantial change was 
observed. The compound adopted a different pose with the pyridine ring placed between V165 and 
M133 with the formation of a hydrogen bond (1.6 Å) between the N-pyridine and water molecule, as 
seen for all the Maybridge compounds investigated. Additionally, due to the change in orientation, the 
second pyridine group was located in the centre of the aromatic cage and the amine linker made a 
further hydrogen bond with the MC of W164. The new orientation and interactions led to an improved 
ICM score of -21.0 (from -12.4). 
Deletion of the CF3 group of 2c and re-docking to AcAChBP:apo was also conducted. This led to minimal 
orientation changes, however, a decrease in ICM score was observed (-18.9). This is perhaps due to the 
loss of the extra hydrophobic and van der Waals interactions that the group made. 
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5.5.8.4 Improving AcAChBP binding scores by extending scaffolds 
The top compound docked to AcAChBP:nicotine is 4b with an ICM score of -29.6. Due to the small pocket 
and size of the compound, the extension of the scaffold is limited. There are two possible locations to 
extend the scaffold into: 1) from the hydroxyl towards R96 and 2) from the phenyl ring below loop C. 
Three positions of the ligand were investigated by screening the set of 46 common groups. A baseline 
value for position A of -17.1 and positions B/C of -22.4 were obtained. Removal of the hydroxyl, at 
position A, led to a decrease of the VLS score by 5.3, which suggests the hydrogen bond to Y212 is 
important for binding. The removal of the hydroxyl is also the reason why there is a difference in baseline 
scores for different positions. Again, the top three groups for each position are shown (Figure 5.19). The 
highest-ranking groups were re-docked with AcAChBP:nicotine and it was found the highest-scoring 
combination was for positions B and C, with a VLS score of -42.3, an improvement of 19.8. 
 
Figure 5.19 Extension of the top-ranking AcAChBP:nicotine small molecule, 4b. Three positions (A, B and 
C) were chosen to exploit different pockets within the binding site (PDB code: 5O87). The table shows 
the top three groups for each position that gave an improved binding score. 
Finally, the top-scoring small molecule for AcAChBP:apo, 5c (ICM score -26.2), was investigated. Due to 
the open pocket, several large areas could be exploited by compound extension from the scaffold. Three 
positions were chosen to exploit three different pockets: 1) methyl toward Y193 (A), 2) phenyl alongside 
Y53 (B) and 3) methyl towards Y91 (C). Due to the open pocket, residues were far apart therefore, 
interactions could not be fully optimised as is seen by the low VLS scores. Also, owing to space within 
the pocket optimisation of modified compounds was harder, as many orientations were feasible. 
Eventually, the phenyl (position A) and amine (position C) were found to be optimal (Figure 5.20). These 
groups made additional interactions with the protein, including a hydrogen bond with Y53. This led to a 
VLS score of - 30.9, an improvement of 4.4. 
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Figure 5.20 Extension of the top-ranking AcAChBP:apo small molecule, 5c. Three positions (A, B and C) 
were chosen to exploit different pockets within the binding site (PDB code: 2Y7Y). The table shows the 
top three groups for each position that gave an improved binding score. 
 
5.6 Summary 
Identification of several compounds that potentially bind to AcAChBP or GBP have been found by 
experimental and computational approaches. Analyses of the orientations and binding interactions 
these compounds make with the relevant receptor have led to similarities and differences being 
recognised. The binding of two of the small molecules have been validated by WF. Sequence and 
structure comparisons suggest that many of the conclusions derived from the surrogate proteins can be 
translated to the native receptors, nAChR and GlyR, with some exceptions. Examples of potential 
compound extensions have been shown to highlight the possibility of developing lead compounds from 
these small molecule hits. However, these observations would need to be experimentally validated. 
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6. Design of and attempted production of selected proteins 
 
6.1 Construct design 
6.1.1 GlyR β+α- 
Except for GBP, there are no other models of the GlyR heteromeric orthosteric binding site, therefore a 
new construct was designed. The new construct represents the β+α- heteromeric interface of GlyR, which 
is the physiologically relevant site of glycine binding (39) but one formed by a homomeric assembly. The 
full length α3 homomer, which has been produced previously by Huang et al. was used as a template (24). 
Comparison of AcAChBP and human GlyR α3 as a template suggests increased residue conservation in the 
orthosteric binding site and potentially fewer substitutions required to form a β+α- interface. A sequence 
alignment of human GlyR α1-3 and β was first used to identify residue differences between subunits (Figure 
6.1). 
Figure 6.1 Sequence alignment of the main loops in the orthosteric binding site of pLGICs, A-C of the 
principal-(+) subunit and D-G of the complementary-(-) subunit. Sequences of GlyR α1-3 and β were 
retrieved from Uniprot. The sequence of the GlyR α3 structure (PDB code: 5TIN) was also compared. The 
residues that make up the β+α- heteromeric interface are shown in bold. Highlighted residues show the 
required substitutions required to transform a principal-α3 subunit into β. 
Heteromeric β+α- receptors are formed by the only β subunit and either α1 or α3 (288). The sequence 
alignment indicates a high level of conservation between the α subunits when considering the relevant 
binding loops (D-G). Only two, conserved substitutions were identified between α3 and α1, E213D and 
K100Q. Therefore, model ligand binding within the GlyR β+α- should hold for interactions for both α 
receptor subtypes. To form a principal-(+) β subunit, only loops A-C need to be considered. From the 
alignment, it was proposed that six substitutions translate an α3 principal subunit to β (I93L, H201Y, 
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N203KG, K206Y and F207Y). The conservative substitution, I93L, was not considered significant and was 
ignored. The major difference between α and β involves loop C, which, as noted elsewhere, is essential 
for the correct functioning of all pLGICs (25). The loop also provides many interactions, including two 
residues, which contribute to the aromatic cage, a feature of the pLGIC family (293). Similar to GBP, the 
C loop should be altered to potentially provide β subunit ligand interactions. Unlike GBP, the flanking 
tyrosine residues (Y246 and Y253) of GlyR β will also be included as these may provide additional 
interactions or stabilise the loops’ conformation. Additionally, the N38Q substitution from the Huang et 
al. construct will be maintained to prevent glycosylation (24). 
 
 
Figure 6.2 GlyR β+α- model showing the loop C substitutions (blue sticks) of the principal subunit (blue). 
The residue E173 (red sticks) from the complementary subunit (red) is shown as it may form a salt bridge 
with K203. Due to the size of the sidechains of G204 and G206, they are not shown. T205 is also not shown 
as this clashes with Y208. Oxygen (red), nitrogen (blue) and carbon (chain colour) atoms are shown. 
A model of the GlyR β+α- was produced utilising the GlyR α3 homomer protein sequence (24). The five 
substitutions (H201Y, N203KG, K206Y and F207Y) are potentially well-supported by the protein and should 
not affect stability. In the model, T205 and Y208 appear likely to clash, however, either due to a different 
rotamer of Y208 or loop flexibility this should not occur. The two aromatic residues, Y202 and Y208, often 
display as different rotamers in structural models as noted in the GBP:N-methylbicuculline complex 
(Chapter 4.5) and may form a stabilising hydrogen bonding interaction that maintains loop 
conformation. No other clashes with residues of the binding pocket are observed. The substitutions 
maintain Y202 and T205 in the orthosteric site but also add the SC of Y208. Even though T205 is 
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maintained, it occupies a different position. This appears to be due to the presence of an additional 
residue, G204 in the loop. K203 is positioned 3 Å away from the SC of E173, this distance could support a 
salt bridge. Such a strong interaction could stabilise the conformation of the loop. The Y201 and Y207 
substitutions also point away from the binding pocket, nonetheless, these residues may contribute 
additional stabilising interactions in certain loop conformations. 
 
6.1.2 HisR homomer 
Two HisR subunits are commonly identified within different insect species, HisR1 (type-1) and HisR2 
(type-2) (294). A sequence alignment of selected examples reported in Uniprot (137) is shown in Figure 
6.3. 
There is a high degree of conservation between different HisR receptor subtypes and species (Table 6.1). 
Some receptors have alternate sequences due to splicing (295), therefore there is a degree of uncertainty 
when utilising such sequences for protein production. Both type-1 and 2 receptors can form homomers 
with HisR1 channels being shown to be more sensitive to histamine (EC50 3 µM) (296). The two subunits 
can also form heteromers (297), however, for initial protein production, only a single subunit will be 
investigated. Structural predictions identified that the type-1 HisRs were similar for most of the calculated 
parameters. Small differences were observed with the instability index and prediction of the number of 
transmembrane helices. The instability index calculation considers the number of specific dipeptides in a 
primary amino acid sequence that have a higher frequency in stable or unstable proteins. All proteins 
with a half-life >15 h had a score below 40 and were classified as stable, whereas unstable proteins with 
a half-life <5 h had a score greater than 40 (298). However, comparisons of HisRs demonstrated neither 
the number of transmembrane helices nor the instability index scores were significantly different. Due 
to these similarities, it was decided that any of the channels would be viable for protein production, the A. 
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Table 6.1 Percentage sequence identity for HisR1 and HisR2 from different species D. melanogaster 
(Dm), A. mellifera (Am), N. vitripennis (Nv) and T. castaneum (Tc). 
 
6.2 Attempted protein production in baculovirus 
Attempts to produce both the GlyR β+α- and HisR proteins were carried out in insect cells, following the 
protocol used by Huang et al. to produce the homomeric GlyR α3 (24). Fractions of insoluble, soluble and 
detergent-solubilised membrane proteins were analysed by Western blot utilising the relevant 
antibodies (Figure 6.4). The molecular weight of a single subunit of GlyR β+α- and HisR are 45.6 kDa and 
50.3 kDa, respectively. No soluble or detergent-solubilised proteins were detected. Multiple bands were 
observed in insoluble fractions suggesting several forms of recombinant protein were present. No bands 
were detected in the negative control, which suggests that the bands in the experimental condition are 
due to the viral infection. Further experiments were carried out in an attempt to produce soluble protein. 
Such efforts included attempting to increase the production of proteins by altering baculovirus 
concentration, culture volume and incubation length, whilst at the same time attempts to solubilise the 
proteins including trialling different detergents, buffers and protocols. Analysis of different fractions 
throughout the experiments was conducted, however, the proteins remained insoluble. 
Again, this raised questions about the production of a functional receptor and trafficking of it to the cell 
membrane in insect cells. If the proteins are produced and correctly trafficked, maybe there is an issue 
with the extraction of proteins from the membrane. 
 
6.3 Localisation at the membrane 
To examine if the receptors were being produced and trafficked to the cell membrane they were tagged 
with GFP. A preliminary experiment utilised GlyR β+α- model tagged with GFP at the C-terminus. A 
baculovirus expression system was used; infected and uninfected cells were visualised after 24 and 48 h 
(Figure 6.5). 
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Figure 6.4 Example of an SDS-PAGE gel and Western blot for GlyR β+α- (A, B) and HisR (C, D). Stained 
(SM) and unstained (M) markers were used for size comparison. The intervals were marked on the 
Western blot from comparison with the SDS-PAGE gel for clarity. S and P are supernatant and pellet, 
respectively. In both cases, an Sf9 negative control was conducted in tandem to detect background 
signals. An anti-His primary antibody was used for the detection of HisR, whereas an anti-Strep 
primary antibody was used to detect GlyR β+α-. 
 
Figure 6.5 shows that the infected cells are producing the protein compared to uninfected cells. By the 
difference in intensity, it can also be inferred that cells are still producing the protein after 48 h. However, 
this experiment also raised some questions. Due to the replication of the virus in the nucleus, the size of 
this organelle increases (299), therefore there is uncertainty about the localisation of the recombinant 
protein. Also, there was a risk that the GFP could have been cleaved from the protein, therefore the 
experiment may only show GFP localisation. Due to these reasons, a second experiment was set up. 
Both GlyR β+α- and HisR were N-terminally tagged with GFP and baculovirus’ were produced. 
Experiments were run and visualised with the relevant controls, uninfected and GFP only infected cells. 
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Figure 6.5 Microscopy images of C-terminal GFP-tagged constructs. The presence of GlyR β+α- model 
tagged with GFP at the periphery of infected Sf9 insect cells. The signal intensity increases between 24- 




The experiment showed no GFP signal in the uninfected cells (Figure 6.6), therefore there is no 
background signal. There is a clear difference between cells infected with the GFP only virus and the 
virus with GFP-tagged receptor. The GFP only cells have a widespread signal that occludes that of the 
nuclear stain in some cases. Whereas, the signal of the GFP-tagged receptor is localised to the 
membrane. Differences between signal intensity of Figure 6.5 and 6.6 are noted, this may be due to 
difficulty passing the GFP molecule through the membrane if it has already folded in the cytoplasm (300). 
These experiments suggest that the receptors are produced and localised to the membrane, therefore 
the issue may be due to inefficient extraction and solubilisation of the proteins during the purification 
process. However, membrane association does not guarantee correct folding, therefore such a sample 
may not be suitable for detergent extraction. 
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Figure 6.6 Microscopy images of N-terminal GFP-tagged constructs. Uninfected, GFP only, GFP-GlyR β+α- 
and GFP-HisR infected cells are shown. No GFP (green) signal is detected in the uninfected control. 
Widespread GFP signal is observed for the GFP only infected cells demonstrating that it is present in the 
cytoplasm. A lower GFP signal, located at the periphery of the cell is observed for both GFP-GlyR β+α- 
and GFP-HisR. This demonstrates that the receptors are most likely membrane-associated. In each 
condition, the nuclei (blue) were stained with Hoechst. 
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One possible explanation for the inability to extract the proteins from the membrane is detergent-
resistant membranes. These membranes can occur in microdomains within the phospholipid bilayer and 
cannot be solubilised by detergents, even at high concentrations (301). These microdomains are known 
as lipid rafts and are subsections of the membrane that are comprised of different phospholipid 
components, compared to the rest of the membrane (302). It has been shown previously that members 
of the pLGIC family are located in detergent-resistant membranes that could not be solubilised with 
Triton X-100 (303). However, others have shown that detergent extraction of pLGICs, including GlyR, is 
possible (24,25). This suggests that either the most efficient extraction conditions have not been 
obtained or there are problems with protein production, in the case of the GlyR β+α- and HisR. 
Another explanation is that during the extraction process aggregation of the protein may occur which 
leads to solubility issues. It has been suggested to limit exposure of membrane proteins to detergents as 
they may cause damage (29). To counter this, weaker detergents could be used or other methods such 
as a nanodisc protocol. However, less harsh detergents may extract the proteins with a lower 
efficiency, which generates other problems. 
6.4 Attempted protein production in lentivirus 
A different expression system was trialled to produce GlyR β+α- and HisR utilising the lentiviral system. 
Using the protocol by Elegheert et al., previously used to produce GABAAR (150), an attempt to 
produce the receptors in HEK293 cells was conducted. Correct glycosylation may be essential for 
assembly and function as reported for GABAAR by Phulera et al. (31). After generating the stably- 
transfected cells, a preliminary analysis was carried out to determine receptor production. Soluble, 
detergent-solubilised and insoluble fractions were taken from cultures and analysed by Western blot. 
However, no bands were observed for either protein in any of the fractions. 
6.5 Design of a HisR orthosteric binding site model 
As HisR could not be detergent-solubilised, an AcAChBP surrogate was proposed to study binding in 
these receptors. Based on the homology of HisR to GlyR α subunits and evidence of histamine binding 
to GABAAR (21), these proteins were used to infer relevant substitutions to form a histamine-binding 
orthosteric pocket. Histamine has a positive and negative modulatory effect on GABAAR and GlyR, 
respectively (304). A molecular model was also made using the sequence of A. mellifera HisR. 
Histamine was docked into the orthosteric binding site of the HisR model (Figure 6.7B). The volume of 
the pocket is 285 Å3, which is comparable to that in the AcAChBP:nicotine complex (260 Å3). The docking 
calculations suggest that the imidazole ligand forms a π-π interaction with Y142. One nitrogen atom of 
the ring and the primary amine make hydrogen bonds with the MC of the protein. The primary amine is 
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Figure 6.7 Information used to guide the design of a histamine-binding protein (HisBP). A) Model of the 
A. mellifera HisR generated by Phyre2 and SymmDock shows the major residue side chains (sticks), which 
contribute to the HisR orthosteric binding site. The principal (blue) and complementary (red) subunits 
are shown. Atoms are coloured as in Figure 6.2 with the addition of sulfur (yellow). B) Histamine (green 
carbon atoms) docked into the HisR model (grey). Residues involved in close interactions are shown as 
sticks. Two main chain hydrogen bonds (coloured spheres) are shown. C) Sequence alignment of the 
main loops that contribute to binding in the principal (A-C) and complementary (D-G) subunits. 
Sequences of human GlyR α1, GABAAR β1, A. mellifera HisR1 and AcAChBP are compared. Residues in 
red are suggested to be involved in histamine binding in (B). Bold and highlighted residues are suggested 
substitutions to form HisBP. 
likely protonated under physiological conditions (pKa 9.8), therefore can make a π-cation interaction 
with the SC of F231. The ligand may be involved in van der Waals interactions with the residues F124, 
W144, E182, S183, L184, S185 and Y226. Histamine does not make extensive van der Waals 
interactions (VDW energy -14.9 kcal mol-1), leading to a low ICM binding score of -16.9, however, this is 
potentially due to its small size. Possibly, more interactions between histamine and HisR would be 
formed upon binding in solution, due to loop and residue flexibility, which is not accounted for in the 
docking simulation. 
Using the sequence alignment, HisR and histamine-docking model, eleven substitutions are suggested 
to generate a histamine-binding protein (HisBP) from an AcAChBP template. The two substitutions 
W164L and V125W should be considered together. W164L removes one of the main aromatic cage 
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residues in AcAChBP and opens up a deeper part of the pocket. The aromaticity is partly replaced by the 
phenyl ring of V125W. Due to the large SC of tryptophan, the V125W substitution also blocks binding 
to the upper part of the pocket towards R96 in AcAChBP. In the GBP:N-methylbicuculline complex, this 
arginine can provide additional interactions with ligands. These two substitutions are not conserved in 
GlyR or GABAAR, therefore are specific for HisR. These changes alter the residues involved in binding. 
Due to the removal of W164, the substitution I123Y could position a Tyr residue in its stead, as is seen 
in the histamine-binding model (Y142, Figure 6.7) replacing the aromaticity lost from the W164 
substitution. This change is also not observed in the other pLGICs compared. 
The substitutions G162E and Y110K in AcAChBP should be considered in tandem as well. To generate 
GBP these residues were also substituted, G162E and Y110A (75). G162E is maintained in both GlyR and 
GABAAR and directs an acidic residue into the binding site, which may aid in orientating ligands. Y110K 
removes the bulk of tyrosine, therefore allowing the G162E substitution. The lysine in the HisR model, 
together with F87, provides the bottom boundary of the binding site. This lysine could also make a salt 
bridge with Q224 of loop C. Loop C substitutions (S206CCPE_NTG) are conserved across GABAAR β, GlyR 
α and HisR and lead to the removal of the Cys loop in AcAChBP. These substitutions also include the 
deletion of two residues in loop C decreasing loop flexibility. The final substitution Q74A would remove 
a polar group from the binding site, this is a HisR-specific alteration as a Gln is maintained in GABAAR and 
a different polar residue, Arg, is present in GlyR. 
The suggested substitutions could form the basis of generating HisBP, however, some may not be 
tolerated by AcAChBP. In particular, the W164L substitution, as the tryptophan provides interactions 
with all ligands that bind in the pocket and forms a link between two β strands. When attempting to 
generate GBP, Dawson et al. replaced W164 with Phe, however, this was not well-tolerated and the 
protein stability decreased (75). Nonetheless, the use of the I123Y substitution may negate this 
destabilisation. 
Comparison of the data above and mutational studies investigating histamine binding in GABAAR suggest 
that the molecule interacts differently with the distinct receptors. One electrophysiology study 
suggested that the Q64A substitution of GABAAR β3 decreases histamine potency (EC50 480 µM), whereas 
Q64E increases it (EC50 40 µM) compared to the unsubstituted form (EC50 200 µM) (305). In HisR this 
residue is A89 therefore inferring that distinct binding conformations are adopted. This statement is 
supported by Thiel et al. who demonstrated that residues R120 (α1), Y157, D163 (β2), V175 and Q185 
(β3) are important for histamine binding to GABAAR (304). However, all but one of these residues are 
outside the binding pocket of HisR. The β2 residue Y157 is not conserved in HisR, instead, the aromatic 
group is replaced by leucine (L184). The hypothesis that histamine may adopt separate conformations 
when bound to the receptors can only be proven by direct comparison of GABAAR and HisR structures. 
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Nonetheless, it is conceivable that a small molecule could bind multiple receptors in different positions 
as shown with N-methylbicuculline. 
 
6.3 Summary 
A full length human GlyR with a β+α- interface was designed as a surrogate of the physiologically relevant 
heteromeric receptor. A construct encoding A. mellifera HisR was prepared. An attempt to produce both 
of these pLGIC family members was carried out via baculovirus and lentivirus expression systems. Protein 
production was detected in the baculovirus but not the lentivirus system. Attempts to solubilise these 
proteins were unsuccessful. Microscopy data for GFP-tagged proteins suggested that the receptors are 
produced and trafficked to the membrane. This, therefore, suggests that there may be issues with 
folding or solubilisation with the detergents tested. 
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7. Conclusions and future work 
 
Due to similarities with other pLGICs, which are proven drug targets, and its implication with various 
conditions, GlyR is attracting interest as a potential therapeutic target (273,306,307). Structural 
studies of human GlyR have been confined to the homomeric forms (24,25), possibly due to 
experimental challenges linked with producing a heteromeric receptor. These homomeric GlyR 
models represent a major advance to the field. However, a structural model of a physiologically 
relevant heteromeric binding site is sought to progress the search for and characterization of ligands 
to inform early-stage drug discovery. GBP, a surrogate of the heteromeric β+α- interface has been 
characterised. The data support that GBP is a good model of the physiologically relevant binding site 
of glycine and can be used for the discovery of novel ligands. 
Data presented in Chapter 4 and 5 emphasised a difference between GBP and heteromeric GlyR, 
residue E210 in loop C. In the sequence alignment of GBP and the β principal subunit, E210 is not 
present. The structures of GBP:strychnine and GBP:N-methylbicuculline suggest that E210 makes 
mostly van der Waals interactions with the ligands. Computational docking of a Maybridge small 
molecule library to GBP suggested that some compounds are predicted to interact directly with E210 
making close van der Waals interactions and hydrogen bonds. These interactions are not 
representative of the GlyR heteromer, therefore these small molecules may not bind to the 
receptor. Due to these reasons, a GBP E210 deletion mutant may be required. The deletion will 
shorten loop C but should not affect structural stability drastically as it is a surface residue (308). This 
alteration will make GBP more representative of the GlyR β+α- interface and may allow loop C to 
close more tightly/form closer interactions with ligands in the orthosteric binding site. 
Three biophysical techniques SPR, ITC and WF were used to investigate interactions between 
AcAChBP and ligands. A comparison of three ligands interacting with AcAChBP revealed only small 
differences between KD values from ITC and the other two techniques. These differences could have 
been caused by incomplete ITC titration curves. It was concluded that WF is the best technique due 
to its sensitivity, ease of use and accuracy. As well as providing comparable KD values, using the 
techniques in tandem can give information about the thermodynamic and kinetic parameters of 
binding interactions. Kinetic parameters were not deduced for the three ligands, however, further 
optimisation of experiments could lead to binding curves being observed. Optimisation could be 
carried out by changing several variables including temperature, flow rate and concentration to 
allow calculation of kon and koff. 
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N-methylbicuculline is a promiscuous ligand of the pLGIC family. Structures presented in this work 
show N-methylbicuculline bound to GBP and AcAChBP, surrogates for GlyR and nAChR. Structures of 
the ligand bound the GABAAR (29,33) have also been reported in the literature. These data support 
previously published binding parameters that demonstrate bicuculline binding to all members of the 
pLGIC family (245-248). Improved structural data are required for AcAChBP:N-methylbicuculline to 
confirm the orientation as suggested by the preliminary complex. 
GBP can be used for early-stage drug discovery. The NMR and computational ligand screens identified 
a variety of potential ligands for GBP and AcAChBP. Two of these compounds have been validated by 
WF, thereby preliminary validating the use of the screening methods with GBP. Further validation of 
selected compounds from the two screens is required. Direct ITC methods did not result in binding 
curves for selected small molecules, however, a competition-based approach may give some 
indication of affinity (309). 
Attempts to produce recombinant proteins corresponding to a GlyR β+α- surrogate and HisR were 
unsuccessful. The former construct was designed using GlyR α3 as a template. Selection of a HisR 
construct was carried out following the generation of homology models and sequence comparisons. 
Baculovirus and lentivirus expression systems were tested. However, the proteins were never 
solubilised by detergent, raising questions about trafficking to the membrane and the purification 
protocol. Microscopy data demonstrated both proteins were membrane-associated but this cannot 
be taken as being correctly folded and incorporated into the membrane. Patch-clamp 
electrophysiology could be used to confirm if the two proteins are functional at the membrane, 
thereby answering the questions raised by microscopy. The technique can be used to detect ionic 
currents passing through a membrane and thus ion channel opening and closing (310). If successful, 
additional data could be gathered about the binding interactions of the two proteins. 
An alternative route to investigate binding in HisR is to produce an AcAChBP-based surrogate, as 
suggested in Chapter 6. A similar approach as used with GBP can be taken to examine the role of 
different amino acid substitutions on binding the native ligand, histamine. This data could then be 
compared with published results from GABAAR studies, which suggest a potential role of histamine in 
modulating receptor function (21). Upon completion, the HisR surrogate, HisBP, could be utilised as 
a model of the orthosteric binding site to investigate interactions with other ligands and for early-
stage drug discovery targeting mammalian or insect HisRs. 
Over the last three years several structures of the tri-heteromeric GABAAR have been reported 
(27,29,31,33). Further insights about GABAAR receptor function and modulation have been gained 
from these structures. They also provide models for drug discovery and the investigation of binding in 
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the physiologically relevant receptor. Presently, GBP is the only model of a heteromeric GlyR. It is 
hoped that a structure of a GlyR heteromer is imminent and will revolutionise the field as it has done 
for GABAAR. Nonetheless, even with a full length model of a GlyR heteromer, GBP can play a role in 
initial investigations and screening of ligand binding, as a cheap and easy to use resource. 
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A. Crystallographic statistics for structural complexes 
 
Structure GBP:N-methylbicuculline AcAChBP:N-methylbicuculline 
Unit cell dimensions   
a, b, c (Å) 71.24, 132.24, 132.63 79.46, 100.03, 100.22 
α, β, γ (°) 90.00, 90.00, 90.00 89.55, 88.08, 66.92 
Space group P212121 P1 
Source In-house Synchrotron - Soleil 
Wavelength (Å) 1.5418 0.9801 
Subunits per asymmetric unit 5 10 
Resolution range 46.82 – 2.40 (2.48-2.40) 48.42-2.90 (2.98-2.90) 
   
Total number of reflections 306823 (27829) 187440 (13631) 
Unique reflections 49817 (4510) 59954 (4566) 
Redundancy 6.2 (6.2) 3.1 (3.0) 
Rmerge 0.130 (0.776) 0.127 (0.777) 
Wilson B-factor (Å2) 48.1 54.9 
Completeness (%) 100 (100) 95.3 (97.5) 
<I/σ(I)> 7.9 (1.8) 6.3 (1.4) 
CC(1/2) 0.995 (0.826) 0.995 (0.644) 
Refinement 
Rwork/Rfree (%) 20.29 / 23.61 27.72 / 30.86 
Number of reflections for Rwork/Rfree 44310 / 2381 56915 / 2943 
Protein residues 1025 2077 
N-methylbicuculline molecules 5 3 
Water molecules 404 - 
Chloride ions 5 10 
RMSDs 
Bonds (Å) 0.009 0.006 
Angles (°) 1.42 1.44 
Ramachandran plot 
Residues in favoured regions (%) 991 (98.4) 1865 (92.1) 
Residues in allowed regions (%) 16 (1.6) 123 (6.1) 
Residues in outlier regions (%) - 38 (1.9) 
Mean B-factors (Å2) 
Protein atoms 43.5 / 40.3 / 45.5 / 52.3 / 66.9 / 69.3 / 60.0 / 56.6 / 66.6 
 46.0 / 64.7 / 65.3 / 69.3 /61.9 / 
  56.9 
Water molecules 38.2 - 
N-methylbicuculline 95.7 / 67.2 / 101.9 / 
111.9 / 116.3 
95.1 / 61.5 / 73.9 
Chloride ions 37.5 / 37.1 / 49.1 / 56.4 / 59.5 / 55.9 / 46.9 / 39.6 / 55.3 
 58.4 / 58.2 / 61.3 / 58.4 / 41.1 / 
  40.9 
PDB Code 5OBH - 
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B. Theoretical interaction parameters predicted by Molsoft 
 
 
Table B.1 The main docking outputs for simulations using the NMR hits with GBP (PDB code: 5OBG), 
AcAChBP:nicotine (PDB code: 5O87) and AcAChBP:apo (PDB code: 2Y7Y). For descriptions of the 
different parameters see Chapter 2.5.2. Strychnine and nicotine were re-docked to the relevant 
receptor as controls. The series relates to the common substructure in Figure 5.2 of Chapter 5.5. 
Appendix B 






Table B.2 The main docking outputs for simulations using the Maybridge hits with GBP (PDB code: 
5OBG), AcAChBP:nicotine (PDB code: 5O87) and AcAChBP:apo (PDB code: 2Y7Y). For descriptions of 
the different parameters see Chapter 2.5.2. Strychnine and nicotine were re-docked to the relevant 
receptor as controls. The series relates to the common substructure in Figures 5.7, 5.9 and 5.11 of 
Chapter 5.5. 
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C. Preliminary work on the amino acid transporters, GlyT1C and PutP 
 
C.1 Introduction 
C.1.1 Human glycine transporters 
 
At synaptic junctions, specific amino acid transporters recycle the neurotransmitters released into the 
cleft by transporting them into the presynaptic neuron and/or glial cells. Of relevance here are glycine 
transporters (GlyT1 and 2), GABA transporters and monoamine transporters, which transport 
serotonin (1). The reuptake of neurotransmitters is driven by a Na+ electrochemical gradient, a counter 
Cl- ion is also transported (2). 
GlyTs are predicted to consist of twelve transmembrane helices, five intracellular and six extracellular 
loops (3). There are two transporters, GlyT1 can operate in both directions and is present in multiple 
cell and neuron types, whereas GlyT2 can only take up glycine into the cell for glycinergic neurons (4). 
Their essential role at the synapse means that mutations have been linked to disease including 
motor-sensory deficits and neuromotor disorder (3). 
 
 
C.1.2 Bacterial proline transporter 
 
Orthologues of the neurotransmitter transporters exist in prokaryotes and are used to transport 
amino acids. Amino acid transport in bacteria plays an essential role in metabolism (5), however, 
proline transport is involved in a wider range of biological processes including signalling and protection 
from oxidative stress (6,7). In some bacterium, proline is the only source of carbon and nitrogen for 
metabolism (8). ESKAPE pathogens are six bacterial classes (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas aeruginosa and Enterobacter) 
that are on the rise in hospitals as well as being multidrug-resistant, therefore are of keen research 
interest (9). It has been shown that some ESKAPE pathogens possess the proline transporter, PutP, 
and mutants of the protein affect virulence (10,11), therefore the protein may be a candidate for 
target validation for early-stage drug discovery. 
 
C.2 Materials and methods 
C.2.1 Construct design 
Uniprot sequences of HsGlyT1C (P48067), HsGlyT2 (Q9Y345) and Pseudomonas aeruginosa (Pa) PutP 
(Q9I5F5) were extracted. At the time of the work, no structures for any of the proteins existed, 
therefore structural models were made using Phyre2. 
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C.2.2 Cloning of GlyT1C for expression in insect cells 
The gene for GlyT1C was ordered from Integrated DNA Technologies (IDT). This included an N- 
terminal Kozak sequence and a C-terminal TEV cleavage site with His6 tag, in a pUCIDT-Amp vector 
(IDT). Flanking restriction sites (NdeI and XhoI) were also included. The gene was codon optimised 
for baculovirus expression. A PCR was conducted to amplify the gene. PCR products were analysed 
by gel electrophoresis and the desired product was isolated. The insert was then digested, to form 
‘sticky ends’ and ligated into a pFastBac1 vector, which was then transformed into NovaBlue 
competent cells (Novagen) and plated onto a LB-agar ampicillin plate. 
 
C.2.3 Cloning of PutP for expression in E. coli 
The gene encoding PutP was ordered from IDT in a pUCIDT-Amp vector (IDT). Due to the potential 
requirement for using multiple vectors with different tags, restriction sites were not included. Codon 
sequences were optimised for expression in E. coli. A PCR was conducted to introduce the start and 
end restriction sites required to insert the gene into a modified pET21a vector (Novagen). The PCR 
product was ligated into TOPO (Invitrogen) and the integrity of the construct was confirmed by 
sequencing. PCR products were analysed by gel electrophoresis, then the relevant DNA was extracted 
and purified (Qiagen kit). The PCR amplified PutP gene and pET21a plasmid were digested with the 
appropriate restriction enzymes (Table C.1). The cut plasmid and insert were purified by gel 
electrophoresis and then extracted (Qiagen kit). The pET21a plasmid and PutP insert were ligated 
and transformed into DH5α (NEB) using the Clonables kit (Novagen, Merck) and plated onto a LB-agar 
ampicillin plate. The plate was incubated for 24 h, after which colonies were picked and grown in LB 
(20 mL, Media Kitchen, University of Dundee) at 37 °C with shaking at 200 rpm for 24 h. Each colony 
was also analysed by colony PCR. The cultures were centrifuged at 1,912 g for 15 m at 4 °C (Sigma 
4K15 centrifuge, 11150 rotor), then the plasmid was extracted by miniprep (Qiagen kit). The purified 




Vector Restriction Sites Tags [(C) or (N) 
terminal] 
GlyT1C Baculovirus pFastBac1 BamHI/EcoRI TEV- His8 (C) 
PutP E. coli pET21a NdeI/XhoI His6 (C) 
Table C.1 Vectors used for protein production attempts of GlyT1C and PutP. 
 
C.2.4 Attempt at recombinant production of PutP in E. coli 
 
A fresh transformation of plasmid DNA (1 µL, 10 ng) into competent cells (15 µL, C43 [DE3]) was 
conducted and then the culture was plated out onto LB-agar ampicillin plates, which were incubated 
at 37 °C for 24 h. C43 (DE3) cells are widely used for the production of recombinant membrane 
proteins (12). A single colony was picked to start a small LB culture (25 mL), which was incubated at 
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37 °C for 24 h, shaking at 200 rpm. The starter culture was transferred to a flask containing auto-
induction (AI) media (500 mL). The culture was grown for around 3 h at 37 °C with shaking at 200 rpm, 
until an optical density (Abs600) of 0.6 was reached. The temperature was then lowered to 20 °C and 
the culture was maintained for 24 h with shaking at 200 rpm. AI media contains a limited amount of 
glucose (0.1% maximum), which is preferentially metabolised by the bacteria. When the glucose is 
depleted, they switch to consuming glycerol (1.2% maximum) then lactose (0.6% maximum). By-
products of lactose release the lac repressor leading to the expression of genes encoding the protein 
of interest (13). 
Cells were pelleted at 1,912 g for 15 m at 4 °C (Sigma 4K15 centrifuge, 11150 rotor) and the pellet was 
kept on ice. Cells were resuspended in buffer A1 (50 mM Bis-Tris-HCl pH 6, 150 mM NaCl, 0.1 mg  
mL-1 L-proline) with the addition of protease inhibitors (10 µL, 100x, Expedeon, Abcam) and DNase 
(100 µL, 10 mg mL-1 in 0.15 M NaCl, Sigma). The cells in the suspension were broken open by the use 
of a chilled cell disruptor (30 kpsi, Constant Systems). Intact cells were removed by centrifuging at 
5,000 g for 15 m at 4 °C (Beckman Avanti J25 with a JA-25.50 rotor). The supernatant was then 
centrifuged again at 45,000 g for 1 h at 4 °C (Beckman Optima L-100K ultracentrifuge with a 70 Ti 
rotor) to pellet the membranes. The supernatant was removed, this contains the soluble fraction. 
The pellet was resuspended and manually homogenised in buffer A1 with the addition of lipids (1 mg 
mL-1, SigmaAldrich) and n-dodecyl-β-D-maltopyranoside (DDM, 1% [w/v], Anatrace). The solution 
was centrifuged at 45,000 g for 1 h at 4 °C (Beckman Optima L-100K ultracentrifuge with a 70 Ti 
rotor). Samples were taken at each stage to analyse by SDS-PAGE and Western blot. 
 
C.3 Attempted production of GlyT 
Homology models were prepared for both GlyT1 and GlyT2 followed by sequence and structural 
alignments. Models used the D. melanogaster dopamine (47% sequence ID) (14) and human serotonin 
(43% sequence ID) (15) transporters as templates. There are different isoforms (A-C) for GlyT1, with C 
being the canonical version. The two proteins, GlyT1C and GlyT2, share a sequence identity of 44% 
and have good structural conservation (RMSD 0.6 Å). The model predicts there are three large loops 
(out of the eleven in total), these may have a role in function and localisation, two intracellular and 
one extracellular. In the models these loops are disordered. In addition, no structural or biophysical 
data are available for either transporter. Due to the lack of structure for the protein and its interesting 
role in biology, GlyT1C was taken forward for cloning. A tagged full length gene encoding GlyT1C was 
cloned successfully and baculovirus production was underway but due to time constraints, no further 
work was conducted on this protein. Recently, a crystal structure of GlyT at 3.4 Å was reported (20). 
This study could be used as a basis for further work. 
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C.4 Cloning and attempted production of PutP 
A structural model of PutP was generated using the Proteus mirabilis Na+-coupled sialic acid (20% 
sequence ID) (16) and Vibrio parahaemolyticus Na+-coupled galactose (19% sequence ID) (17) 
transporters as templates. Using the model, structural predictions and evidence of full length E. coli 
PutP purification (18,19), it was decided the full length PutP protein should be trialled before making 
alterations to the sequence. The putP gene was cloned into a pET21a vector with a C-terminal His6 tag 
and expressed utilising the E. coli C43 (DE3) strain for membrane protein production. A modified 
protocol for the production of the E. coli homologue was used (19) to produce PutP and analysis at 
different stages was conducted by SDS-PAGE and Western blot with an anti-His antibody (Figure C.1). 
Preliminary results showed the presence of several bands, one between 37-50 kDa and another 
around 75 kDa. The molecular weight of full length PutP is 55.5 kDa, which is similar in weight to that 
of the lower band, however, the results are ambiguous and more work is required. As this was only a 
preliminary test, no controls were conducted, therefore a negative control should be run in tandem 
to check for background signals in the Western blot. Mass spectrometry protein identification analysis 
could also be performed on the different bands to suggest if the protein has been produced and to 
identify the relevant band. 
 
Figure C.1 Example of (A) SDS-PAGE protein gel and (B) Western blot for PutP. Stained (SM) and 
unstained (M) markers were used for size comparison. The intervals were marked on the Western blot 
from comparison with the SDS-PAGE gel for clarity. S and P are supernatant and pellet, respectively. 
A negative control (-) protein was run in tandem. An anti-His primary antibody was used for the 
detection of PutP. 
 
C.5 Summary 
GlyT1C was cloned and a baculovirus expression system was set up, however, due to time constraints 
protein production was not attempted. Preliminary data for PutP is inconclusive. However, more work 
is required to identify if it is PutP and to optimise the conditions. 
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Protein-engineering methods have been exploited to produce a surrogate 
system for the extracellular neurotransmitter-binding site of a heteromeric 
human ligand-gated ion channel, the glycine receptor. This approach 
circumvents two major issues: the inherent experimental difficulties in working 
with a membrane-bound ion channel and the complication that a heteromeric 
assembly is necessary to create a key, physiologically relevant binding site. 
Residues that form the orthosteric site in a highly stable ortholog, acetylcholine- 
binding protein, were selected for substitution. Recombinant proteins were 
prepared and characterized in stepwise fashion exploiting a range of biophysical 
techniques, including X-ray crystallography, married to the use of selected 
chemical probes. The decision making and development of the surrogate, which 
is termed a glycine-binding protein, are described, and comparisons are 
provided with wild-type and homomeric systems that establish features of 
molecular recognition in the binding site and the confidence that the system is 




Pentameric ligand-gated ion channels (pLGICs) are important 
neurotransmitter receptors in the human central nervous 
system (CNS). The pLGIC family includes the y-aminobutyric 
type A receptors (GABAARs), nicotinic acetylcholine recep- 
tors (nAChRs), the 5-hydroxytryptamine type 3 receptor (5-
HT3R) and, of particular interest to us, glycine receptors 
(GlyRs). The proportionate activation of these receptors 
ensures a balance between neuronal excitation and inhibition 
(Corringer et al., 2012; Lemoine et al., 2012; Thompson et al., 
2010), and mutations that perturb the balance are associated 
with neurological and psychiatric disorders (Helbig et al., 2008; 
Shiang et al., 1993). The pharmacological relevance of pLGICs 
is well recognized, with members being targeted by anesthetics 
or drugs to treat anxiety as examples (Lemoine et al., 2012; 
Olsen, 2018). The successful use of relatively few drugs against 
the large pLGIC family suggests future opportunities for drug 
discovery if an improved understanding of specific structure– 
activity relationships, appropriate chemical tools and tech- 
niques were available. However, there are inherent difficulties 
in targeting complex, multi-subunit membrane-bound ion 
channels for drug discovery. The presence of detergents can 
complicate compound screens, and multiple ligand-binding 
sites that vary depending on the conformational state of the 
ion channel are also problematic. To this we add the very 
 













A schematic of a heteropentameric GlyR. The stoichiometry is (a1)2(/3)3, with the a1 subunit in red 
and the /3 subunit in cyan. Plus and minus symbols indicate the positions of the principal and 
complementary sides of the binding site, respectively. In this arrangement there are three types of 
binding site: two a1(+)//3( ), two a1( )//3(+) and one /3(+)//3( ). (b) Comparison of the loop 
segments that create the orthosteric ligand-binding sites in AcAChBP, human GlyR-a1 and GlyR-/3. 
The residues colored red indicate where amino-acid substitutions have been carried out to create 
GBP. The four residues colored blue contribute to the binding site but have not been changed owing 
to structural conservation. 
stoichiometry. Firstly, mutagenesis 
experiments implicate residues in the /3 
subunit in binding glycine to a1/3 
receptors expressed in Xenopus oocytes 
(Grudzinska et al., 2005). Secondly, 
experiments with concatenated a1-/3 
tandem constructs demonstrated that 
functional receptors were only 
expressed with the additional inclusion 
of the /3 subunit, but not the a1 subunit, 
implicating 2a1:3/3. Thirdly, atomic 
force microscopy with epitope-tagged 
a1 and /3 subunits expressed in HEK293 
cells indicated a 2a1:3/3 stoichiometry 
(Yang et al., 2012). Mutations affecting 
key residues in the orthosteric agonist 
site at the a1( )//3(+) interface affect 
the potency of both activation by 
glycine and inhibition by strychnine 
(Grudzinska et al., 2005). We therefore 
set out to generate a high-fidelity 
surrogate of this a1( )//3(+) orthosteric 
binding site using the 2a1:3/3 stoich- 
iometry [Fig. 1(a)] by exploiting 
protein-engineering methods and the 
thermal stability of acetylcholine- 
binding protein from Aplysia californica 
(AcAChBP). Acetylcholine-binding 
protein is a highly conserved ortholog of 
significant complication that the overwhelming majority of 
human pLGICs of physiological and pharmacological rele- 
vance are heteromeric, with distinct subunit combinations that 
display unique biophysical and pharmacological profiles. 
These assemblies are unevenly distributed throughout the 
CNS and its periphery, and the heterogeneity provides an 
opportunity for the development of ligands with receptor- 
subtype specificity (Dutertre et al., 2012; Shan et al., 2012; 
Webb & Lynch, 2007). In large part, owing to difficulties in 
the recombinant protein production of heteromeric samples, 
structural studies are largely restricted to homomeric pLGICs, 
with a limited capacity to characterize the details of selectivity 
that can guide the development of selective chemical probes 
necessary to support fundamental studies or drug discovery. 
There have been modeling exercises (Bergmann et al., 2013; 
Richter et al., 2012) and very recently highly significant 
progress with studies of the heteromeric human a4/32 nAChR 
(Morales-Perez et al., 2016; Walsh et al., 2018) and a/3y 
GABAA receptors (Laverty et al., 2019; Masiulis et al., 2019; 
Phulera et al., 2018; Zhu et al., 2018). 
Our interest is the GlyR subtype, a particularly appealing 
target for the development of novel muscle relaxants and the 
treatment of neuropathic pain (Burgos et al., 2016; Imlach, 
2017; Lynch, 2009; Lynch et al., 2017). The prevalent forms of 
human GlyR are a1/3 heteropentamers with 2:3 or 3:2 
stoichiometry (Durisic et al., 2012; Grudzinska et al., 2005; 
Yang et al., 2012). Several lines of evidence support the 
existence of mammalian glycine receptors with the 2a1:3/3 
the pLGIC extracellular ligand-binding domain (ECD) with 
properties similar to nAChR (Lemoine et al., 2012; Rucktooa 
et al., 2012; Sauguet et al., 2015; Shahsavar et al., 2016; Sixma & 
Smit, 2003). Studies on AcAChBP and the Lymnaea stagnalis 
protein (LsAChBP) have defined the selective recognition of 
ligands and provided surrogates for the excitatory nAChR and 
5-HT3R ECDs (Kesters et al., 2013; Price et al., 2016). We 
outline comparative informatics that guided decision making 
and the characterization of the resulting proteins as we, in 
stepwise fashion, converted AcAChBP to a glycine-binding 
protein (GBP) displaying an orthosteric site with the struc- 
tural features of heteromeric human a1( )//3(+) GlyR. 
Crystallographic and cryo-EM structures of homomeric 
human GlyR-a3 (Huang et al., 2015; Huang, Chen et al., 2017; 
Huang, Shaffer et al., 2017) and zebrafish GlyR-a1 (Du et al., 
2015) provide templates that validate our approach. 
 
 
2. Materials and methods 
2.1. Site-directed mutagenesis and protein production 
The amino-acid sequences corresponding to AcAChBP 
(Q8WSF8) and human GlyR-a1 (P23415) and GlyR-/3 (P48167) 
were retrieved from UniProt (http://www.uniprot.org/). Our 
numbering scheme correlates with the full-length sequences in 
these entries. A series of models were prepared using Phyre 
(Kelley et al., 2015). Sequences were aligned with Clustal 
Omega (Sievers & Higgins, 2014), and the structure of 
 
 







AcAChBP (for example PDB entry 2xys; Brams et al., 2011) 
and homology models were inspected, and mutations were 
modeled in Coot (Emsley & Cowtan, 2004) to inform the 
design of substitutions. A stepwise approach was adopted, 
leading to assessments of which substitutions were important 
and tolerated, i.e. produced soluble, stable protein that was 
able to bind known ligands, taking into consideration ligand 
selectivity compared with the wild type (WT). The DNA 
encoding AcAChBP, together with several other constructs, 
was purchased from GenScript. Site-directed mutagenesis was 
carried out and altered genes were ligated into the pFastBac 
system for secretion using the baculovirus/Sf9 system. Protein 
preparation followed published methods (see, for example, 
Hansen et al., 2004) and included the use of affinity and size- 
exclusion chromatography. 
 
2.2. Thermostability and ligand binding 
Fluorescence-based screening by differential scanning 
fluorimetry (DSF; see, for example, Eadsforth et al., 2012) was 
used to determine the melting temperature (Tm) values. An 
Mx3005P RT PCR system (Stratagene) was used to monitor 
protein unfolding by the increase in fluorescence of SYPRO 
Orange dye (Invitrogen). Assays were carried out in 40 ml 
volumes with proteins at around 10 mM in 50 mM Tris–HCl, 
250 mM NaCl pH 7.5 in 96-well RT PCR plates (ABgene). To 
investigate the influence of the chemical probe strychnine, 1 ml 
of strychnine dissolved in DMSO or buffer and then diluted 
with buffer was incubated with the protein solutions for 5 min 
prior to 71 cycles of 10C temperature increments starting at 
250C. After each 10C increase the sample was excited at 
492 nm and fluorescence emission was recorded at 610 nm. 
The melting temperatures were plotted against a reference 
control sample of DMSO only. The strychnine concentration 
varied between 0.1 and 65 mM, with a requirement to limit the 
concentration of DMSO in the final mixture to <2.5%. Data 
are presented in Supplementary Table S1. 
 
2.3. Isothermal titration calorimetry (ITC) 
The interaction of strychnine with AcAChBP and GBP was 
investigated using ITC. Measurements were carried out with a 
MicroCal PEAQ-ITC (Malvern Panalytical) at 250C. The 
protein solutions (10 mM AcAChBP, 40 mM GBP) were 
prepared by dialysis against buffer (50 mM Tris–HCl pH 7.5, 
250 mM NaCl) at 40C overnight. Strychnine solutions 
(concentrations of 100 and 500 mM) were prepared in the 
same buffer. For the experiments, the initial injection of one 
0.4 ml aliquot was followed by 17 2 ml injections at 3 min 
intervals. In each case the injection needle acted as a paddle, 
stirring the cell contents at 750 rev min-1, and the reference 
was set at 10 mcal s-1. Data were analyzed using the software 
supplied by the manufacturer to calculate Kd, D.H, TD.S, D.G 
and N, which were derived from a one-binding-site model. 
Control measurements, buffer into buffer, strychnine into 
buffer and buffer into protein solutions, were used to deter- 
mine an appropriate offset adjustment. Examples of the data, 
averaged parameters and standard errors derived from three 
titrations are presented in Supplementary Fig. S1. 
 
2.4. Tryptophan fluorescence-quenching assay 
Measurements were recorded using a PerkinElmer LS-55 
spectrophotometer with the detector sensitivity set to 750 V. 
Stock  solutions  of  10 mg ml-1  GBP  and  AcAChBP  were 
prepared, along with two strychnine stock solutions of 100 mM 
and 1 mM in the same buffer as used for the ITC experiments. 
The protein samples (2 ml) were excited at a wavelength of 
280 nm, and emission was recorded between 300 and 400 nm. 
For GBP, aliquots of 20 ml of the 1 mM strychnine stock were 
used, followed by mixing. For AChBP, additions of 2 ml of the 
100 mM strychnine stock were made, followed by mixing. 
Experiments were carried out in triplicate and the percentage 
change in fluorescence was calculated. Data were analyzed 
using Microsoft Excel and GraphPad Prism 7. Examples of the 
data, parameters and standard errors derived from three 
titrations are presented in Supplementary Fig. S2. 
 
2.5. Crystallographic analyses 
Each protein sample (4 mg ml-1 in 50 mM Tris–HCl pH 7.5, 
250 mM NaCl) was incubated with the appropriate ligand for 
1 h before setting up crystallization trials using sitting-drop 
vapor diffusion with standard sparse-matrix screens. Initial 
conditions were identified and then optimized for each sample 
(Supplementary Table S2). Ultimately, this led to six distinct 
crystal forms. Crystals were harvested using a nylon loop, 
cryoprotected with reservoir solution adjusted to contain 30% 
ethane-1,2-diol or 30% glycerol and then flash-frozen in liquid 
N2. Diffraction data were recorded in-house, using beamline 
I04-1 at Diamond Light Source or beamline ID23-1 at the 
European Synchrotron Radiation Facility. Images were 
indexed and integrated using XDS (Kabsch, 2010). The data 
were scaled using AIMLESS (Evans & Murshudov, 2013) 
from the CCP4 suite (Winn et al., 2011) and the structures 
were solved by molecular replacement with Phaser (McCoy et 
al., 2007). The initial model for molecular-replacement 
calculations was the wild-type structure (PDB entry 2xys). 
Multiple rounds of automated restrained refinement in 
REFMAC5 (Murshudov et al., 2011) combined with electron- 
density and difference density map inspection and inter- 
pretation using Coot (Emsley & Cowtan, 2004) were carried 
out. Asn91 is glycosylated and N-acetyl-d-glucosamine was 
modeled onto several subunits. Whilst inspecting the different 
maps it was clear that additional ligands present in the crys- 
tallization mixture were ordered in the structures. These were 
assigned and refined satisfactorily as chloride, citrate, ethane- 
1,2-diol, isopropyl alcohol or phosphate. Water molecules and 
side-chain conformers were included in the models as appro- 
priate. The asymmetric units of the different crystal forms 
contained either five, ten or 15 subunits, and strict noncrys- 
tallographic symmetry restraints were applied during most of 
the refinement and were relaxed towards the end of the 
process. Dictionaries of ligand restraints were assembled using 
grade (Smart et al., 2014). Model geometry was assessed with 
 
 









Contributions of key residues in the orthosteric site of AcAChBP and the human GlyR-a1(-)//3(+) heteromeric site. 
Residues in bold were substituted with the human equivalents to create glycine-binding protein (GBP). 
 
AcAChBP    GlyR-/3(+)  
Residue Loop Role  Residue Comment 
Tyr110 A Aromatic lining of the site, with hydroxyl 
 
Ala146 Reduction in size, makes space for Glu202 
  contribution    
Gly162 B Adjacent to Tyr110  Glu202 Increase in size and introduces negative charge 
Ser163 B Hydroxyl forms a hydrogen bond to the Tyr166  Ser203 Strictly conserved 
  amide to hold Trp164 and Val165 in place    
Trp164 B Aromatic contribution to site, inter-subunit  Phe204 Conserved aromatic with slight reduction in 
  hydrogen bond to Ile135 carbonyl   bulk, no hydrogen bond 
Val165 B Hydrophobic contribution  Gly205 Reduction in size 
Tyr205, Tyr212 C Tyrosine pair contributes aromatic lining and  Tyr247, Tyr253 Strictly conserved 
  hydroxyls to site    
Ser206, Cys207, C Disulfide contributes hydrophobic lining to site Lys248, Gly249, Changes likely to give more conformational 
Cys208, Pro209  and restrains the loop conformation Thr250, Gly251 freedom to loop C 











Tyr72 D Aromatic contribution Phe91 Conserved 
Gln74 D Abuts Ile135, Met133 Arg93 Introduction of bulk and positive charge 
Ile123, Ala124, 
Val125 
E Hydrophobic contributions from Val125 and 
Ala124 Ca; Ile123 carbonyl directed into site 
Leu145, Leu146, 
Arg147 
Conserved Ile/Leu but increase in size for 
Leu146 and Arg147; aliphatic part of Arg147 
    side chain lines site 
Met133 E Hydrophobic lining to site, inter-subunit van der Leu155 Conserved 
  Waals interactions with loop C disulfide    
Ile135 E Hydrophobic lining Ser157 Reduction in size allows space for Arg93, 
addition of a polar group in site 
Thr53 G Abuts Tyr72 Phe72 Increase in bulk and hydrophobicity to position 
Phe91 
Gln55 G Inter-subunit hydrogen bond to carbonyl serves 
to place Tyr110 and van der Waals 





MolProbity (Chen et al., 2010) and the PDB validation tools. 
Figures were generated using PyMOL (Schro¨ dinger). Further 
details, including relevant statistics, are presented in Supple- 
mentary Table S3 and Fig. S3. 
 
 
3. Results and discussion 
3.1. Comparison of AcAChBP and GlyR sequences to inform 
surrogate design 
The alignment of the amino-acid sequences of AcAChBP, 
human GlyR-a1 and human GlyR-/3 [Fig. 1(b)], and homology 
modeling together with published mutagenesis data (see, for 
example, Grudzinska et al., 2005; Pless, Hanek et al., 2011; 
Pless, Leung et al., 2011; Yu et al., 2014) on the effects of 
specific substitutions were used to guide the conversion of the 
orthosteric site of AcAChBP to that of a human GlyR-a1(   )/ 
/3(+) heteromer. The  orthosteric site is constructed at the 
subunit–subunit interface by seven loop segments. Three of 
these loops (labeled A–C) form the (+) or principal side of the 
site and four (labeled D–G) form the ( ) or complementary 
side [Fig. 1(b)]. Loop F was judged to be sufficiently distant 
from the orthosteric binding site to be ignored. Residues with 
side chains directed into the orthosteric site were marked for 
attention (Fig. 2, Table 1). In stepwise fashion, we generated 
baculovirus expression systems encoding genes for WT and 
altered versions of AcAChBP, purified and characterized the 
recombinant proteins to understand the consequences of 




Schematic to describe the construction of and key residues in the 
orthosteric binding site of AcAChBP and the corresponding amino acids 
in the human GlyR-a1( )//3(+) heteromeric site. Substitutions in red 
convert AcAChBP into GBP. 
 
 








to measure the changes in stability (Tm) as a consequence of 
amino-acid substitutions and ligand binding (Supplementary 
Table S1). Tryptophan fluorescence provided data relating to 
binding affinity, and crystallographic analyses of eight ligand 
complexes provided structural data (Supplementary Table S3, 
Figs. S2 and S3). Three well characterized pLGIC modulators, 
nicotine, tropisetron and strychnine, were used as chemical 
probes to provide control data. 
 
3.2. Characterization of variants I and II 
The AcAChBP–nicotine complex crystal structure provided 
a check of the orthosteric binding site and direct comparison 
with the LsAChBP complex (Celie et al., 2004), and confirmed 
that the binding sites and protein–ligand interactions are 
highly conserved. The orthosteric site is a narrow hydrophobic 
cavity dominated by five aromatic residues on one side, a 
disulfide bond and four aliphatic residues on the other. Of 20 
residues that contribute to this site (Table 1), 17 are conserved 
between AcAChBP and LsAChBP, with only three differences 
of note: Val125 in AcAChBP changes to arginine, Thr53 to 
lysine and Gln55 to isoleucine. The Thr53/Gln55 combination 
contributes to the positioning of Tyr72, which interacts directly 
with ligands. In LsAChBP, the aliphatic parts of the lysine and 
the isoleucine side chains help to position a tryptophan, which 
occupies the place of Tyr72 in AcAChBP. In AcAChBP, the 
side chain of Val125 contributes to a hydrophobic surface of 
the orthosteric site and also serves to position the side chain of 
Arg96, which participates in an inter-subunit salt bridge with 
Glu170. In LsAChBP, the glutamate is conserved and the 
equivalent residues to Arg96 and Val125 are serine and argi- 
nine, respectively. The smaller serine side chain provides space 
for the arginine to occupy the same position to also form a salt 
bridge with the conserved glutamate, whilst the aliphatic 
component of the arginine essentially mimics the contribu- 
tions of Val125 to the binding site. 
Variant I incorporated five changes: T53F, Q74R, Y110A, 
I135S and W164F. The key observation from the structure of 
the variant I strychnine complex concerned the Y110A, W164F 
and I135S substitutions. Trp164 NE1 donates a hydrogen bond 
to the carbonyl of Ile135, thus linking two /3-strands from 
different subunits. Removal of the stabilizing interaction is 
likely to contribute to D.Tm of this variant (   400C) compared 
with the wild-type protein. We also note a biphasic melting 
curve that may represent first dissociation of the pentamer 
followed by unfolding of the subunit. The electron density of 
the phenylalanine (Phe164) was poorly ordered, perhaps as 
the reduction in the side-chain size of an adjacent residue 
(Y110A) opened up one side of the binding site, allowing a 
greater degree of conformational freedom. This variant 
nevertheless retained the ability to bind strychnine, as 
revealed in the complex crystal structure and by a D.Tm of 
+200C. The structure also indicted that the Y110A substitution 
created space to accommodate a G162E substitution (see 
later). Thr108 abuts Trp164 on adjacent /3-strands in 
AcAChBP, and we reasoned that Trp164 could be retained 
since the residue equivalent to the adjacent Thr108 is Phe144 
in human GlyR-/3 and the six-membered ring of the indole 
would replicate the Phe144/Phe204 combination in the human 
system. The retention of tryptophan also preserved the ability 
to exploit fluorescence measurements for binding studies. 
Variant II therefore reverted back to Trp164, but with the 
inclusion of a G162E substitution. The residues now changed 
(Thr53, Gln74, Tyr110, Ile135 and Gly162) correspond to 
Phe72, Arg93, Ala146, Ser157 and Glu202 in the human GlyR- 
a1( )//3(+) orthosteric site [Figs. 1(b) and 2]. The important 
aromatic residues Tyr72 (Phe91), Trp164 (Phe204), Tyr205 
(Tyr247) and Tyr212 (Tyr253) are well conserved in the two 
systems [Figs. 1(b) and 2]. The Tm of 800C for variant II is an 
increase of 250C compared with variant I and is only 100C 
lower compared with the WT protein. The incorporation of 
the inter-strand hydrogen bond between Trp164 and Ile135 is 
likely to support this recovery of thermal stability. Strychnine 
binding to variant II resulted in a D.Tm of +50C. 
Crystal structures of variant II with HEPES, tropisetron and 
strychnine revealed that the G162E substitution was accom- 
modated with the structure essentially unperturbed compared 
with variant I, although now incorporating two charged resi- 
dues (Arg74 and Glu162) to polarize the binding site such that 
the principal side is negatively charged and the complemen- 
tary side is positive. The complex structure with HEPES 
showed this crystallization buffer component binding in two 
orientations in the orthosteric site in a similar fashion to that 
reported for LsAChBP (Celie et al., 2004). The variant II 
complex showed tropisetron [Fig. 3(a)] to be present in two of 
the ten orthosteric sites in the asymmetric unit, with the other 
sites being occupied by the cryoprotectant ethane-1,2-diol and 
the N-terminal histidine tails of symmetry-related molecules. 
Although the tropisetron occupies the same space, our inter- 
pretation of the electron density is that this modulator of 
GlyR (Yang et al., 2007) displays two poses [Supplementary 
Figs. S3(c) and S3(d)]. One pose is similar to that observed in 
the WT AcAChBP (Hibbs et al., 2009) complex, whilst the 
other is rotated approximately 1800 (Fig. 3). When bound to 
the WT protein, the tropane-bridged piperidine binds in the 
same position as the pyrrolidine moiety of nicotine, forming 
van der Waals interactions with the side chains of Tyr72 from 
one subunit and Tyr205, Tyr212 and Trp164 from the other 
subunit. The quaternary amine N1 donates a hydrogen bond 
to the carbonyl of Trp164 and the methyl substituent forms 
van der Waals interactions with Tyr110. A solvent-mediated 
hydrogen-bonding network links the tropisetron carbonyl to 
the carbonyl of Val165 and Tyr212 hydroxyl group of one 
subunit and the carbonyl groups of Ile106 and Met133 on the 
partner subunit. The ether/carbonyl link between the tropane 
and indole groups forms van der Waals contacts to the 
Cys207–Cys208 disulfide part of loop C on the (+) side and the 
side chain of Ile135 on the ( ) side. The indole group is 
positioned with van der Waals contacts to Cys207 on one side 
and to the side chains of Tyr72, Gln74 and Met133 on another 
subunit. The indole N10 forms a hydrogen bond to a water 
molecule, which in turn interacts with Thr53 and Asp181 and 
other solvent molecules that form a network of hydrogen 
bonds in and around the binding site. The second pose is 
 
 







influenced by the Y110A and G162E substitutions, which 
allow a solvent-bridged interaction between the glutamate and 
tropisetron N1. van der Waals interactions between the 
tropane and aromatic residues are maintained in both poses 
with minor adjustments of side chains. The T53F substitution 
and the placement of the aromatic group help to place the 
arginine from the Q74R substitution to participate in a cation– 
n stacking arrangement of the guanidinyl moiety and the 
indole system, pushing tropisetron over towards the disulfide 
linkage on loop C. A solvent-mediated link between Ser135 
and Arg74 may also contribute to the placement of the 
guanidinyl moiety. The indole N10 is directed out towards 
bulk solvent, whilst the carbonyl group accepts a hydrogen 
bond donated from the side chain of Tyr72. 
Of note is the observation that tropisetron can adopt two 
poses in the same binding site. It is not unusual to observe a 
statistical disorder in which two orientations of a ligand are 
present in the population of molecules in a crystal (see, for 
example, Khalaf et al., 2014). The possibility exists that here 
also tropisetron adopts more than one orientation in the 
binding site, in effect a mixed population, but the electron- 
density maps suggest a dominant pose in each of the two 




Tropisetron adopts two poses in the orthosteric site of variant II. (a) The 
chemical structure of tropisetron. (b) The interacting residues of variant 
II are shown with C positions colored white for the principal side and 
cyan for the complementary side, with one tropisetron pose (yellow C 
positions). Two water molecules discussed in the text are depicted as blue 
spheres; O and N positions are red and blue, respectively. Selected 
hydrogen-bonding interactions are shown as blue dashed lines. The 
second pose, which is common with that adopted in WT AcAChBP (PDB 
entry 2wnc), is shown with black C atoms. 
S3(d)]. This observation matches well with previous work on 
tropisetron and derivatives interacting with the 5-HT3R that 
indicate that different binding orientations are possible 
(Ruepp et al., 2017). 
The Kd values for the binding of nicotine and tropisetron to 
AcAChBP are 250 and 480 nM by monitoring intrinsic tryp- 
tophan fluorescence quenching with stopped-flow spectro- 
fluorimetry (Hansen et al., 2005). Comparable values were 
obtained with our tryptophan fluorescence measurements: 
245 ( 20) and 275 ( 15) nM. This validated assay was applied 
to investigate how the substitutions might influence ligand 
affinity. Neither variant I nor variant II appeared to be able to 
bind nicotine. The combined Y110A and I135S substitutions 
may open up the binding site such that nicotine can longer 
bind in an optimal fashion. However, we were unable to co- 
crystallize these variants with glycine, neither did the fluor- 
escence assay register any glycine binding. 
 
3.3. Variant III is a glycine-binding protein 
Variants I and II presented structural features consistent 
with site-directed mutagenesis and electrophysiological data 
that suggest interacting roles for specific residues (see, for 
example, Yu et al., 2014). However, our structures also 
emphasized that accurately replicating the a( )//3(+) hetero- 
meric site required changes to the /3(+) side loop C, where the 
major differences between a-form and /3-form sequences 
occur (Figs. 1 and 2). Single-site substitutions were not obvious 
and we judged it necessary to make a major change, with four 
substitutions being incorporated (S206K, C207G, C208T and 
P209G). These substitutions had the potential to release the 
conformational restraint of the Cys207–Cys208 disulfide and, 
with two glycine residues now included, to increase the 
conformational mobility of the loop. Variant III was produced 
in recombinant form and characterized. 
The substitutions did not have an adverse effect on the 
stability of the protein, with Tm values of 80 and 810C noted 
for variants II and III, respectively (Supplementary Table S1). 
The binding of strychnine to variant III led to a small increase, 
+30C, in D.Tm, and when glycine was tested a D.Tm of +20C was 
observed. These changes are small and are unlikely to be 
significant. Attempts to observe an association between 
variant III and glycine using the fluorescence assay, ITC and 
biolayer interferometry failed to show any binding. This may 
be a consequence of testing a compound with such a low mass 
(about 75 Da). However, variant III co-crystallized with 
glycine and the ligand occupies four of the five orthosteric 
binding sites in the asymmetric unit. With this proof of binding 
we named variant III glycine-binding protein (GBP). The 
molecular packing in the crystal lattice of the GBP–glycine 
complex places a histidine from the affinity tag in the other 
site. The structure of wild-type AcAChBP in complex with 
strychnine, the archetypal GlyR antagonist, reported here as a 
control (PDB entry 2xys; Brams et al., 2011) provided a 
comparison for the GBP–strychnine complex, which we also 
crystallized. During our study, crystal structures of homomeric 
human GlyR-a3 complexes with glycine (PDB entry 5tin) and 
 
 












strychnine (PDB entry 5cfb) became available (Huang, Chen 
et al., 2017; Huang, Shaffer et al., 2017), allowing direct 
comparisons. 
The orthosteric site in the GBP–glycine structure is highly 
conserved with that of the WT GlyR homomer structures and 
variants I and II, with the notable exception of loop C, which 
now adopts a configuration that allows two tyrosine residues 
(Tyr205 and Tyr212) to contribute to the binding site (Fig. 4). 
One edge of the Tyr205 side chain helps to form one side of 
the binding site, with the hydroxyl group placed to donate a 
hydrogen bond to the carbonyl of Tyr166 (not shown), thereby 
linking two segments, and to accept a hydrogen bond from the 
glycine ligand. Tyr212 is aligned with Tyr205, creating a n-
electron-rich region to interact with the glycine amino group. 
Solvent-mediated interactions link the Tyr212 hydroxyl with 
the carboxylate of Glu162 (not shown), which in turn interacts 
with the glycine amino group. The glycine is tucked between 
and participates in van der Waals interactions with the edge 
of Tyr205 and the face of the Trp164 indole. The glycine 
carboxylate is directed towards the Arg74 guanidinyl 
moiety, but the distances (   3.8 Å ) are too long to represent 
direct hydrogen-bonding interactions and a solvent-mediated 
association is noted. 
In the structure of the homomeric GlyR-a3 glycine complex 
(Huang, Shaffer et al., 2017), the glycine carboxylate accepts 
hydrogen bonds donated by the side chains of Arg65, Ser129 
and Thr204, the latter on loop C. The amino group of the 
ligand makes a solvent-mediated interaction with Glu157 and 
a direct hydrogen bond to the carbonyl of Phe159. The glycine 
participates in van der Waals interactions with the side chains 
of Phe63 and Phe159, whilst the amino group occupies a n-
electron-rich area between Phe159 and Phe207. A water 
molecule bridges this amino group to the carbonyl of Ser158 
and the carboxylate of Glu157 with three hydrogen bonds. The 
major differences between the two structures and the key to 
forming a heteromeric site reside in loop C, the part of the 
binding site that distinguishes the a- and /3-forms of the 
receptor. In GlyR-a3 the loop segment comprising residues 
199–207 is in a closed conformation, whilst the equivalent 
residues 202–211 in GBP form a more open structure. 
 
Figure 4 
Glycine in an orthosteric site of GBP. A similar color scheme as shown in 
Fig. 3 is used, with glycine C positions in black. 
However, in GBP the loop conformation places the side chains 
of the tyrosine pair (205 and 212) directed into the binding 
site, whereas in GlyR-a3 only one tyrosine, Tyr202, is thus 
positioned, forming a hydrogen bond with the conserved 
acidic Glu157. 
The structure of the GBP–strychnine complex displays a 
well ordered ligand in three out of five binding sites per 
asymmetric unit. In two sites the density is less clear, the 
thermal parameters are elevated (Supplementary Table S3) 
and different strychnine orientations are noted. A previously 
published structure of the WT AcAChBP–strychnine complex 
shows a single molecule occupying four of the five orthosteric 
sites in the asymmetric unit and one site with two ligands 
bound (Brams et al., 2011). In both of these structures the 
molecular packing in the crystal lattice affects the conforma- 
tion of loop C in one subunit and results in a more open 
binding site, providing room for ligands to adopt different 
orientations. We note also that this alkaloid displays a 
propensity to dimerize or aggregate at high concentrations 
(Reinscheid et al., 2016). Our structure of the WT AcAChBP– 
strychnine complex displays a single well ordered strychnine 
in all five binding sites per asymmetric unit and we confine our 
comparison to this binding pose (Fig. 5). 
The orientation and the position of the alkaloid in both WT 
AcAChBP structures is very similar. There is a single direct 
hydrogen bond between the alkaloid and the protein donated 
by the protonated tertiary amine to the carbonyl of Trp164. 
The pKa of strychnine is approximately 8.3 (Haynes, 2015), 
hence the confidence that protonation has occurred. The 
potential hydrogen-bond acceptors on strychnine, ether and 
amide O atoms, are placed to interact with solvent and in so 
doing then form bridges to the protein. Extensive van der 
Waals interactions involving four tyrosine residues (110, 205, 
212 and 72), Trp164, Met133, Ile135 and the Cys20–Cys208 
disulfide are likely to explain the high affinity of strychnine for 
this binding site, with a reported Ki of 38 nM (Brams et al., 
2011) and Kd of 15 nM (Hansen et al., 2004), the latter based 
on a stopped-flow spectrofluorimetry assay. The use of ITC 
and a radioligand saturation assay to characterize the inter- 
action between strychnine and a recombinant homomeric 
GlyR-a1 system gave Kd values of 138 ( 55) and 52 ( 6) nM, 
respectively (Wo¨ hri et al., 2013). The application of ITC and 
surface plasmon resonance methods with recombinant 
homomeric GlyR-a3 produced Kd values of 52 (   2) and 43 
( 3) nM, respectively (Huang et al., 2015). For comparative 
purposes we employed ITC to characterize the binding of 
strychnine to WT AcAChBP and GBP (Supplementary Fig. 
S1). The resulting Kd for the interaction with WT AcAChBP is 
74.1 ( 22.6) nM and that with GBP is 28.8 ( 3.2) mM. 
Corroboration of these data was sought using a fluorescence- 
based  assay,  where  Kd  values  of  155  (  7) nM  and  27 
( 0.5) mM were determined for WT AcAChBP and GBP, 
respectively. 
Strychnine is a promiscuous ligand that is active against 
different receptors. Electrophysiological assays indicate that 
the alkaloid, although the prototypical competitive antagonist 
of GlyR, also displays the same activity against some nAChR 
 
 





subtypes, with IC50 values that range from 350 nM to around 
40 mM (Albuquerque et al., 1998; Garc´ıa-Colunga & Miledi, 
1999; Jensen et al., 2006). The affinity of strychnine interacting 
with AcAChBP is consistent with the activity that this ligand 
displays against the orthologous binding sites presented by 
nAChRs. The substitutions that were introduced to engineer a 
glycine-binding site in GBP have however reduced the affinity 
for strychnine significantly away from that of the wild-type 
template as well as from that observed with recombinant 
homomeric GlyR samples. The thermodynamic parameters 
[Supplementary Fig. S1(e)] indicate that whilst the enthalpic 
contribution to strychnine binding is similar for AcAChBP 
and GBP, there is a significant penalty in the entropic contri- 
bution that explains the reduced affinity of GBP for this 
ligand. We speculate that this may be linked to a reduction in 
thermal stability of GBP relative to the wild-type protein and/ 
or be influenced by the increased flexibility introduced into 
loop C. The observation does have an important implication 
for our use of the GBP surrogate, suggesting that care should 
be applied when using this system with larger ligands that 
might engage with residues distant from those involved 
directly in neurotransmitter binding. 
The WT AcAChBP, GlyR-a3 homomer and GBP complexes 
display different orientations of strychnine in the binding site 
that are directly linked to the substitutions that have been 
incorporated to produce GBP (Fig. 5). An overlay of the 
protein structures (data not shown) places the tertiary amines 





Strychnine bound to GBP. (a) The chemical structure of the natural product. (b) The key residues and orientation of strychnine bound to GBP. A similar 
color scheme as shown in Fig. 3 is used, with C positions of strychnine in black and C positions of acetate and ethanediol (EDO) in green. (c) The binding 
of strychnine to the human GlyR-a3 homomer from PDB entry 5cfb (Huang et al., 2015); the residue numbers in the PDB entry are retained. (d) For 
comparative purposes the alignment of GBP [see Fig. 1(b)] with human GlyR-a3 is shown using the numbering scheme of the PDB entry. Residues 
shown in (c) are shown in gray for the principal side and in cyan for the complementary side. 
 






essentially pivoting around this N atom. In the GBP–strych- 
nine complex the tertiary amine is protonated and donates a 
hydrogen bond to a highly ordered water that forms hydrogen 
bonds to the carbonyl groups of Ser163 and Tyr166 and 
contributes to a solvent network that burrows into the protein 
fold (data not shown). The Y110A substitution removes the 
possibility of van der Waals interactions between the aromatic 
side chain and any ligand. The G162E change directs a polar 
side chain into the bindng site and this forces the strychnine to 
adopt a different orientation. On the other side of the binding 
site, the Q74R substitution serves to place a polar group 
further into the cleft. This would clash with the ligand orien- 
tation noted in the wild-type AcAChBP complex and thus 
works in concert with the presence of Ala110 and Glu162 to 
position the ligand. The I135S and T53F changes allow Tyr72 
to adopt a different rotamer conformation: in the former by 
providing space and in the latter with stabilizing van der Waals 
interactions. The position of Phe53 also serves to stabilize the 
side-chain position of Arg74. The change in orientation of 
strychnine results in the amide carbonyl O atom rotating by 
about  900  and  relocating  by  almost  8 Å   directed  towards 
Met133 and with the indole system placed to interact with loop 
C. Here also there are significant changes to the protein 
structure. The side chain of Tyr205 adopts a different rotamer, 
participates in van der Waals interactions with strychnine and 
now occupies the space that is filled by the Cys207–Cys208 
disulfide bond in WT AcAChBP, in essence forming a lid over 
the binding site. Tyr212 also displays a different rotamer, 
partially filling the space vacated by Tyr205, and this allows the 




We sought to investigate the orthosteric binding site of the 
heteromeric a1( )//3(+) form of human GlyR but circum- 
venting the experimental difficulties of working with a multi- 
subunit membrane-bound protein. Based on existing 
sequence, structural and functional data, we considered which 
amino acids of the homolog AcAChBP might be substituted, 
allowing us to create a convenient surrogate system. In stages, 
we modified AcAChBP and characterized variant proteins to 
interrogate the binding site. Ultimately, the highly stable 
AcAChBP framework has allowed us to introduce nine amino- 
acid substitutions that have resulted in a stable surrogate for a 
heteromeric neurotransmitter site that binds glycine. This 
system could be exploited in early-stage drug discovery by use 
as a target for the screening of chemical libraries, for structural 
elucidation of receptor–ligand interactions, and for biophys- 
ical characterization of kinetic and thermodynamic para- 
meters relating to ligand binding. 
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Bicuculline, a valued chemical tool in neurosciences research, receptor (GlyR). The 2.4 a resolution crystal structure of the 
is a competitive antagonist of specific GABAA receptors and af- GBP:N-methylbicuculline complex, sequence and structural 
fects other pentameric ligand-gated ion channels including the alignments reveal similarities and differences between GlyR 
glycine, nicotinic acetylcholine and 5-hydroxytryptamine type 3 and the GABAA receptor–bicuculline interactions. N-methylbi- 
receptors. We used a fluorescence-quenching assay and iso- cuculline displays a similar conformation in different structures, 
thermal titration calorimetry to record low-micromolar dissoci- but adopts distinct orientations enforced by interactions and 
ation constants for N-methylbicuculline interacting with acetyl- steric blocks with key residues and plasticity in the binding 
choline-binding protein and an engineered version called gly- sites. These features explain the promiscuous activity of bicu- 
cine-binding protein (GBP), which provides a surrogate for the culline against the principal inhibitory pentameric ligand-gated 





A Structural Rationale for N-Methylbicuculline Acting as a 
Promiscuous Competitive Antagonist of Inhibitory 
Pentameric Ligand-Gated Ion Channels 






The alkaloid bicuculline competitively antagonises activation of 
the inhibitory GABAA receptor (GABAAR) by the native agonist 
g-aminobutyric acid.[1–3] This natural product played a seminal 
role in early studies of synaptic transmission, in particular help- 
ing to characterise the role of g-aminobutyric acid as a neuro- 
transmitter.[3,4] Subsequently, concerns linked to compound in- 
stability, poor solubility and activities on other receptors were 
raised.[5,6] Bicuculline has poor aqueous solubility and is highly 
susceptible to hydrolysis of the lactone moiety, with a half-life 
of 45 minutes at physiological pH, to produce inactive bicu- 
cine.[7] These complicating factors can be overcome by using 
the N-methylbicuculline salts (Figure 1 A), which are more 
stable and soluble.[2,8,9] However, an issue previously described 
is the haphazard reporting of which variant has been used in 
experiments;[2] a point we shall mention again. The alkaloid is 
also active against related pentameric ligand-gated ion chan- 
nels (pLGICs) including the other inhibitory system, the glycine 
receptor (GlyR),[10] and the excitatory serotonin and nicotinic 
acetylcholine receptors (nAChR). This complication is com- 
pounded by activity against the unrelated calcium-activated 
potassium channels.[11,12] A range of IC50 values for activity 
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Figure 1. A) The structure of (@)-N-methylbicuculline. N and O atoms are 
numbered. B) Ribbon diagram of GBP showing the five subunits and the 
principal [+] and complementary [@] sides at the orthosteric binding sites. 
N-methylbicuculline (grey van der Waals spheres) occupies each site. Chlo- 
ride (green spheres) bound in each subunit are shown. C) Molecular image 
of an orthosteric binding pocket of GBP showing, the principal subunit-do- 
nating loops A (red), B (orange), C (yellow) and the complementary subunit- 
contributing loops D (blue), E (blue), F (purple), G (cyan). The aromatic cage 
side chains (Tyr72, Trp164, Tyr205 and Tyr212) are shown as sticks with C po- 
sitions coloured according to which loop they belong with. D) Schematic 
representation of the GBP-binding site, starred residues are responsible for 
the aromatic cage. Arg96 is not associated with any of the loops. 
 
against different receptors is presented in Table S1 in the Sup- 
porting Information. 
Bicuculline is GABA competitive and interacts with the or- 
thosteric site of pLGICs.[3] The compound also acts as an in- 
verse agonist, inhibiting GABAAR-subtype activity independent 
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of agonist binding to the orthosteric site.[13,14] As receptor-spe- 
cific residues at key positions influence pLGIC ligand specificity 
and affinity,[15–17] we sought to understand how this semirigid 
compound was able to antagonise the transmission of inhibi- 
tory potentials in the distinctive GlyR and GABAAR systems. 
These receptors consist of intracellular, transmembrane and 
extracellular domains.[15,16] The acetylcholine-binding protein 
from Aplysia californica (AcAChBP) shares sequence identity 
and structural homology with the extracellular domain (ECD) 
of pLGICs, and has been exploited as a surrogate system.[18–20] 
We engineered an AChBP derivative called glycine-binding pro- 
tein (GBP) as a surrogate for the physiologically relevant b[+]/ 
a[@] heteromeric interface of GlyR.[21] The orthosteric binding 
site is formed at the interface of two subunits with three loops 
(termed A–C) contributed by the principal [+]-subunit; the 
[@]-complementary subunit donates another four loops, D–G 
(Figure 1 B–D). We have characterised the interactions between N-
methylbicuculline, also termed (@)-bicuculline methiodide, with 
AcAChBP and GBP. Affinity and thermodynamic data are 
derived from a tryptophan fluorescence-quenching assay and 
isothermal titration calorimetry (ITC). We attempted to co-crys- 
tallise N-methylbicuculline with wild-type AcAChBP and var- 
iants generated by site-directed mutagenesis to investigate 
aspects of GlyR and GABAAR activity, but to no avail. We did, 
however, obtain a crystal structure of the N-methyl derivative 
with GBP at 2.4 a resolution that provides a description of 
interactions in the neurotransmitter or orthosteric binding site 
and implies how the ligand modulates GlyR activity. Compari- 
sons with GABAAR amino acid sequences and a structure 
derived by cryogenic-electron microscopy (cryo-EM)[22] inform a 
discussion about the promiscuous activity of the alkaloid 
against this subgroup of the pLGIC family. 
 
Results and Discussion 
Bicuculline, and the more stable N-methyl derivative are pri- 
marily hydrophobic, and semirigid with a single C@C bond 
about which rotation defines the alignment of the dioxoloph- 
thalide and dioxoloisoquinolinium moieties with respect to 
each other (Figure 1 A). The solvent-accessible surface area 
(SASA) of N-methylbicuculline is around 520 a2, with a polar 
surface area of only about 70 a2. There are six oxygen atoms 
capable of accepting hydrogen bonds and with an estimated 
pKa of 14.7; under physiological conditions, bicuculline is pro- 
tonated, and a hydrogen bond can be donated by the quater- 
nary ammonium. The N-methyl derivative lacks this hydrogen- 
bond-donating capacity. 
There is a requirement to use DMSO to dissolve the ligand 
at a concentration required to investigate binding. Given the 
potential complications of using this solvent,[23] we first ascer- 
tained how it might affect GBP. We characterised the thermal 
stability of GBP by recording the inflection point of a melting 
curve in different levels (0 to 10 %) of DMSO. The results indi- 
cated that 2% DMSO could be appropriate. Next, a time- 
course experiment indicated that, for binding assays, the 2% 
DMSO level was not deleterious to the sample. Control experi- 
ments were carried for ITC and fluorescence measurements 
allowing us to take into account the presence of DMSO in the 
binding assays. 
The binding of N-methylbicuculline to GBP and AcAChBP 
was investigated by using a fluorescence-quenching assay 
exploiting the presence of Trp164 in the binding site; it gave 
dissociation constant (Kd) values of 8.7 : 0.5 and 1.2 : 0.1 mm, 
respectively (Figure S1). An orthogonal ITC assay resulted in 
thermodynamic dissociation constant (KD) values of 29.6 : 10.0 
and 4.7 : 1.6 mm (Figure S2). We note, however, that the molar 
ratios for N-methylbicuculline binding (mol ligand/mol pen- 
tamer) derived from the ITC data are not 5:1, as would be 
expected for a single-site binding event, but rather 4:1 for the 
association with AcAChBP and nearly 12:1 with GBP. In compar- 
ison, use of a [3H]strychnine competition binding assay gave 
IC50 values of 5–6 mm for bicuculline acting on the GlyR,[24,25] 
whereas electrophysiology experiments recorded values in the 
range 169–300 mm for N-methylbicuculline.[26,27] When tested 
against mammalian nAChRs, again in an electrophysiology 
assay, bicuculline retained antagonist properties, with IC50 
values in the range 12–34 mm; moreover, with Hill coefficients 
demonstrated to be close to unity.[28] It has been noted, from 
using ITC,[28] that certain ligands, for example, carbamylcholine, 
bind the pentameric AcAChBP with a molar ratio of 2.5:1, yet 
there is no evidence for cooperativity or allosteric transitions in 
this protein. Carbamylcholine displays a similar affinity for 
AcAChBP, 7.6 : 0.4 mm,[29] as N-methylbicuculline, and the 
reason for the low molar ratio is unclear. Other ligands (e.g., 
acetylcholine) fit the 5:1 ratio. Our ITC data were derived from 
curves with low c values of between 3 and 7. Although not op- 
timal, such values are considered acceptable[30] with the provi- 
so that some caution should be exercised when drawing con- 
clusions. In our case, we note a consistency in the data derived 
from two distinct biophysical assays. We note also that the 
binding of N-methylbicuculline and bicuculline occurs with 
comparable affinity to AcAChBP, GBP and to members of the 
pLGIC superfamily. Contrary to observations with AcAChBP, the 
molar ratio with GBP might indicate the presence of multiple 
binding sites. 
The crystal structure of the GBP:N-methylbicuculline com- 
plex has a pentamer in the asymmetric unit, with each ortho- 
steric site occupied by a single molecule of ligand (Figures 1B 
and S3, Table S2) and no evidence for any other binding site. 
Of course, the conditions under which crystals are obtained 
are different from those employed for binding studies. The 
subunits are labelled A–E, and ligands are assigned to the sub- 
unit that forms the principal side of the binding site. We im- 
posed noncrystallographic symmetry (NCS) in the initial refine- 
ment of the complex, but on observing deviations, released 
these restraints in the binding site. This in particular applies to 
key residues Tyr205 and Tyr212 in different orthosteric sites 
and will be discussed below. The electron density is well de- 
fined for most of the polypeptide chains, indeed in places suf- 
ficiently so that dual rotamers were modelled. However, at the 
periphery of the binding sites involving subunits B–E, the elec- 
tron density is diffuse for part of loop C, and several residues 
could not be modelled reliably. Gly207 and Thr208 were omit- 
ted in subunits B–E, Lys206 also from B, C and E. Our observa- 
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tion is consistent with conformational flexibility previously 
noted for this part of the binding site and which is relevant to 
function.[15,20] The crystallographic order of the ligands differs 
as indicated by variability in definition of the electron density 
and the average B-factors. Our interpretation of the crystallo- 
graphic data is a model with two similar poses of the ligand in 
a 3:2 ratio, which identify the orientation of the ligand bound 
to a site that possesses a degree of conformational flexibility. 
Pose I is observed for ligands B, D, E and pose II for A and C. 
The B-factors, or displacement parameters, indicate that the 
most ordered subunits are A and B, with average B-factors of 
43.5 and 40.3 a2, respectively. The most ordered ligand display- 
ing pose I is at the interface formed between subunits B[+]/ 
C[@] with an average B-factor of 65.2 a2 and real-space correla- 
tion coefficient (RSCC) value of 0.90. The most ordered pose II 
is at the A[+]/B[@] interface with an average B-factor of 95.7 a2 
and RSCC = 0.88. The SASA values are similar for each pose, 
varying between 519 and 532 a2, and when N-methylbicucul- 
line is bound to GBP, approximately 60 % of the SASA is lost. 
We describe the details of the most ordered pose I because 
this correlates with the highest level of crystallographic order 
(Figure 2) and comment briefly on pose II (Figure S4). 
A feature, deep in the orthosteric binding site, is the well- 
ordered arrangement of aromatic residues Trp164, Tyr212 and 
Tyr72, which creates a p-electron-rich environment to interact 
with the positively charged methylated amine. Such an interac- 
tion is an important feature of pLGIC ligand complexes.[17,18,31] 
In addition, there are van der Waals interactions between 
ligand and protein involving these residues. The side chain of 
Glu162, juxtaposed between Trp164 and Tyr212, is directed to 
the quaternary amine, thereby making an electrostatic contri- 




Figure 2. N-methylbicuculline binding to GBP. The ligand, pose I, is shown as 
sticks with C positions silver. The protein surface is presented as a semitrans- 
parent van der Waals surface (grey). Residues from the [+]-principal (C posi- 
tions cyan) and [@]-complementary (C positions magenta) subunits are 
shown. N, O and S positions are blue, red and yellow, respectively. Two 
water molecules are depicted as blue spheres. Putative hydrogen bonds are 
represented as black dashed lines. 
phthalide part of the ligand makes van der Waals contacts to 
Phe53, Arg74, Met133 and Ser135. The last two residues act 
like a wedge between the phthalide and isoquinolium compo- 
nents and, together with Tyr212 from the other subunit, help 
to orient the ligand. The dioxoloisoquinolium occupies a de- 
pression between loops B and C of the principal subunit. Here, 
there are van der Waals interactions with main-chain atoms of 
the tripeptide segment Val165, Tyr166 and Ser167 and side- 
chain atoms of Tyr205, Glu210 and Tyr212. The side chain of 
Val125 also has van der Waals interactions with this end of the 
ligand; here the position of Arg96 is noted. 
The dioxolo group associated with the phthalide can accept 
two hydrogen bonds donated by Arg96 on the complementa- 
ry side and a protonated Glu210 on the principal side. Al- 
though the geometry is not ideal, the distance of 3.3 a sug- 
gests that the dioxolo group attached to the isoquinolium 
may accept a hydrogen bond donated by the side chain of 
Arg74. The other oxygen is solvent accessible, 4.1 a from the 
hydroxy group of Tyr205 on the flexible loop C. The remaining 
two hydrogen-bond-acceptor groups are from the lactone. 
These oxygen atoms are 3.1 and 3.2 a from a well-ordered 
water molecule (B-factor of 31 a2), with an environment and 
geometry suggestive of a bifurcated hydrogen bond. The 
water in turn donates a hydrogen bond to the carbonyl of 
Trp164 then accepts a hydrogen bond from another highly or- 
dered water, (B-factor of 31 a2). An overlay of the AcAChBP nic- 
otine complex (PDB ID: 5O87)[18] with the structure reported 
here indicates that the first water maps to the position of the 
pyridine N atom of nicotine. The second water represents a 
highly conserved hydration point that forms hydrogen bonds 
to main-chain residues Ile123 and Ile135 in AcAChBP, Ser135 in 
GBP, and to another water that continues a solvent network 
through to the surface of the protein (data not shown). This 
ordered solvent structure is consistently noted in high-resolu- 
tion structures of AChBP ligand complexes.[15,20] 
In pose II, the conformation of the ligand is preserved, with 
a similar orientation of the dioxolophthalide and dioxoloisoqui- 
nolinium entities with respect to each other, and the quaterna- 
ry amine occupies the same relative position in the orthosteric 
site (Figures S4 and S5 A). Pose II participates in similar inter- 
actions to those described for pose I, for example, the key 
cation–p interaction of the quaternary amine with the protein. 
However, the orientation differs slightly in that, for pose II, the 
ligand pivots as a rigid body about the amine, and the dioxo- 
loisoquinolinium is placed closer to Phe53 and Tyr72, further 
from Met133. Although an ordered water molecule occupies 
the same position as that discussed above, the lactone is now 
too far for a hydrogen bond to form. The dioxolophthalide is 
positioned further from the tripeptide segment Val165– 
Tyr166–Ser167 on the principal side. The side chains of Tyr205 
and Tyr212 adopt different rotamer conformations compared 
to those involved in binding pose I, and accommodate this 
slight rigid-body adjustment whilst maintaining van der Waals 
interactions with the ligand. The hydrogen bonds with Arg96 
and Glu210, however, are lost. 
We considered first whether the GBP:N-methylbicuculline 
complex was representative of how a GlyR b[+]/a1[@] ortho- 
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Figure 3. Sequence alignment of segments involved in creating the orthosteric binding sites of GBP, two human GlyR forms (a1 and b) and three GABAA-R 
forms (a1, b3, 11). The loops are identified and split into principal and complementary sides. Residues in red were engineered into AChBP to create GBP, a 
surrogate for a heteromeric GlyR orthosteric site and are key to ligand interactions. Residues that contribute to heteromeric binding sites are shown in bold. 
 
steric site might interact with the ligand. The alignment of se- 
quences and the crystal structure of the human GlyR-a3 homo- 
mer in complex with strychnine (PDB ID: 5CFB)[32] were used to 
inform on similarity between the orthosteric sites of GBP and 
the GlyR b[+]/a1[@] combination (Figure 3). Arg96, a contribu- 
tion from the complementary side of the orthosteric site, is not 
usually considered as part of the binding site and is not includ- 
ed in Figure 3. This residue corresponds to Asp112 in GlyR-a1. 
The contributions of 15 residues in GBP that interact with N- 
methylbicuculline have been described earlier. Seven of the 
residues are strictly conserved in the relevant human GlyR sub- 
units (Phe53, Arg74, Ser135, Glu162, Tyr166, Tyr205 and 
Tyr212). A further four involve conservative substitutions 
(Met133Leu, Trp164Phe, Tyr72Phe, Ser167Thr). The differences 
involve the substitutions Arg96Asp, Val125Arg and Val165Gly, 
as well as Glu210. The Val165Gly substitution is unlikely to be 
significant as the residue forms van der Waals interactions with 
the ligand by using the main chain. Glu210 and Tyr212 are on 
the flexible loop C, some uncertainty about which residues on 
the GlyR b-subunit they would align with. If GBP Tyr212 aligns 
with GlyR-b Tyr253, as we think most likely (Figure 3), then the 
interactions with the ligand and loop C would be conserved. 
Tyr252 could also provide stabilising associations including a 
hydrogen-bond-donor group to interact with the ligand. That 
leaves Val125 to consider together with Arg96. These residues 
are close together on adjacent b-strands. In human GlyR-a1, 
they correspond to Arg147 and Asp112, respectively, and both 
are conserved in GlyR-a3. A superposition with the GlyR-a3 
crystal structure indicates that the Arg96Asp difference directs 
the acidic group away from the binding site, but critically, the 
Val125Arg substitution places the guanidinium groups at the 
same position to interact with the ligand (Figure S6). 
Alkaloids carrying a tetrahydroisoquinoline core can induce 
convulsions.[10] We were particularly interested in features rele- 
vant to recognition of that part of N-methylbicuculline. There 
are nine residues that interact with the dioxoloisoquinolinium 
entity (Phe53, Tyr72, Arg74, Met133, Ser135, Glu162, Trp164, 
Tyr205 and Try212). Six of these are strictly conserved, and 
three represent conservative substitutions in GlyR (Tyr72Phe, 
Met133Leu and Trp164Phe). This suggests that the N-methyl- 
bicuculline complex is indeed representative of how isoquinoli- 
um antagonists bind a heteromeric GlyR orthosteric site to 
effect competitive antagonism. 
Figure 3 also presents alignments of GBP with three GABAAR 
subunits, this being the other inhibitory pLGIC. Again, Arg96, 
which corresponds to Arg112 in human GABAA-a1, is not 
shown. The recent cryo-EM structure of the complex between 
bicuculline and the human GABAA-[a1]2[b3]2[g] receptor[22] of- 
fered the opportunity for comparison and further analysis. First 
a comment; there is an inconsistency in the description of 
what was used to derive the structure in PDB ID: 6HUK.[19] The 
publication and PDB entry describe bicuculline methochloride 
being used, but the coordinates and chemical diagram indicate 
bicuculline in both b3[+]/a1[@] sites, and that is used in our 
comparisons. We calculate RSCC values of 0.84 and 0.81 for 
the ligands, comparable to values in our crystal structure. 
The conformation of the semirigid molecule is essentially 
identical between the two complex structures (Figure S5 B). An 
overlay of two subunits that create an orthosteric site in each 
protein positions the quaternary ammonium groups within 
0.8 a. The environment of the cationic group is similar in the 
two structures. The acidic Glu162 of GBP is strictly conserved 
as Glu180, and the cluster of aromatic residues also main- 
tained. These are Phe53, Tyr72, Trp164, Tyr205 and Tyr212 in 
GBP, which correspond to Phe73, Phe92, Tyr182, Phe225 and 
Tyr230, respectively, in GABAAR (Figure 4). A significant differ- 
ence involves Thr108 in GBP, which is Tyr122 in the GABAAR-b3 
sequence. The increase in size of the side chain places the ty- 
rosine hydroxy group into the cation binding pocket, thereby 
helping to orient the ligand. 
However, although the interactions between the receptors 
and the cationic group are conserved, the orientation of the 
ligands in the orthosteric sites is different (Figure 4). The iso- 
quinolium entities occupy a similar position in the binding site 
but are orthogonal to each other, and their distinct orienta- 
tions are accompanied by concerted adjustments of side-chain 
rotamers for several of the aromatic residues deep in the bind- 
ing site. This alteration of the isoquinolium, together with a tilt 
about the ammonium, places the dioxolophthalide compo- 
nents of the ligands in completely different positions. In the 
Full Papers 
doi.org/10.1002/cbic.201900680 ChemBioChem 







Figure 4. Comparison of the key residues of GBP and GABAAR. The alignment of the structures is based on a least-squares overlay with the cryo-EM structure 
(PDB ID: 6HUK). A) The principal subunits with GBP residue side chains shown as sticks with C positions coloured cyan and O red, the corresponding GABAAR 
residues are shown with C positions green. B) The complementary subunits with GBP C positions coloured magenta. C)A schematic diagram of pose I in the 
GBP:N-methylbicuculline complex. Blue and magenta distinguish residues of GBP (+) and (@) sides, respectively. The corresponding residues in GABAAR are la- 
belled in green. D) An overlay to show the distinct orientations of N-methylbicuculline bound to GBP (silver C) and bicuculline bound to GABAAR (yellow C) in 
the GABAAR orthosteric site. GABAAR is shown as a semitransparent van der Waals surface (grey) with key residues in the binding pocket shown as in (A) and 
(B). The numbering of the GABAAR residues is taken from the Uniprot entries (a1 P14867 and b3 P28472). 
 
case of GBP, this part of the ligand is placed over towards the 
principal loop C on one side and the complementary side 
loop E on the other. In the GABAAR structure, the dioxoloph- 
thalide component is directed towards the other end of the or- 
thosteric site, near loop G (Figure 4 D). The nature of the amino 
acid at two positions on the complementary side and one on 
loop C of the principal side appear to contribute to the obser- 
vation of two distinct orientations. In GBP, the positions of 
Arg96 and Val125, discussed above, align to Arg112 and 
Arg147 in the GABAAR orthosteric site. The juxtaposition of the 
two arginine residues in the GABAAR orthosteric site places the 
side chain of Arg147 to hydrogen bond with Tyr230 from 
loop C on the principal side to, in effect, provide a steric block 
preventing the dioxolophthalide from adopting the orientation 
observed when in complex with GBP. The crystal structure of 
bicuculline itself has been determined.[33] Superposition of this 
structure on that of the models derived from the protein com- 
plex structures indicates that, in isolation, a different conforma- 
tion is observed with the two ring systems rotated about 908 
relative to each other (Figure S5 C). Our comparisons therefore 
suggest that, although the semirigid alkaloid can adopt differ- 
ent conformations, only one is observed when the ligand 
binds to inhibitory pLGICs. However, this conformation can be 
present in two distinct orientations in distinct neurotransmitter 
binding sites, so explaining the promiscuous activity of bicu- 
culline on these inhibitory ion channels. 
The 1-class GABAAR, also known as the GABAC receptor, is 
insensitive to bicuculline,[34] so we sought to test our under- 
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standing by exploring this aspect of ion-channel pharmacolo- 
gy. The alignment of the human GABAAR-11 sequence with the 
sequences and structures described is presented in Figure 3. A 
previous attempt to promote a gain of function in GABAAR- 
11with respect to bicuculline antagonism was based on molec- 
ular modelling, site-directed mutagenesis and electrophysiolo- 
gy.[34] The combination of Tyr127Ser (loop D) and Phe159Tyr 
(loop A) substitutions, and the tripeptide Phe261–Tyr262– 
Ser263 (loop C) changed to a dipeptide Val–Phe gave the larg- 
est increase in bicuculline sensitivity, though still at least an 
order of magnitude reduced from that of the GABAA-b3[+]/ 
a1[@] system. The introduction of the serine would be predict- 
ed to open up space behind a conserved arginine (Arg125 in 
GABAAR-11, Arg74 in GBP) and allow it to act to interact with 
bicuculline. The Phe159Tyr change would place the hydroxy 
group to form stabilising interactions with the quaternary am- 
monium and create an environment to interact with the cat- 
ionic group similar to position of Tyr122 on the b3 subunit of 
the GABAA b3[+]/a1[@] structure. The changes to a tripeptide 
on loop C might simply provide space to accommodate the 
ligand or to place the phenylalanine to mimic Phe226 of the 
b3 structure. That these changes only produce a limited gain 
of function indicates that other features must be important. 
Our comparisons drew attention to the role of loop C and 
Phe53 in GBP, conserved as Phe73 in the GABAAR-a1 subunit. 
In the GABAA-b3[+]/a1[@] orthosteric binding site, Phe73 
aligns to Gln104 in the 11 sequence. The presence of a polar 
glutamine would remove van der Waals interactions between 
the phenyl group and both dioxolo groups of the ligand, and 
would be likely to prevent bicuculline binding in the orienta- 
tion noted in the cryo-EM structure. Loop C is more highly con- 
served with the a1 sequence, which is on the principal side 
not the complementary one. It is difficult without structural 
data on the 11 receptor to be certain about what happens 
with loop C, but the presence of a bulky Trp267 on the 11 sub- 
unit could potentially block access to the ligand. Further data 
would however be required to address the selectivity issues of 
the GABAA-11 receptor more completely. 
 
Conclusions 
In summary, N-methylbicuculline binds to GBP with low-micro- 
molar affinity, comparable to that displayed against members 
of the pLGIC family (Table S1). The crystal structure of the com- 
plex with GBP has been elucidated with the ligand modelled 
in two similar poses that represent an orientation of the com- 
pound in the binding site. Comparisons of sequences and 
structures identify significant similarities between GBP and 
GlyR orthosteric sites, and we conclude that the orientation of 
N-methylbicuculline is representative of how the alkaloid acts 
as a competitive antagonist against GlyR. When bicuculline 
binds the human GABAAR, the natural product displays the 
same molecular conformation as when bound to GBP, with 
conservation of interactions involving the quaternary ammoni- 
um group. However, the molecule adopts a different orienta- 
tion in the binding site. This observation is likely a conse- 
quence of only a few specific amino acid differences between 
the two proteins. The binding of this promiscuous competitive 
antagonist appears to be driven by the charge–p interaction 
of the quaternary ammonium with the protein and van der 
Waals interactions that can be accommodated by flexibility in- 




Protein production: A recombinant source of AcAChBP (Uniprot 
ID: Q8WSF8) and GBP with a C terminus tobacco etch virus cleav- 
age site and His6 tag were produced in baculovirus-infected Sf9 
insect cells by using the Bac-to-Bac expression system (Thermo- 
Fisher). Suspension High Five insect cells, cultured in Express Five 
medium plus 100 U mL@1 penicillin/streptomycin and 2 mm l-gluta- 
mine (Thermo-Fisher), were used for protein production. Typically, 
15 V 105 cells mL@1 were infected with 5% of baculovirus carrying 
the appropriate gene and incubated at 278C in shaking flasks for 
48 h before being harvested by centrifugation (1500 g, 10 min, 
12 8C followed by 4000 g, 10 min, 128C). The proteins are secreted 
out to the medium, and by using the Sartojet system with a 
10 kDa cut-off Sartocon Slice filter (Sartorius), the medium was ex- 
changed for buffer A (50 mm Tris·HCl, 250 mm NaCl, pH 7.5), and 
the sample was concentrated. The protein solution was applied to 
a 5 mL Ni2+ HisTrap column (GE Life Sciences) equilibrated in buf- 
fer A for immobilised metal anion chromatography. The column 
was washed with 15 column volumes of buffer A + 7.5 % buffer B 
(50 mm Tris·HCl, 250 mm NaCl, 800 mm imidazole pH 7.5), then the 
product was eluted with 30 column volumes by using a combina- 
tion of a stepped and linear gradient of buffer B. A native-page gel 
(Figure S7 A) identified the presence of monomer, the desired pen- 
tamer and a higher-order multimer, possibly a dimer of pentamers. 
For size-exclusion chromatography, a Superdex 200 10/300 GL 
column was equilibrated overnight in buffer A, then samples were 
loaded and run over 1.5 column volumes (Figure S7 B). The reten- 
tion time of each peak was recorded, and the molecular weight 
was deduced from a previously determined calibration curve. The 
use of stain-free SDS-PAGE gels (Bio-Rad, Figure S7 C) allowed us to 
confirm the presence of the protein, and fractions corresponding 
to the desired pentameric assembly were pooled, and samples 
were concentrated by using 10 kDa centrifugal concentrators (Pall). 
Crystallographic analysis: GBP at a concentration of 4 mg mL@1 in 
buffer A was incubated with 2 mm bicuculline methiodide (Sigma– 
Aldrich; 20 mm stock in buffer A, 20 % DMSO), diluted in buffer A 
for 1h  before crystallisation trials with commercially available PEGS 
(Qiagen) and JCSG (Molecular Dimensions) screens. Sitting-drops 
(final volume 0.2 mL) containing a 1:1 mix of protein and reservoir 
(a volume of 50 mL was used in the plates) were prepared with a 
Rigaku Phoenix automated dispenser and incubated at 188C for 
one month. A suitable crystal (rectangular prism, 0.7 V 0.25 V 
0.25 mm) appeared from a condition with a reservoir of 0.2 m am- 
monium formate and 20 % (w/v) PEG 3350. The crystal was im- 
mersed in liquid nitrogen, then placed under a stream of nitrogen 
gas at around @170 8C, and diffraction data were collected with a 
Rigaku M007HF copper-anode generator, Varimax Cu-VHF optics, 
Saturn 944HG + CCD detector and AFC-11 4-axis partial c goniome- 
ter. The data were integrated with XDS[35] and scaled with AIM- 
LESS;[36] the structure was solved by molecular replacement with 
PHASER,[37] exploiting the already refined structure of GBP with gly- 
cine (PDB ID: 5OAN).[19] Multiple rounds of automated restrained 
refinement were completed by using REFMAC5,[38] interspersed 
with model adjustment based on inspection of electron and differ- 
ence density maps in COOT.[39] NCS restraints were employed at 
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the onset of the refinement, but when real differences became ap- 
parent, these were released. Ligand models and restraints were 
generated with the GRADE server [Global Phasing: http://grade.- 
globalphasing.org/cgi-bin/grade/server.cgi]. Ligands, water mole- 
cules and chloride ions, together with several dual rotamers were 
incorporated into the model. Asn91 was glycosylated and N-acetyl- 
d-glucosamine was modelled onto several subunits at this position. 
Several residues that were not well defined by the electron density 
were omitted from the model. All the above software was available 
through the CCP4 suite.[40] All structural figures were prepared by 
using PyMOL (www.pymol.org) and annotated in Microsoft Power- 
Point. Crystallographic statistics are given in Table S2. 
 
Assessing the effect of DMSO on the thermal stability of GBP: 
Solutions of GBP (0.5 mg mL@1) were prepared with varying con- 
centrations of DMSO (0–10 %) and incubated at room temperature 
for 5 min. The inflection point (Ti) of the unfolding transition as the 
samples were heated was determined based on the ratio of fluo- 
rescence at 350:330 nm on a Nanotemper Tycho NT.6 instrument. 
Experiments were carried out in triplicate, then the mean and stan- 
dard deviation of each measurement were determined and plotted 
(Figure S8). A further assessment was carried out in which GPB was 
incubated with 2% DMSO at room temperature, and the Ti was de- 
termined at 15 min intervals over 45 mins. Experiments were con- 
ducted in triplicate, then the mean and standard deviation of each 
were calculated. These values were then compared to the 0% 
DMSO control. The data indicated that over 45 mins, the time 
period required for the biophysical assays, there is no determinan- 
tal effect on protein stability from a 2 % level of DMSO. 
Fluorescence quenching assay: Stock solutions of 10 mg mL@1 GBP 
and AcAChBP were prepared, along with a 4 mm stock of bicucul- 
line methiodide (100 mm stock in DMSO) in buffer A. Data were 
collected on a LS-55 PerkinElmer spectrometer with the detector 
sensitivity set to 750 V. Protein samples (volume 2 mL) were excit- 
ed at a wavelength of 280 nm, and emissions between 300 and 
400 nm were monitored. Additions of 1–2 mL of the N-methylbicu- 
culline stock were dispensed, each followed by mixing, for a total 
of 20 mL. Experiments were carried out in triplicate, and the per- 
centage change in fluorescence was calculated. Control measure- 
ments were conducted by adding buffer to the protein solutions 
whilst matching the concentration of DMSO. These were then sub- 
tracted from the percentage change in fluorescence to provide a 
correction for the presence of DMSO (Figure S9). 
Isothermal titration calorimetry: Experiments were carried out by 
using a PEAQ-ITC (MicroCal, Malvern Panalytical) at 258C. GBP and 
AcAChBP solutions (40 mm) were prepared by dialysis against buf- 
fer A at 4 8C overnight, then DMSO was added to match that in the 
titrant. Bicuculline methiodide (2 mm, 2 % DMSO) was prepared in 
the same buffer. The injection needle acted as a paddle to stir the 
cell contents at 750 rpm. An initial injection of 0.4 mL was followed 
by twelve 3 mL injections at 3 min intervals. Data were analysed by 
using the software supplied by the manufacturer assuming a one- 
binding-site model with mean composite controls: buffer–buffer, 
buffer–protein, ligand–buffer considered. Titrations were conduct- 
ed in triplicate. The controls, original traces plus derived titration 
curves and parameters with average values are given in Figure S10 
and Table S3. Representative data are presented in Figure S2 E. 
Sequence and structure alignments: Sequences for GlyR (Uniprot 
codes: a1 P23415 and b P48167) and GABAA (Uniprot codes: a1 
P14867, b3 P28472, 11 P24046) were extracted from Uniprot and 
aligned by using Clustal Omega on the Jalview platform.[41] GBP 
(PDB ID: 5OBH) and the GABAA receptor (PDB ID: 6HUK) files were 
retrieved from the Protein Data Bank and superimposed in COOT 
by SSM superimpose. Images were then produced in PyMOL, after 
using the align function to obtain an optimal overlay of the two 
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